"Refid","Bibliography","User","Ris Code","Level","test_k","sampCountry
Country where study was performed","sampY
Year the study was conducted
(-1 if not reported)","agent *
Causative agent of the disease","agentSubtypeType
What type of further detailed information is given regarding the agent. Select here, and type below. Give the highest subtype information available - for instance serotype if available, instead of strain. ","agentSubtypeType
What type of further detailed information is given regarding the agent. Select here, and type below. Give the highest subtype information available - for instance serotype if available, instead of strain. _comment","agentDetails
The further information given regarding the sutype type given above. ","studyID *
Unique ID to link all observations from the same study, experiment, or time point evaluations.","studyTargetSpecies *
Species used in study","studyTargetSpecies *
Species used in study_comment","ageMonths
Age of animals in months
(-1 if not reported)","sampUnit *
Type of unit sampled in the study and reported in sampUnitSize","sampUnit *
Type of unit sampled in the study and reported in sampUnitSize_comment","sampUnitSize *
Number of units in the group (the number of units listed above (e.g. herds))","Animal status","Animal status_comment","testsubstance
select the vaccine used","testsubstance
select the vaccine used_comment","Type of vaccine","Type of vaccine_comment","route
Method of application or treatment regime or administration method of vaccine","route
Method of application or treatment regime or administration method of vaccine_comment","Day dose 1
The day, from the start of the experiment (day 0), when the first vaccine dose was given.","Vaccine dose 1
Dose of vaccine given for the first time (dose 1).","Day dose 2
The day, from the start of the experiment (day 0), when the second vaccine dose was given. Leave empty if not second dose was administered.","Vaccine Dose 2
Dose of vaccine given for the second time (dose 2). Leave empty if no second dose was administered.","Day dose 3
IF a third dose was given, enter the number of days since the start of the experiment (day 0), when it was administered. Leave empty otherwise","Vaccine Dose 3
IF a third dose was given (dose 3), enter the dose of vaccine given. Leave empty if no third dose was administered.","Challenge type","route
Method of application of the challenge","route
Method of application of the challenge_comment","Challenge substance","Challenge dose
Plese describe (free-text) the dosage information given","Challenge day
From the beginning of the experiment","deadUnits
Number of dead animals ","mortalityTime minimum
If provided in the paper, please report the time between application of the treatment and first recorded mortality. Use this question for the numerical value and the next for the unit.","mortalityTimeUnits_min
The units for the first reported time to mortality.","mortalityTime maximum
If provided in the paper, please report the time between application of the treatment and last recorded mortality. Use this question for the numerical value and the next for the unit.","mortalityTimeUnits_max
The units for the last reported time to mortality.","efficacy
1-RR. Report as given in the paper.
If not reported, leave it empty.","coverage
Coverage in %","Direct vaccine costs
Decsribe DIRECT vaccine costs, if given. ","Indirect vaccine costs
Decsribe any indirect vaccine costs reported in the paper, for instance loss of productivity, food conversion, etc.","Withdrawal period (in days)
Minimum number of days since last vaccine dose before animals can be sent to slaughter.
 ","vaccine storage
Does the vaccine need to be kept cold or in any other specific conditions? please report any details about logistical constraints given in the paper.","TIME POINT
Indicate time point in days from the start of the study to which the reported parameters below correspond","STAGE of experiment
At which step of the experiment do the information to be reported relate to.","LAB TEST *
Laboratory test used to detect agent, antibdies, or antigens associated with the disease","LAB TEST details
Description of laboratory method (where relevant include method of calculation of cut-offs)","Target of laboratory test","Target of laboratory test_comment","Tissue sampled for testing
(Note: as part-nature = the tissue has not been processed)","Tissue sampled for testing
(Note: as part-nature = the tissue has not been processed)_comment","Number of samples tested","Number of samples positive","testValue
The reported value for the test, for instance titers of SNT, IP for ELISA test, CQ/CT for a PCR, or a clinical score. GROUP AVERAGE, for the POSITIVE animals only.","UNITS
the units for the value reported to the left.","UNITS
the units for the value reported to the left._comment","Scale MIN
If a scale is needed in order to understand the test value (for instance the maximum score in a clinical score scale), then report the minimum here","Scale MAX
If a scale is needed in order to understand the test value (for instance the maximum score in a clinical score scale), then report the maximum here","QUALITY check If you have noted any significant weakness in the study design, or details worth of note which could not be captured in the current form, please enter comments here. All papers with comments in this section will be reviewed by a second reviewer. "
50265,"El-Shall, N.A., Awad, A.M., Sedeik, M.E. (2021).  Examination of the protective efficacy of two avian influenza H5 vaccines against clade 2.3.4.4b H5N8 highly pathogenic avian influenza virus in commercial broilers Research in Veterinary Science, 140(#issue#),  125",e.royall,,4,,Egypt,2021,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"A/chicken/Egypt/ Alex-2/2017 H5N8 clade 2.3.4.4b",4,"Chickens (Gallus)",,0.3,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Marek’s Disease vaccine of serotype 3 (turkey Herpesvirus or HVT) expressing Avian Influenza key protective antigens",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify","eye drop and intranasal routes (50 μl/each route)",A/chicken/Egypt/Alex-2/2017,"10^6.3 EID50/100 μl",35,2,3,days,,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","using AI H5N1 antigen",Antibody,,"Animal blood",,-1,-1,"8.37 ± 0.26","Other: specify","log base 2 geometric mean titre",,,"Values estimated from graphical presentation of results. These commercial chicks had maternal derived antibodies (MDA) against H5 AI mentioned in results section. All chicken groups additionally received inactivated ND vaccine (Intervet International B. V., Boxmeer, The Netherlands) intramuscularly and MA5 + Clone30 (Intervet International B.V., Boxmeer, The Netherlands) and Bursine plus (Zoetis Inc., Kalamazoo, USA) vaccines via eye drops."
50265,"El-Shall, N.A., Awad, A.M., Sedeik, M.E. (2021).  Examination of the protective efficacy of two avian influenza H5 vaccines against clade 2.3.4.4b H5N8 highly pathogenic avian influenza virus in commercial broilers Research in Veterinary Science, 140(#issue#),  125",e.royall,,4,,Egypt,2021,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"A/chicken/Egypt/ Alex-2/2017 H5N8 clade 2.3.4.4b",1,"Chickens (Gallus)",,0.3,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","eye drop and intranasal routes (50 μl/each route)",A/chicken/Egypt/Alex-2/2017,"10^6.3 EID50/100 μl",28,10,3,days,,,,,,,,,31,"After challenge","Real-Time PCR (qualitative or quantitative)",,"Nucleic acid",,"Other (specify)","cloacal swab",4,4,10^4.5,titer,,,,"These commercial chicks had maternal derived antibodies (MDA) against H5 AI mentioned in results section. All chicken groups additionally received inactivated ND vaccine (Intervet International B. V., Boxmeer, The Netherlands) intramuscularly and MA5 + Clone30 (Intervet International B.V., Boxmeer, The Netherlands) and Bursine plus (Zoetis Inc., Kalamazoo, USA) vaccines via eye drops."
50265,"El-Shall, N.A., Awad, A.M., Sedeik, M.E. (2021).  Examination of the protective efficacy of two avian influenza H5 vaccines against clade 2.3.4.4b H5N8 highly pathogenic avian influenza virus in commercial broilers Research in Veterinary Science, 140(#issue#),  125",e.royall,,4,,Egypt,2021,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"A/chicken/Egypt/ Alex-2/2017 H5N8 clade 2.3.4.4b",3,"Chickens (Gallus)",,0.3,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","eye drop and intranasal routes (50 μl/each route)",A/chicken/Egypt/Alex-2/2017,"10^6.3 EID50/100 μl",35,10,4,days,,,,,,,,,38,"After challenge","Real-Time PCR (qualitative or quantitative)",,"Nucleic acid",,"Other (specify)","tracheal swab",7,7,10^4.5,titer,,,,"These commercial chicks had maternal derived antibodies (MDA) against H5 AI mentioned in results section. All chicken groups additionally received inactivated ND vaccine (Intervet International B. V., Boxmeer, The Netherlands) intramuscularly and MA5 + Clone30 (Intervet International B.V., Boxmeer, The Netherlands) and Bursine plus (Zoetis Inc., Kalamazoo, USA) vaccines via eye drops."
50265,"El-Shall, N.A., Awad, A.M., Sedeik, M.E. (2021).  Examination of the protective efficacy of two avian influenza H5 vaccines against clade 2.3.4.4b H5N8 highly pathogenic avian influenza virus in commercial broilers Research in Veterinary Science, 140(#issue#),  125",e.royall,,4,,Egypt,2021,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"A/chicken/Egypt/ Alex-2/2017 H5N8 clade 2.3.4.4b",3,"Chickens (Gallus)",,0.3,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","eye drop and intranasal routes (50 μl/each route)",A/chicken/Egypt/Alex-2/2017,"10^6.3 EID50/100 μl",35,10,4,days,,,,,,,,,38,"After challenge","Real-Time PCR (qualitative or quantitative)",,"Nucleic acid",,"Other (specify)","cloacal swab",7,7,10^4.25,titer,,,,"These commercial chicks had maternal derived antibodies (MDA) against H5 AI mentioned in results section. All chicken groups additionally received inactivated ND vaccine (Intervet International B. V., Boxmeer, The Netherlands) intramuscularly and MA5 + Clone30 (Intervet International B.V., Boxmeer, The Netherlands) and Bursine plus (Zoetis Inc., Kalamazoo, USA) vaccines via eye drops."
50265,"El-Shall, N.A., Awad, A.M., Sedeik, M.E. (2021).  Examination of the protective efficacy of two avian influenza H5 vaccines against clade 2.3.4.4b H5N8 highly pathogenic avian influenza virus in commercial broilers Research in Veterinary Science, 140(#issue#),  125",e.royall,,4,,Egypt,2021,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"A/chicken/Egypt/ Alex-2/2017 H5N8 clade 2.3.4.4b",4,"Chickens (Gallus)",,0.3,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Marek’s Disease vaccine of serotype 3 (turkey Herpesvirus or HVT) expressing Avian Influenza key protective antigens",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify","eye drop and intranasal routes (50 μl/each route)",A/chicken/Egypt/Alex-2/2017,"10^6.3 EID50/100 μl",35,2,3,days,,,,,,,,,38,"After challenge","Real-Time PCR (qualitative or quantitative)",,"Nucleic acid",,"Other (specify)","cloacal swab",10,3,10^1.3,titer,,,,"Values estimated from graphical presentation of results. These commercial chicks had maternal derived antibodies (MDA) against H5 AI mentioned in results section. All chicken groups additionally received inactivated ND vaccine (Intervet International B. V., Boxmeer, The Netherlands) intramuscularly and MA5 + Clone30 (Intervet International B.V., Boxmeer, The Netherlands) and Bursine plus (Zoetis Inc., Kalamazoo, USA) vaccines via eye drops."
50265,"El-Shall, N.A., Awad, A.M., Sedeik, M.E. (2021).  Examination of the protective efficacy of two avian influenza H5 vaccines against clade 2.3.4.4b H5N8 highly pathogenic avian influenza virus in commercial broilers Research in Veterinary Science, 140(#issue#),  125",e.royall,,4,,Egypt,2021,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"A/chicken/Egypt/ Alex-2/2017 H5N8 clade 2.3.4.4b",1,"Chickens (Gallus)",,0.3,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","eye drop and intranasal routes (50 μl/each route)",A/chicken/Egypt/Alex-2/2017,"10^6.3 EID50/100 μl",28,10,3,days,,,,,,,,,31,"After challenge","Real-Time PCR (qualitative or quantitative)",,"Nucleic acid",,"Other (specify)","tracheal swab",4,4,10^4.8,titer,,,,"These commercial chicks had maternal derived antibodies (MDA) against H5 AI mentioned in results section. All chicken groups additionally received inactivated ND vaccine (Intervet International B. V., Boxmeer, The Netherlands) intramuscularly and MA5 + Clone30 (Intervet International B.V., Boxmeer, The Netherlands) and Bursine plus (Zoetis Inc., Kalamazoo, USA) vaccines via eye drops."
50265,"El-Shall, N.A., Awad, A.M., Sedeik, M.E. (2021).  Examination of the protective efficacy of two avian influenza H5 vaccines against clade 2.3.4.4b H5N8 highly pathogenic avian influenza virus in commercial broilers Research in Veterinary Science, 140(#issue#),  125",e.royall,,4,,Egypt,2021,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"A/chicken/Egypt/ Alex-2/2017 H5N8 clade 2.3.4.4b",2,"Chickens (Gallus)",,0.3,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Marek’s Disease vaccine of serotype 3 (turkey Herpesvirus or HVT) expressing Avian Influenza key protective antigens",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify","eye drop and intranasal routes (50 μl/each route)",A/chicken/Egypt/Alex-2/2017,"10^6.3 EID50/100 μl",28,5,5,days,,,,,,,,,31,"After challenge","Real-Time PCR (qualitative or quantitative)",,"Nucleic acid",,"Other (specify)","tracheal swab",8,7,10^3.9,titer,,,,"Values estimated from graphical presentation of results. These commercial chicks had maternal derived antibodies (MDA) against H5 AI mentioned in results section. All chicken groups additionally received inactivated ND vaccine (Intervet International B. V., Boxmeer, The Netherlands) intramuscularly and MA5 + Clone30 (Intervet International B.V., Boxmeer, The Netherlands) and Bursine plus (Zoetis Inc., Kalamazoo, USA) vaccines via eye drops."
50265,"El-Shall, N.A., Awad, A.M., Sedeik, M.E. (2021).  Examination of the protective efficacy of two avian influenza H5 vaccines against clade 2.3.4.4b H5N8 highly pathogenic avian influenza virus in commercial broilers Research in Veterinary Science, 140(#issue#),  125",e.royall,,4,,Egypt,2021,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"A/chicken/Egypt/ Alex-2/2017 H5N8 clade 2.3.4.4b",2,"Chickens (Gallus)",,0.3,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Marek’s Disease vaccine of serotype 3 (turkey Herpesvirus or HVT) expressing Avian Influenza key protective antigens",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify","eye drop and intranasal routes (50 μl/each route)",A/chicken/Egypt/Alex-2/2017,"10^6.3 EID50/100 μl",28,5,5,days,,,,,,,,,33,"After challenge","Real-Time PCR (qualitative or quantitative)",,"Nucleic acid",,"Other (specify)","tracheal swab",5,2,10^1.5,titer,,,,"Values estimated from graphical presentation of results. These commercial chicks had maternal derived antibodies (MDA) against H5 AI mentioned in results section. All chicken groups additionally received inactivated ND vaccine (Intervet International B. V., Boxmeer, The Netherlands) intramuscularly and MA5 + Clone30 (Intervet International B.V., Boxmeer, The Netherlands) and Bursine plus (Zoetis Inc., Kalamazoo, USA) vaccines via eye drops."
50265,"El-Shall, N.A., Awad, A.M., Sedeik, M.E. (2021).  Examination of the protective efficacy of two avian influenza H5 vaccines against clade 2.3.4.4b H5N8 highly pathogenic avian influenza virus in commercial broilers Research in Veterinary Science, 140(#issue#),  125",e.royall,,4,,Egypt,2021,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"A/chicken/Egypt/ Alex-2/2017 H5N8 clade 2.3.4.4b",2,"Chickens (Gallus)",,0.3,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Marek’s Disease vaccine of serotype 3 (turkey Herpesvirus or HVT) expressing Avian Influenza key protective antigens",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify","eye drop and intranasal routes (50 μl/each route)",A/chicken/Egypt/Alex-2/2017,"10^6.3 EID50/100 μl",28,5,5,days,,,,,,,,,31,"After challenge","Real-Time PCR (qualitative or quantitative)",,"Nucleic acid",,"Other (specify)","cloacal swab",8,7,10^3.5,titer,,,,"Values estimated from graphical presentation of results. These commercial chicks had maternal derived antibodies (MDA) against H5 AI mentioned in results section. All chicken groups additionally received inactivated ND vaccine (Intervet International B. V., Boxmeer, The Netherlands) intramuscularly and MA5 + Clone30 (Intervet International B.V., Boxmeer, The Netherlands) and Bursine plus (Zoetis Inc., Kalamazoo, USA) vaccines via eye drops."
50265,"El-Shall, N.A., Awad, A.M., Sedeik, M.E. (2021).  Examination of the protective efficacy of two avian influenza H5 vaccines against clade 2.3.4.4b H5N8 highly pathogenic avian influenza virus in commercial broilers Research in Veterinary Science, 140(#issue#),  125",e.royall,,4,,Egypt,2021,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"A/chicken/Egypt/ Alex-2/2017 H5N8 clade 2.3.4.4b",2,"Chickens (Gallus)",,0.3,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Marek’s Disease vaccine of serotype 3 (turkey Herpesvirus or HVT) expressing Avian Influenza key protective antigens",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify","eye drop and intranasal routes (50 μl/each route)",A/chicken/Egypt/Alex-2/2017,"10^6.3 EID50/100 μl",28,5,5,days,,,,,,,,,33,"After challenge","Real-Time PCR (qualitative or quantitative)",,"Nucleic acid",,"Other (specify)","cloacal swab",5,2,10^1.5,titer,,,,"Values estimated from graphical presentation of results. These commercial chicks had maternal derived antibodies (MDA) against H5 AI mentioned in results section. All chicken groups additionally received inactivated ND vaccine (Intervet International B. V., Boxmeer, The Netherlands) intramuscularly and MA5 + Clone30 (Intervet International B.V., Boxmeer, The Netherlands) and Bursine plus (Zoetis Inc., Kalamazoo, USA) vaccines via eye drops."
50265,"El-Shall, N.A., Awad, A.M., Sedeik, M.E. (2021).  Examination of the protective efficacy of two avian influenza H5 vaccines against clade 2.3.4.4b H5N8 highly pathogenic avian influenza virus in commercial broilers Research in Veterinary Science, 140(#issue#),  125",e.royall,,4,,Egypt,2021,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"A/chicken/Egypt/ Alex-2/2017 H5N8 clade 2.3.4.4b",2,"Chickens (Gallus)",,0.3,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Marek’s Disease vaccine of serotype 3 (turkey Herpesvirus or HVT) expressing Avian Influenza key protective antigens",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify","eye drop and intranasal routes (50 μl/each route)",A/chicken/Egypt/Alex-2/2017,"10^6.3 EID50/100 μl",28,5,5,days,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","using AI H5N8 antigen",Antibody,,"Animal blood",,-1,-1,"6.2 ± 0.37","Other: specify","log base 2 geometric mean titre",,,"Values estimated from graphical presentation of results. These commercial chicks had maternal derived antibodies (MDA) against H5 AI mentioned in results section. All chicken groups additionally received inactivated ND vaccine (Intervet International B. V., Boxmeer, The Netherlands) intramuscularly and MA5 + Clone30 (Intervet International B.V., Boxmeer, The Netherlands) and Bursine plus (Zoetis Inc., Kalamazoo, USA) vaccines via eye drops."
50265,"El-Shall, N.A., Awad, A.M., Sedeik, M.E. (2021).  Examination of the protective efficacy of two avian influenza H5 vaccines against clade 2.3.4.4b H5N8 highly pathogenic avian influenza virus in commercial broilers Research in Veterinary Science, 140(#issue#),  125",e.royall,,4,,Egypt,2021,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"A/chicken/Egypt/ Alex-2/2017 H5N8 clade 2.3.4.4b",2,"Chickens (Gallus)",,0.3,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Marek’s Disease vaccine of serotype 3 (turkey Herpesvirus or HVT) expressing Avian Influenza key protective antigens",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify","eye drop and intranasal routes (50 μl/each route)",A/chicken/Egypt/Alex-2/2017,"10^6.3 EID50/100 μl",28,5,5,days,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","using AI H5N1 antigen",Antibody,,"Animal blood",,-1,-1,"5.6 ± 0.4","Other: specify","log base 2 geometric mean titre",,,"Values estimated from graphical presentation of results. These commercial chicks had maternal derived antibodies (MDA) against H5 AI mentioned in results section. All chicken groups additionally received inactivated ND vaccine (Intervet International B. V., Boxmeer, The Netherlands) intramuscularly and MA5 + Clone30 (Intervet International B.V., Boxmeer, The Netherlands) and Bursine plus (Zoetis Inc., Kalamazoo, USA) vaccines via eye drops."
50265,"El-Shall, N.A., Awad, A.M., Sedeik, M.E. (2021).  Examination of the protective efficacy of two avian influenza H5 vaccines against clade 2.3.4.4b H5N8 highly pathogenic avian influenza virus in commercial broilers Research in Veterinary Science, 140(#issue#),  125",e.royall,,4,,Egypt,2021,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"A/chicken/Egypt/ Alex-2/2017 H5N8 clade 2.3.4.4b",4,"Chickens (Gallus)",,0.3,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Marek’s Disease vaccine of serotype 3 (turkey Herpesvirus or HVT) expressing Avian Influenza key protective antigens",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify","eye drop and intranasal routes (50 μl/each route)",A/chicken/Egypt/Alex-2/2017,"10^6.3 EID50/100 μl",35,2,3,days,,,,,,,,,38,"After challenge","Real-Time PCR (qualitative or quantitative)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,3,10^1.2,titer,,,,"Values estimated from graphical presentation of results. These commercial chicks had maternal derived antibodies (MDA) against H5 AI mentioned in results section. All chicken groups additionally received inactivated ND vaccine (Intervet International B. V., Boxmeer, The Netherlands) intramuscularly and MA5 + Clone30 (Intervet International B.V., Boxmeer, The Netherlands) and Bursine plus (Zoetis Inc., Kalamazoo, USA) vaccines via eye drops."
50265,"El-Shall, N.A., Awad, A.M., Sedeik, M.E. (2021).  Examination of the protective efficacy of two avian influenza H5 vaccines against clade 2.3.4.4b H5N8 highly pathogenic avian influenza virus in commercial broilers Research in Veterinary Science, 140(#issue#),  125",e.royall,,4,,Egypt,2021,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"A/chicken/Egypt/ Alex-2/2017 H5N8 clade 2.3.4.4b",4,"Chickens (Gallus)",,0.3,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Marek’s Disease vaccine of serotype 3 (turkey Herpesvirus or HVT) expressing Avian Influenza key protective antigens",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify","eye drop and intranasal routes (50 μl/each route)",A/chicken/Egypt/Alex-2/2017,"10^6.3 EID50/100 μl",35,2,3,days,,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","using AI H5N8 antigen",Antibody,,"Animal blood",,-1,-1,"8.75 ± 0.16","Other: specify","log base 2 geometric mean titre",,,"Values estimated from graphical presentation of results. These commercial chicks had maternal derived antibodies (MDA) against H5 AI mentioned in results section. All chicken groups additionally received inactivated ND vaccine (Intervet International B. V., Boxmeer, The Netherlands) intramuscularly and MA5 + Clone30 (Intervet International B.V., Boxmeer, The Netherlands) and Bursine plus (Zoetis Inc., Kalamazoo, USA) vaccines via eye drops."
50268,"Hegazy, A.M.E., Yehia, N., Hassan, A.F.I., El-Saadony, M.T., Aboelenin, S.M., Soliman, M.M., Tolba, H.M.N. (2021).  The potency of newly development H5N8 and H9N2 avian influenza vaccines against the isolated strains in laying hens from Egypt during 2019 Saudi Journal of Biological Sciences, 28(9),  5310",e.royall,,4,,Egypt,2019,"HPAI - Highly Pathogenic Avian Influenza","Other: specify","clade 2.3.4.4","Influenza virus A/ chicken/ Egypt/ AB1/ 2018 (H5N8)",1,"Chickens (Gallus)",,3.3,animal,,10,SPF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Real-Time PCR (qualitative or quantitative)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",-1,-1,7.206 X 10^4,titer,,,,"Values were given as means so it wasn't possible to determine whether all or only some of the birds in a cohort tested positive"
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8)",1,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,-1,9,days,,,,85,,,,,29,"After challenge","Haemagglutination inhibition test (HIT)","Hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"5.2 log base 2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8)",1,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,-1,9,days,,,,85,,,,,18,"After challenge","Virus Isolation (VI)","procedures performed according to Dufour-Zavala, L. (2008) A Laboratory Manual for the Isolation, Identification, and Characterization of Avian Pathogens. American Association of Avian Pathologists, United States. p129-224.]. Virus shedding titers calculated following method of Spearman–Karber.  Results reported as EID50/0.1 mL equivalents, with lower limit of detection being <1 log10 EID50/0.1 mL.",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.2 EID50/0.1 mL equivalents",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8)",1,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,-1,9,days,,,,85,,,,,20,"After challenge","Virus Isolation (VI)","procedures performed according to Dufour-Zavala, L. (2008) A Laboratory Manual for the Isolation, Identification, and Characterization of Avian Pathogens. American Association of Avian Pathologists, United States. p129-224.]. Virus shedding titers calculated following method of Spearman–Karber.  Results reported as EID50/0.1 mL equivalents, with lower limit of detection being <1 log10 EID50/0.1 mL.",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.0 EID50/0.1 mL equivalents",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8)",1,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,-1,9,days,,,,85,,,,,22,"After challenge","Virus Isolation (VI)","procedures performed according to Dufour-Zavala, L. (2008) A Laboratory Manual for the Isolation, Identification, and Characterization of Avian Pathogens. American Association of Avian Pathologists, United States. p129-224.]. Virus shedding titers calculated following method of Spearman–Karber.  Results reported as EID50/0.1 mL equivalents, with lower limit of detection being <1 log10 EID50/0.1 mL.",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.4 EID50/0.1 mL equivalents",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8)",1,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,-1,9,days,,,,85,,,,,25,"After challenge","Virus Isolation (VI)","procedures performed according to Dufour-Zavala, L. (2008) A Laboratory Manual for the Isolation, Identification, and Characterization of Avian Pathogens. American Association of Avian Pathologists, United States. p129-224.]. Virus shedding titers calculated following method of Spearman–Karber.  Results reported as EID50/0.1 mL equivalents, with lower limit of detection being <1 log10 EID50/0.1 mL.",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.2 EID50/0.1 mL equivalents",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",3,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,,days,,,,100,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"4.8 log base 2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",3,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,,days,,,,100,,,,,24,"After challenge","Virus Isolation (VI)","procedures performed according to Dufour-Zavala, L. (2008) A Laboratory Manual for the Isolation, Identification, and Characterization of Avian Pathogens. American Association of Avian Pathologists, United States. p129-224.]. Virus shedding titers calculated following method of Spearman–Karber.  Results reported as EID50/0.1 mL equivalents, with lower limit of detection being <1 log10 EID50/0.1 mL.",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.3 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",3,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,,days,,,,100,,,,,26,"After challenge","Virus Isolation (VI)","procedures performed according to Dufour-Zavala, L. (2008) A Laboratory Manual for the Isolation, Identification, and Characterization of Avian Pathogens. American Association of Avian Pathologists, United States. p129-224.]. Virus shedding titers calculated following method of Spearman–Karber.  Results reported as EID50/0.1 mL equivalents, with lower limit of detection being <1 log10 EID50/0.1 mL.",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.5 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",3,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,,days,,,,100,,,,,28,"After challenge","Virus Isolation (VI)","procedures performed according to Dufour-Zavala, L. (2008) A Laboratory Manual for the Isolation, Identification, and Characterization of Avian Pathogens. American Association of Avian Pathologists, United States. p129-224.]. Virus shedding titers calculated following method of Spearman–Karber.  Results reported as EID50/0.1 mL equivalents, with lower limit of detection being <1 log10 EID50/0.1 mL.",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.6 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",3,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,,days,,,,100,,,,,31,"After challenge","Virus Isolation (VI)","procedures performed according to Dufour-Zavala, L. (2008) A Laboratory Manual for the Isolation, Identification, and Characterization of Avian Pathogens. American Association of Avian Pathologists, United States. p129-224.]. Virus shedding titers calculated following method of Spearman–Karber.  Results reported as EID50/0.1 mL equivalents, with lower limit of detection being <1 log10 EID50/0.1 mL.",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.4 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",4,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"HPAIV 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,8,days,,,,92,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"5.2 log base 2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",4,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"HPAIV 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,8,days,,,,92,,,,,24,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"3.2 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",4,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"HPAIV 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,8,days,,,,92,,,,,26,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.8 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",4,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"HPAIV 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,8,days,,,,92,,,,,28,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.9 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",4,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"HPAIV 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,8,days,,,,92,,,,,31,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.0 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",5,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated; RG A/duck/Anhui/1/2006(H5N1)(Re-5)",SUBCUTANEOUS,,0,,,,,,"Not challenged",,,,,,0,,,,,,,,,,,7,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"1.0 log base 2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",5,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated; RG A/duck/Anhui/1/2006(H5N1)(Re-5)",SUBCUTANEOUS,,0,,,,,,"Not challenged",,,,,,0,,,,,,,,,,,14,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"3.4 log base 2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",5,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated; RG A/duck/Anhui/1/2006(H5N1)(Re-5)",SUBCUTANEOUS,,0,,,,,,"Not challenged",,,,,,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"4.6 log base 2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",5,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated; RG A/duck/Anhui/1/2006(H5N1)(Re-5)",SUBCUTANEOUS,,0,,,,,,"Not challenged",,,,,,0,,,,,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"5.3 log base 2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",2,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,-1,4,days,,,,0,,,,,18,"After challenge","Virus Isolation (VI)","procedures performed according to Dufour-Zavala, L. (2008) A Laboratory Manual for the Isolation, Identification, and Characterization of Avian Pathogens. American Association of Avian Pathologists, United States. p129-224.]. Virus shedding titers calculated following method of Spearman–Karber.  Results reported as EID50/0.1 mL equivalents, with lower limit of detection being <1 log10 EID50/0.1 mL.",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.5 EID50/0.1 mL equivalents",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",2,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,-1,4,days,,,,0,,,,,20,"After challenge","Virus Isolation (VI)","procedures performed according to Dufour-Zavala, L. (2008) A Laboratory Manual for the Isolation, Identification, and Characterization of Avian Pathogens. American Association of Avian Pathologists, United States. p129-224.]. Virus shedding titers calculated following method of Spearman–Karber.  Results reported as EID50/0.1 mL equivalents, with lower limit of detection being <1 log10 EID50/0.1 mL.",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.6 EID50/0.1 mL equivalents",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",2,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"H5N1 Re-5",,"Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,-1,4,days,,,,0,,,,,22,"After challenge","Virus Isolation (VI)","procedures performed according to Dufour-Zavala, L. (2008) A Laboratory Manual for the Isolation, Identification, and Characterization of Avian Pathogens. American Association of Avian Pathologists, United States. p129-224.]. Virus shedding titers calculated following method of Spearman–Karber.  Results reported as EID50/0.1 mL equivalents, with lower limit of detection being <1 log10 EID50/0.1 mL.",Virus,,"Other (specify)","tracheal swab",-1,-1,"3 log base 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results.  Vaccine dose as per manufacturer's instructions."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8)",6,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,-1,10,days,,,,92,,,,,29,"After challenge","Haemagglutination inhibition test (HIT)","Hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"4.2 log base 2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8)",6,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,-1,10,days,,,,92,,,,,18,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.2 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8)",6,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,-1,10,days,,,,92,,,,,20,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.1 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8)",6,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,-1,10,days,,,,92,,,,,25,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.5 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",7,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,-1,3,days,,,,0,,,,,18,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.0 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",7,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,-1,3,days,,,,0,,,,,20,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"3.0 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",7,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,-1,3,days,,,,0,,,,,22,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.5 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",8,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,8,days,,,,92,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"4.2 log base2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",8,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,8,days,,,,92,,,,,24,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.4 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",8,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,8,days,,,,92,,,,,26,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.5 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",8,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,8,days,,,,92,,,,,28,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.2 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",8,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,8,days,,,,92,,,,,31,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.1 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",9,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,3,days,,,,70,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"4.5 log base 2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",9,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,3,days,,,,70,,,,,24,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.4 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",9,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,3,days,,,,70,,,,,26,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.8 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",9,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,3,days,,,,70,,,,,28,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.5 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",9,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,-1,3,days,,,,70,,,,,31,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.6 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",10,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Not challenged",,,,,,0,,days,,,,,,,,,7,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"0.5 log base2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",10,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Not challenged",,,,,,0,,days,,,,,,,,,14,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"3.2 log base2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",10,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Not challenged",,,,,,0,,days,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"3.5 log base2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",10,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Not challenged",,,,,,0,,days,,,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"3.7 log base2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8)",6,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N2: A/chicken/ Mexico/232/1994(H5N2); manufactured in Mexico","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,-1,10,days,,,,92,,,,,22,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.8 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8)",11,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N3: A/chicken/Vietnam/ C58/2004","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,,,days,,,,100,,,,,29,"After challenge","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"3.8 log base 2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",12,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N3: A/chicken/Vietnam/ C58/2004","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,,4,days,,,,0,,,,,22,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.5 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",12,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N3: A/chicken/Vietnam/ C58/2004","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,,4,days,,,,0,,,,,20,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.5 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",12,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N3: A/chicken/Vietnam/ C58/2004","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,,4,days,,,,0,,,,,18,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"3.0 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8)",11,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N3: A/chicken/Vietnam/ C58/2004","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,,,days,,,,100,,,,,25,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.7 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8)",11,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N3: A/chicken/Vietnam/ C58/2004","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,,,days,,,,100,,,,,22,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.8 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8)",11,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N3: A/chicken/Vietnam/ C58/2004","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,,,days,,,,100,,,,,20,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.9 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8)",11,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","H5N3: A/chicken/Vietnam/ C58/2004","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",15,,,days,,,,100,,,,,18,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.0 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",13,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","A/chicken/Vietnam/ C58/2004 (H5N3)","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,0,,days,,,,100,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"4.7 log base 2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",13,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","A/chicken/Vietnam/ C58/2004 (H5N3)","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,0,,days,,,,100,,,,,24,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.8 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",13,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","A/chicken/Vietnam/ C58/2004 (H5N3)","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,0,,days,,,,100,,,,,26,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.0 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",13,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","A/chicken/Vietnam/ C58/2004 (H5N3)","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,0,,days,,,,100,,,,,28,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.2 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",13,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","A/chicken/Vietnam/ C58/2004 (H5N3)","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,0,,days,,,,100,,,,,31,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"1.1 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",14,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","A/chicken/Vietnam/ C58/2004 (H5N3)","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,0,10,days,,,,92,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"5.0 log base 2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",14,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","A/chicken/Vietnam/ C58/2004 (H5N3)","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,0,10,days,,,,92,,,,,24,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.8 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",14,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","A/chicken/Vietnam/ C58/2004 (H5N3)","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,0,10,days,,,,92,,,,,26,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.5 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",14,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","A/chicken/Vietnam/ C58/2004 (H5N3)","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,0,10,days,,,,92,,,,,28,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.6 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",14,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","A/chicken/Vietnam/ C58/2004 (H5N3)","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","0.1 ml of virus titre 10^6 EID50/0.1 mL",21,0,10,days,,,,92,,,,,31,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"2.6 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",15,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","A/chicken/Vietnam/ C58/2004 (H5N3)","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Not challenged",,,,,,0,,days,,,,,,,,,7,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"1.0 log base 2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",15,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","A/chicken/Vietnam/ C58/2004 (H5N3)","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Not challenged",,,,,,0,,days,,,,,,,,,14,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"3.0 log base 2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",15,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","A/chicken/Vietnam/ C58/2004 (H5N3)","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Not challenged",,,,,,0,,days,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"3.8 log base 2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",15,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Other: specify","A/chicken/Vietnam/ C58/2004 (H5N3)","Other (specify):","commercial inactivated",SUBCUTANEOUS,,0,,,,,,"Not challenged",,,,,,0,,days,,,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","hemagglutination inhibition (HI) test using the universal reference H5 antigen (GD-Netherland) as a heterologous antigen in addition to two local homologous antigens prepared from the two challenge viruses. The HI assay was carried out according to the protocol of the World Organization for Animal Health (OIE)",Antibody,,"Blood serum (as part-nature)",,-1,-1,"5.0 log base 2",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1).",17,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Unvaccinated control",,,,,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","10^6 EID50/0.1 mL",15,,4,days,,,,0,,,,,18,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"4.8 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1).",17,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Unvaccinated control",,,,,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","10^6 EID50/0.1 mL",15,,4,days,,,,0,,,,,20,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"4.5 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1).",17,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Unvaccinated control",,,,,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","10^6 EID50/0.1 mL",15,,4,days,,,,0,,,,,22,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"5.5 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",18,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Unvaccinated control",,,,,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","10^6 EID50/0.1 mL",21,,3,days,,,,0,,,,,24,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"4.0 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",18,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Unvaccinated control",,,,,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","10^6 EID50/0.1 mL",21,,3,days,,,,0,,,,,26,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"3.5 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",18,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Unvaccinated control",,,,,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","10^6 EID50/0.1 mL",21,,3,days,,,,0,,,,,28,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"3.4 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",18,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Unvaccinated control",,,,,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","10^6 EID50/0.1 mL",21,,3,days,,,,0,,,,,31,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"3.0 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",19,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Unvaccinated control",,,,,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","10^6 EID50/0.1 mL",21,,5,days,,,,0,,,,,24,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"4.8 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",19,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Unvaccinated control",,,,,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","10^6 EID50/0.1 mL",21,,5,days,,,,0,,,,,26,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"4.4 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/chicken/Egypt/18FL6/2018(H5N8) GenBank accession No. (MH986133.1)",19,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Unvaccinated control",,,,,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2018","10^6 EID50/0.1 mL",21,,5,days,,,,0,,,,,28,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"3.8 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",16,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Unvaccinated control",,,,,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","10^6 EID50/0.1 mL",15,,3,days,,,,40,,,,,20,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"3.8 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",16,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Unvaccinated control",,,,,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","10^6 EID50/0.1 mL",15,,3,days,,,,40,,,,,22,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"3.6 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",16,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Unvaccinated control",,,,,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","10^6 EID50/0.1 mL",15,,3,days,,,,40,,,,,25,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"3.4 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50270,"El-Moeid, A.A., EL-Deeb, A.H., Elsaied, M.F., Soliman, R.A., EL-Safty, M.M., Hussein, H.A. (2021).  Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018 Veterinary World, 14(8),  2131",e.royall,,4,,Egypt,,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",clade,"H5N8 clade 2.3.4.4 A/duck/Egypt/ F13666A/2017(H5N8) GenBank accession No. (MH498622.1)",16,"Chickens (Gallus)",,0.33,animal,,13,SPF,,"Unvaccinated control",,,,,,0,,,,,,"Challenged with the pathogen","OTHER: specify",oronasal,"H5N8 2017","10^6 EID50/0.1 mL",15,,3,days,,,,40,,,,,18,"After challenge","Virus Isolation (VI)","virus titration in embryonated chicken eggs",Virus,,"Other (specify)","tracheal swab",-1,-1,"4.4 log 10 EID50/ml",titer,,,,"Data for individual animals not given. Survival of group as whole given as percentage (coverage). Titres taken as visual approximations from graphical results."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,0,,,,,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,10,10,6,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,0,,,,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,10,10,9.2,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,0,,,,,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,10,9,2.4,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,0,,,,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,10,10,5.5,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,0,,,,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,6,2.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,0,,,,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,6,2.8,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,0,,,,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,1,1.8,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,10,2,days,2,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,6.8,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,10,2,days,2,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,10,6,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,2,5,days,11,days,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,10,10,6,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,2,5,days,11,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,8,8,9.2,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,2,5,days,11,days,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,10,10,3,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,2,5,days,11,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,8,8,7,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,2,5,days,11,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","orophgaryngeal swab",10,9,4,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,2,5,days,11,days,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","orophgaryngeal swab",10,9,3.8,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,2,5,days,11,days,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,1,4.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",4,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,10,2,days,2,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,6.8,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",4,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,10,2,days,2,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,10,5.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",5,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,1,4,days,4,days,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,10,10,6.2,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",5,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,1,4,days,4,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,9,9,10,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",5,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,1,4,days,4,days,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,10,10,3,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",5,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,1,4,days,4,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,9,9,6.8,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",5,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,1,4,days,4,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,7,2.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",5,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,1,4,days,4,days,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,8,2.8,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",5,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"0.2ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,1,4,days,4,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,2,1.8,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",6,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,10,2,days,2,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,6.4,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",6,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",28,10,2,days,2,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,10,6,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",7,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,10,10,6.5,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",7,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,10,10,9.5,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",7,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,10,10,5.5,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",7,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,10,10,7.8,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",7,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,6,2.8,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",7,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,5,2.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",8,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,10,2,days,2,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,6,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-3237/2017, H5N1 clade 2.3.2.1a",8,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,10,2,days,2,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,10,5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",9,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,10,10,6.4,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",9,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,10,10,8.2,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",9,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,10,10,5.5,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",9,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,10,10,6.8,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",9,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,5,2.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",9,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,6,2.7,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",10,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,10,2,days,3,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,7,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/crow/Bangladesh/NRL-AI-8471/2017, H5N1 clade 2.3.2.1a",10,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,10,2,days,3,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,10,5.2,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",11,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,10,10,7.2,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",11,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,10,10,9.8,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",11,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,10,10,5.5,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",11,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,10,10,8.2,"Other: specify","log2 titer",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",11,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,5,2.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",11,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.3ml/bird according to the manufacturere's instruction",,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,0,,,,,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,5,2.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",12,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,10,2,days,2,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,6.2,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50277,"Kwon, J.-H., Criado, M.F., Killmaster, L., Ali, M.Z., Giasuddin, M., Samad, M.A., Karim, M.R., Brum, E., Hasan, M.Z., Lee, D.-H., Spackman, E., Swayne, D.E. (2021).  Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Vaccine, 39(21),  2824",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Bangladesh/NRL-AI-8323/2017, H5N1 clade 2.3.2.1a",12,"Chickens (Gallus)",,0.5,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intra-choanal,,"10^6 EID50",21,10,2,days,2,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 1.5 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,10,6,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50281,"Spackman, E., Pantin-Jackwood, M.J., Sitaras, I., Stephens, C.B., Suarez, D.L. (2021).  Identification of Efficacious Vaccines against Contemporary North American H7 Avian Influenza Viruses Avian Diseases, 65(1),  113",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/IN/1403-1/2016, H5N8",1,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"A/turkey/IN/16-01571-6/2016 H7N8",,"Other (specify):","Alphavirus vectored RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 viral particles/0.2 ml",,,,,"Challenged with the pathogen","OTHER: specify",intrachoanal,,"10^6 EID50",21,1,4,days,4,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen; cut-off 4 log2",Antibody,,"Blood serum (as part-nature)",,20,20,4.7,"Other: specify","log2 titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50281,"Spackman, E., Pantin-Jackwood, M.J., Sitaras, I., Stephens, C.B., Suarez, D.L. (2021).  Identification of Efficacious Vaccines against Contemporary North American H7 Avian Influenza Viruses Avian Diseases, 65(1),  113",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/IN/1403-1/2016, H5N8",1,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"A/turkey/IN/16-01571-6/2016 H7N8",,"Other (specify):","Alphavirus vectored RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 viral particles/0.2 ml",,,,,"Challenged with the pathogen","OTHER: specify",intrachoanal,,"10^6 EID50",21,1,4,days,4,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 4 log2",Antibody,,"Blood serum (as part-nature)",,20,20,4.6,"Other: specify","log2 titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50281,"Spackman, E., Pantin-Jackwood, M.J., Sitaras, I., Stephens, C.B., Suarez, D.L. (2021).  Identification of Efficacious Vaccines against Contemporary North American H7 Avian Influenza Viruses Avian Diseases, 65(1),  113",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/IN/1403-1/2016, H5N8",1,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"A/turkey/IN/16-01571-6/2016 H7N8",,"Other (specify):","Alphavirus vectored RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 viral particles/0.2 ml",,,,,"Challenged with the pathogen","OTHER: specify",intrachoanal,,"10^6 EID50",21,1,4,days,4,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.1 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",20,18,3.3,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50281,"Spackman, E., Pantin-Jackwood, M.J., Sitaras, I., Stephens, C.B., Suarez, D.L. (2021).  Identification of Efficacious Vaccines against Contemporary North American H7 Avian Influenza Viruses Avian Diseases, 65(1),  113",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/IN/1403-1/2016, H5N8",1,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"A/turkey/IN/16-01571-6/2016 H7N8",,"Other (specify):","Alphavirus vectored RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 viral particles/0.2 ml",,,,,"Challenged with the pathogen","OTHER: specify",intrachoanal,,"10^6 EID50",21,1,4,days,4,days,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.1 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",20,18,3.1,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50281,"Spackman, E., Pantin-Jackwood, M.J., Sitaras, I., Stephens, C.B., Suarez, D.L. (2021).  Identification of Efficacious Vaccines against Contemporary North American H7 Avian Influenza Viruses Avian Diseases, 65(1),  113",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/IN/1403-1/2016, H5N8",1,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"A/turkey/IN/16-01571-6/2016 H7N8",,"Other (specify):","Alphavirus vectored RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 viral particles/0.2 ml",,,,,"Challenged with the pathogen","OTHER: specify",intrachoanal,,"10^6 EID50",21,1,4,days,4,days,,,,,,,28,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.1 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",19,11,0.7,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50281,"Spackman, E., Pantin-Jackwood, M.J., Sitaras, I., Stephens, C.B., Suarez, D.L. (2021).  Identification of Efficacious Vaccines against Contemporary North American H7 Avian Influenza Viruses Avian Diseases, 65(1),  113",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/IN/1403-1/2016, H5N8",2,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intrachoanal,,"10^6 EID50",21,20,2,days,6,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.1 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",20,20,4.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50281,"Spackman, E., Pantin-Jackwood, M.J., Sitaras, I., Stephens, C.B., Suarez, D.L. (2021).  Identification of Efficacious Vaccines against Contemporary North American H7 Avian Influenza Viruses Avian Diseases, 65(1),  113",seungeun.han,,4,,"United States",2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/IN/1403-1/2016, H5N8",2,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intrachoanal,,"10^6 EID50",21,20,2,days,6,days,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.1 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",3,3,4.6,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD01/2019, H5N6",1,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify","Reassortant trivalent vaccine (H5N2 Re-11 strain + Re-12 strain, H7N9 H7-Re-2 strain)","Other (specify):",Inactivated,INTRAMUSCULAR,,0,"Not given",,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,0,,,,,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against Re-11 standard antigen",Antibody,,"Blood serum (as part-nature)",,-1,-1,9.9,"Other: specify","log2 titer",,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD01/2019, H5N6",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,10,-1,,5,days,,,,,,,31,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",6,6,pos,"Other: specify",pos/neg,,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD01/2019, H5N6",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,10,-1,,5,days,,,,,,,31,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,6,6,pos,"Other: specify",pos/neg,,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD02/2019, H5N6",3,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify","Reassortant trivalent vaccine (H5N2 Re-11 strain + Re-12 strain, H7N9 H7-Re-2 strain)","Other (specify):",Inactivated,INTRAMUSCULAR,,0,"Not given",,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,0,,,,,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against Re-11 standard antigen",Antibody,,"Blood serum (as part-nature)",,-1,-1,9.5,"Other: specify","log2 titer",,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD02/2019, H5N6",4,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,10,-1,,5,days,,,,,,,31,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",7,7,pos,"Other: specify",pos/neg,,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD02/2019, H5N6",4,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,10,-1,,5,days,,,,,,,33,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",3,3,pos,"Other: specify",pos/neg,,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD02/2019, H5N6",4,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,10,-1,,5,days,,,,,,,31,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,7,7,pos,"Other: specify",pos/neg,,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD02/2019, H5N6",4,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,10,-1,,5,days,,,,,,,33,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,3,3,pos,"Other: specify",pos/neg,,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD03/2019, H5N6",5,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify","Reassortant trivalent vaccine (H5N2 Re-11 strain + Re-12 strain, H7N9 H7-Re-2 strain)","Other (specify):",Inactivated,INTRAMUSCULAR,,0,"Not given",,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,0,,,,,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against Re-11 standard antigen",Antibody,,"Blood serum (as part-nature)",,-1,-1,9.5,"Other: specify","log2 titer",,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD03/2019, H5N6",6,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,10,-1,,5,days,,,,,,,31,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",6,6,pos,"Other: specify",pos/neg,,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD03/2019, H5N6",6,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,10,-1,,5,days,,,,,,,33,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",2,2,pos,"Other: specify",pos/neg,,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD03/2019, H5N6",6,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,10,-1,,5,days,,,,,,,31,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,6,6,pos,"Other: specify",pos/neg,,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD03/2019, H5N6",6,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,10,-1,,5,days,,,,,,,33,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,2,2,pos,"Other: specify",pos/neg,,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD04/2019, H5N6",7,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify","Reassortant trivalent vaccine (H5N2 Re-11 strain + Re-12 strain, H7N9 H7-Re-2 strain)","Other (specify):",Inactivated,INTRAMUSCULAR,,0,"Not given",,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,0,,,,,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against Re-11 standard antigen",Antibody,,"Blood serum (as part-nature)",,-1,-1,9.7,"Other: specify","log2 titer",,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD04/2019, H5N6",8,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,10,-1,,5,days,,,,,,,31,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",4,4,pos,"Other: specify",pos/neg,,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD04/2019, H5N6",8,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,10,-1,,5,days,,,,,,,33,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",3,3,pos,"Other: specify",pos/neg,,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD04/2019, H5N6",8,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,10,-1,,5,days,,,,,,,31,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,4,4,pos,"Other: specify",pos/neg,,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50289,"Peng, C., Zhao, P., Chu, J., Zhu, J., Li, Q., Zhao, H., Li, Y., Xin, L., Yang, X., Xie, S., Zhu, C., Qi, W., Xu, G., Li, J. (2021).  Characterization of four novel H5N6 avian influenza viruses with the internal genes from H5N1 and H9N2 viruses and experimental challenge of chickens vaccinated with current commercially available H5 vaccines Transboundary and Emerging Diseases, #volume#(#issue#),  #Pages#",seungeun.han,,4,,China,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Shandong/SD04/2019, H5N6",8,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Not mentioned",,"10^6 EID50",28,10,-1,,5,days,,,,,,,33,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,3,3,pos,"Other: specify",pos/neg,,,"Vaccine dose and challenge route were not explained. The number of animals tested and positive by HI assay was not provided. No virus was recovered from oropharyngeal and cloacal swabs from the vaccinated chickens."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,0,,,,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,7,3.83,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,0,,,,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,7,4.05,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,0,,,,,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,3,1.52,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,0,,,,,,,,,,,38,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,3,1.17,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,0,,,,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,2,1.02,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,0,,,,,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,2,1.11,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,0,,,,,,,,,,,38,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,2,0.85,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,0,,,,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,7,3.2,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,0,,,,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,7,3.81,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,0,,,,,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,7,1.25,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,10,-1,,-1,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",3,3,7.48,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,10,-1,,-1,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,3,3,5.76,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",4,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",56,0,,,,,,,,,,,58,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,4,1.84,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",4,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",56,0,,,,,,,,,,,60,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,2,0.92,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",4,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",56,0,,,,,,,,,,,66,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,1,0.35,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",4,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",56,0,,,,,,,,,,,66,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,1,0.3,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",5,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",56,1,-1,,-1,,,,,,,,58,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,7,3.71,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",5,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",56,1,-1,,-1,,,,,,,,60,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,9,5.2,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",5,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",56,1,-1,,-1,,,,,,,,63,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,2,0.93,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",5,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",56,1,-1,,-1,,,,,,,,66,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,1,0.5,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",5,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",56,1,-1,,-1,,,,,,,,60,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,1,0.51,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",6,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",56,10,-1,,-1,,,,,,,,58,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",9,9,8.14,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",6,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",56,10,-1,,-1,,,,,,,,58,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,9,9,6.09,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",7,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,1,-1,,-1,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,7,3.76,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",7,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,1,-1,,-1,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,7,3.4,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",7,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,1,-1,,-1,,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",9,1,0.21,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",7,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,1,-1,,-1,,,,,,,,38,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",9,2,0.52,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",7,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,1,-1,,-1,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,2,0.46,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",7,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,1,-1,,-1,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,2,0.1,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",7,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,1,-1,,-1,,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,9,2,0.34,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",8,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,3,-1,,-1,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,10,6.23,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",8,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,3,-1,,-1,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,6,3.05,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",8,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,3,-1,,-1,,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",7,1,0.5,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",8,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,3,-1,,-1,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,4,1.68,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",9,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,10,-1,,-1,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,10,8.12,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",9,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,10,-1,,-1,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,10,6.3,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",10,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,0,,,,,,,,,,,51,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,8,3.55,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",10,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,0,,,,,,,,,,,53,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,2,0.74,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",10,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,0,,,,,,,,,,,59,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,1,0.28,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",10,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,0,,,,,,,,,,,51,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,3,0.47,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",11,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,1,-1,,-1,,,,,,,,51,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,6,2.83,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",11,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,1,-1,,-1,,,,,,,,53,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,6,1.67,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",11,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,1,-1,,-1,,,,,,,,56,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",9,1,0.45,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",11,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,1,-1,,-1,,,,,,,,59,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",9,1,0.49,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",11,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,1,-1,,-1,,,,,,,,51,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,1,0.08,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",12,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,10,-1,,-1,,,,,,,,51,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,10,8.18,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",12,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,10,-1,,-1,,,,,,,,51,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,10,6.4,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",13,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,0,,,,,,,,,,,72,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,9,4.01,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",13,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,0,,,,,,,,,,,74,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,7,2.27,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",13,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,0,,,,,,,,,,,77,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,2,0.82,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",13,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,0,,,,,,,,,,,72,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,2,0.56,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",13,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,0,,,,,,,,,,,74,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,1,0.23,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",14,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,0,,,,,,,,,,,72,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,6,2.81,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",14,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,0,,,,,,,,,,,74,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,5,2.42,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",14,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,0,,,,,,,,,,,77,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,3,1.09,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",14,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,0,,,,,,,,,,,80,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,1,0.44,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",14,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,0,,,,,,,,,,,77,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,1,0.24,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",15,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,10,-1,,-1,,,,,,,,72,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,10,7.5,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",15,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,10,-1,,-1,,,,,,,,72,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,10,5.59,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",16,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,10,-1,,-1,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,10,3.37,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",16,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,10,-1,,-1,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,10,3.94,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",16,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,10,-1,,-1,,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",1,1,0.14,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",16,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,10,-1,,-1,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,4,1.07,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",16,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,10,-1,,-1,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,6,1.4,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",16,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,10,-1,,-1,,,,,,,,38,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,1,1,2.25,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",17,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,8,-1,,-1,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,9,5.21,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",17,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,8,-1,,-1,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",8,8,6.51,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",17,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,8,-1,,-1,,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",2,2,3.16,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",17,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,8,-1,,-1,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,5,1.8,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",17,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,8,-1,,-1,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,8,5,2.88,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",17,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,8,-1,,-1,,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,2,1,0.59,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",18,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,10,-1,,-1,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,10,5.77,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",18,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,10,-1,,-1,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",7,7,6.99,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",18,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,10,-1,,-1,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,6,3.48,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",18,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,10,-1,,-1,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,7,7,4.61,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",19,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,0,,,,,,,,,,,51,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,9,3.63,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",19,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,0,,,,,,,,,,,56,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,3,1.1,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",19,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,0,,,,,,,,,,,59,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,3,1.08,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",19,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,0,,,,,,,,,,,51,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,1,0.26,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",20,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,2,-1,,-1,,,,,,,,51,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,6,3.05,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",20,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,2,-1,,-1,,,,,,,,53,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,1,0.36,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",20,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,2,-1,,-1,,,,,,,,56,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,2,0.92,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",20,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,2,-1,,-1,,,,,,,,59,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,3,1,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",20,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,2,-1,,-1,,,,,,,,51,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,3,1.42,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",21,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,10,-1,,-1,,,,,,,,51,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,10,6.99,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",21,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",49,10,-1,,-1,,,,,,,,51,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,10,5.47,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",22,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,2,-1,,-1,,,,,,,,72,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,8,3.26,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",22,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,2,-1,,-1,,,,,,,,74,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,8,2.91,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",22,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,2,-1,,-1,,,,,,,,77,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,3,1.01,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",22,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,2,-1,,-1,,,,,,,,80,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,1,0.01,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",22,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5; cryopreserved cell-associated vectored vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,2,-1,,-1,,,,,,,,77,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,1,0.24,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",23,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,1,-1,,-1,,,,,,,,72,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,4,2.14,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",23,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,1,-1,,-1,,,,,,,,74,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",9,8,3.69,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",23,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,1,-1,,-1,,,,,,,,77,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",6,5,2.62,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",23,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,1,-1,,-1,,,,,,,,80,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",9,1,0.03,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",23,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,1,-1,,-1,,,,,,,,72,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,1,0.56,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",23,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryopreserved cell-associated vectored vaccine) along with rHVT-F ND vaccine","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,1,-1,,-1,,,,,,,,74,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,9,7,2.54,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",24,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,10,-1,,-1,,,,,,,,72,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",9,8,6.57,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",24,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,10,-1,,-1,,,,,,,,74,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",1,1,7.27,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",24,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,10,-1,,-1,,,,,,,,72,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,9,8,5.15,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50305,"Rauw, F., Ngabirano, E., Gardin, Y., Palya, V., Lambrecht, B. (2020).  Effectiveness of a simultaneous rHVT-F(ND) and rHVT-H5(AI) vaccination of day-old chickens and the influence of NDV-and AIV-specific MDA on immune response and conferred protection Vaccines, 8(3),  1",seungeun.han,,4,,Belgium,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/1709-6/2008, H5N1 clade 2.2.1",24,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",70,10,-1,,-1,,,,,,,,74,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,1,1,6.4,"Other: specify","log10 EID50/ml",,,"Only protection % (survival 5) was given, min/max or mean mortality day were not provided. Animals in studyID 2, 5, 8, 11, 14, 17, 20, 23 were vaccinated with both AI vaccine and ND vaccine. Animals in studyID 7, 8, 9, 10, 11, 12, 13, 14, 15 were AIV specific MDA (-) at the vaccination. Animals in studyID 16, 17, 18, 19, 20, 21, 22, 23, 24 were AIV specific MDA (+) at the vaccination."
50318,"Nassif, S., Zaki, F., Mourad, A., Fouad, E., Saad, A., Setta, A., Felföldi, B., Mató, T., Kiss, I., Palya, V. (2020).  Herpesvirus of turkey vectored avian influenza vaccine offers cross-protection against antigenically drifted H5Nx highly pathogenic avian influenza virus strains Avian Pathology, #volume#(#issue#),  547",seungeun.han,,4,,Egypt,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/173CAL/2017, H5N1 clade 2.2.1.2",1,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-H5; cyropreserved cell-associated","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"commercial dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,2,5,days,7,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","A Ct value of 35 was selected as the cut-off. Quantification of virus loads (titer) in the swabs was done relative to a standard curve.","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,6,2.1,"Other: specify","log10 EID50/ml",,,
50318,"Nassif, S., Zaki, F., Mourad, A., Fouad, E., Saad, A., Setta, A., Felföldi, B., Mató, T., Kiss, I., Palya, V. (2020).  Herpesvirus of turkey vectored avian influenza vaccine offers cross-protection against antigenically drifted H5Nx highly pathogenic avian influenza virus strains Avian Pathology, #volume#(#issue#),  547",seungeun.han,,4,,Egypt,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/173CAL/2017, H5N1 clade 2.2.1.2",1,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-H5; cyropreserved cell-associated","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"commercial dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,2,5,days,7,days,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)","A Ct value of 35 was selected as the cut-off. Quantification of virus loads (titer) in the swabs was done relative to a standard curve.","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,4,1.1,"Other: specify","log10 EID50/ml",,,
50318,"Nassif, S., Zaki, F., Mourad, A., Fouad, E., Saad, A., Setta, A., Felföldi, B., Mató, T., Kiss, I., Palya, V. (2020).  Herpesvirus of turkey vectored avian influenza vaccine offers cross-protection against antigenically drifted H5Nx highly pathogenic avian influenza virus strains Avian Pathology, #volume#(#issue#),  547",seungeun.han,,4,,Egypt,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/173CAL/2017, H5N1 clade 2.2.1.2",1,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-H5; cyropreserved cell-associated","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"commercial dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,2,5,days,7,days,,,,,,,38,"After challenge","Reverse-transcription PCR (RT-PCR)","A Ct value of 35 was selected as the cut-off. Quantification of virus loads (titer) in the swabs was done relative to a standard curve.","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,2,0.4,"Other: specify","log10 EID50/ml",,,
50318,"Nassif, S., Zaki, F., Mourad, A., Fouad, E., Saad, A., Setta, A., Felföldi, B., Mató, T., Kiss, I., Palya, V. (2020).  Herpesvirus of turkey vectored avian influenza vaccine offers cross-protection against antigenically drifted H5Nx highly pathogenic avian influenza virus strains Avian Pathology, #volume#(#issue#),  547",seungeun.han,,4,,Egypt,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/173CAL/2017, H5N1 clade 2.2.1.2",2,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,20,2,days,4,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","A Ct value of 35 was selected as the cut-off. Quantification of virus loads (titer) in the swabs was done relative to a standard curve.","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,5.9,"Other: specify","log10 EID50/ml",,,
50318,"Nassif, S., Zaki, F., Mourad, A., Fouad, E., Saad, A., Setta, A., Felföldi, B., Mató, T., Kiss, I., Palya, V. (2020).  Herpesvirus of turkey vectored avian influenza vaccine offers cross-protection against antigenically drifted H5Nx highly pathogenic avian influenza virus strains Avian Pathology, #volume#(#issue#),  547",seungeun.han,,4,,Egypt,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Egypt/VG1099/2018, H5N2 clade 2.3.4.4",3,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-H5; cyropreserved cell-associated","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"commercial dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,2,9,days,10,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","A Ct value of 35 was selected as the cut-off. Quantification of virus loads (titer) in the swabs was done relative to a standard curve.","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,7,2.52,"Other: specify","log10 EID50/ml",,,
50318,"Nassif, S., Zaki, F., Mourad, A., Fouad, E., Saad, A., Setta, A., Felföldi, B., Mató, T., Kiss, I., Palya, V. (2020).  Herpesvirus of turkey vectored avian influenza vaccine offers cross-protection against antigenically drifted H5Nx highly pathogenic avian influenza virus strains Avian Pathology, #volume#(#issue#),  547",seungeun.han,,4,,Egypt,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Egypt/VG1099/2018, H5N2 clade 2.3.4.4",3,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-H5; cyropreserved cell-associated","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"commercial dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,2,9,days,10,days,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)","A Ct value of 35 was selected as the cut-off. Quantification of virus loads (titer) in the swabs was done relative to a standard curve.","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,4,0.96,"Other: specify","log10 EID50/ml",,,
50318,"Nassif, S., Zaki, F., Mourad, A., Fouad, E., Saad, A., Setta, A., Felföldi, B., Mató, T., Kiss, I., Palya, V. (2020).  Herpesvirus of turkey vectored avian influenza vaccine offers cross-protection against antigenically drifted H5Nx highly pathogenic avian influenza virus strains Avian Pathology, #volume#(#issue#),  547",seungeun.han,,4,,Egypt,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Egypt/VG1099/2018, H5N2 clade 2.3.4.4",3,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-H5; cyropreserved cell-associated","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"commercial dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,2,9,days,10,days,,,,,,,38,"After challenge","Reverse-transcription PCR (RT-PCR)","A Ct value of 35 was selected as the cut-off. Quantification of virus loads (titer) in the swabs was done relative to a standard curve.","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,2,0.4,"Other: specify","log10 EID50/ml",,,
50318,"Nassif, S., Zaki, F., Mourad, A., Fouad, E., Saad, A., Setta, A., Felföldi, B., Mató, T., Kiss, I., Palya, V. (2020).  Herpesvirus of turkey vectored avian influenza vaccine offers cross-protection against antigenically drifted H5Nx highly pathogenic avian influenza virus strains Avian Pathology, #volume#(#issue#),  547",seungeun.han,,4,,Egypt,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Egypt/VG1099/2018, H5N2 clade 2.3.4.4",4,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,20,3,days,4,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","A Ct value of 35 was selected as the cut-off. Quantification of virus loads (titer) in the swabs was done relative to a standard curve.","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,5.8,"Other: specify","log10 EID50/ml",,,
50318,"Nassif, S., Zaki, F., Mourad, A., Fouad, E., Saad, A., Setta, A., Felföldi, B., Mató, T., Kiss, I., Palya, V. (2020).  Herpesvirus of turkey vectored avian influenza vaccine offers cross-protection against antigenically drifted H5Nx highly pathogenic avian influenza virus strains Avian Pathology, #volume#(#issue#),  547",seungeun.han,,4,,Egypt,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/FL6/2018, H5N8 clade 2.3.4.4",5,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-H5; cyropreserved cell-associated","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"commercial dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,4,5,days,8,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","A Ct value of 35 was selected as the cut-off. Quantification of virus loads (titer) in the swabs was done relative to a standard curve.","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,8,2.99,"Other: specify","log10 EID50/ml",,,
50318,"Nassif, S., Zaki, F., Mourad, A., Fouad, E., Saad, A., Setta, A., Felföldi, B., Mató, T., Kiss, I., Palya, V. (2020).  Herpesvirus of turkey vectored avian influenza vaccine offers cross-protection against antigenically drifted H5Nx highly pathogenic avian influenza virus strains Avian Pathology, #volume#(#issue#),  547",seungeun.han,,4,,Egypt,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/FL6/2018, H5N8 clade 2.3.4.4",5,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-H5; cyropreserved cell-associated","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"commercial dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,4,5,days,8,days,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)","A Ct value of 35 was selected as the cut-off. Quantification of virus loads (titer) in the swabs was done relative to a standard curve.","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,4,1.04,"Other: specify","log10 EID50/ml",,,
50318,"Nassif, S., Zaki, F., Mourad, A., Fouad, E., Saad, A., Setta, A., Felföldi, B., Mató, T., Kiss, I., Palya, V. (2020).  Herpesvirus of turkey vectored avian influenza vaccine offers cross-protection against antigenically drifted H5Nx highly pathogenic avian influenza virus strains Avian Pathology, #volume#(#issue#),  547",seungeun.han,,4,,Egypt,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/FL6/2018, H5N8 clade 2.3.4.4",5,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-H5; cyropreserved cell-associated","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"commercial dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,4,5,days,8,days,,,,,,,38,"After challenge","Reverse-transcription PCR (RT-PCR)","A Ct value of 35 was selected as the cut-off. Quantification of virus loads (titer) in the swabs was done relative to a standard curve.","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,3,0.65,"Other: specify","log10 EID50/ml",,,
50318,"Nassif, S., Zaki, F., Mourad, A., Fouad, E., Saad, A., Setta, A., Felföldi, B., Mató, T., Kiss, I., Palya, V. (2020).  Herpesvirus of turkey vectored avian influenza vaccine offers cross-protection against antigenically drifted H5Nx highly pathogenic avian influenza virus strains Avian Pathology, #volume#(#issue#),  547",seungeun.han,,4,,Egypt,2020,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/FL6/2018, H5N8 clade 2.3.4.4",6,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,20,2,days,3,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","A Ct value of 35 was selected as the cut-off. Quantification of virus loads (titer) in the swabs was done relative to a standard curve.","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,5.8,"Other: specify","log10 EID50/ml",,,
50324,"Said, M., Soliman, M.A., Mousa, S., Arafa, A., Hussein, H.A., Amarin, N., Mundt, E. (2019).  Efficacy of bivalent inactivated vaccine containing insect cell-expressed avian influenza H5 and egg-based newcastle disease virus (NDV) against dual infection with highly pathogenic H5N1 and Velogenic NDV in Chickens Avian Diseases, 63(3),  474",seungeun.han,,4,,Egypt,2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1575s/2015, H5N1 clade 2.2.1.2",1,"Chickens (Gallus)",,0.33,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"256 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,24,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct value of 40, then the results were experessed as the number of PCR copies/ml","Nucleic acid",,"Other (specify)","tracheal swab",10,3,4.7,"Other: specify","log10 PCR copies",,,"There are 2 more study groups where animals were first challenged with HPAI and then challenged again with ND 3 days later or vice versa.  Data were not collected from those groups."
50324,"Said, M., Soliman, M.A., Mousa, S., Arafa, A., Hussein, H.A., Amarin, N., Mundt, E. (2019).  Efficacy of bivalent inactivated vaccine containing insect cell-expressed avian influenza H5 and egg-based newcastle disease virus (NDV) against dual infection with highly pathogenic H5N1 and Velogenic NDV in Chickens Avian Diseases, 63(3),  474",seungeun.han,,4,,Egypt,2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1575s/2015, H5N1 clade 2.2.1.2",1,"Chickens (Gallus)",,0.33,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"256 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,26,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct value of 40, then the results were experessed as the number of PCR copies/ml","Nucleic acid",,"Other (specify)","tracheal swab",10,3,3.9,"Other: specify","log10 PCR copies",,,"There are 2 more study groups where animals were first challenged with HPAI and then challenged again with ND 3 days later or vice versa.  Data were not collected from those groups."
50324,"Said, M., Soliman, M.A., Mousa, S., Arafa, A., Hussein, H.A., Amarin, N., Mundt, E. (2019).  Efficacy of bivalent inactivated vaccine containing insect cell-expressed avian influenza H5 and egg-based newcastle disease virus (NDV) against dual infection with highly pathogenic H5N1 and Velogenic NDV in Chickens Avian Diseases, 63(3),  474",seungeun.han,,4,,Egypt,2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1575s/2015, H5N1 clade 2.2.1.2",1,"Chickens (Gallus)",,0.33,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"256 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,28,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,10,10,7.6,"Other: specify","log2 titer",,,"There are 2 more study groups where animals were first challenged with HPAI and then challenged again with ND 3 days later or vice versa.  Data were not collected from those groups."
50324,"Said, M., Soliman, M.A., Mousa, S., Arafa, A., Hussein, H.A., Amarin, N., Mundt, E. (2019).  Efficacy of bivalent inactivated vaccine containing insect cell-expressed avian influenza H5 and egg-based newcastle disease virus (NDV) against dual infection with highly pathogenic H5N1 and Velogenic NDV in Chickens Avian Diseases, 63(3),  474",seungeun.han,,4,,Egypt,2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1575s/2015, H5N1 clade 2.2.1.2",1,"Chickens (Gallus)",,0.33,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"256 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,10,10,9.3,"Other: specify","log2 titer",,,"There are 2 more study groups where animals were first challenged with HPAI and then challenged again with ND 3 days later or vice versa.  Data were not collected from those groups."
50324,"Said, M., Soliman, M.A., Mousa, S., Arafa, A., Hussein, H.A., Amarin, N., Mundt, E. (2019).  Efficacy of bivalent inactivated vaccine containing insect cell-expressed avian influenza H5 and egg-based newcastle disease virus (NDV) against dual infection with highly pathogenic H5N1 and Velogenic NDV in Chickens Avian Diseases, 63(3),  474",seungeun.han,,4,,Egypt,2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1575s/2015, H5N1 clade 2.2.1.2",1,"Chickens (Gallus)",,0.33,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"256 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,28,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,10,10,5,"Other: specify","log2 titer",,,"There are 2 more study groups where animals were first challenged with HPAI and then challenged again with ND 3 days later or vice versa.  Data were not collected from those groups."
50324,"Said, M., Soliman, M.A., Mousa, S., Arafa, A., Hussein, H.A., Amarin, N., Mundt, E. (2019).  Efficacy of bivalent inactivated vaccine containing insect cell-expressed avian influenza H5 and egg-based newcastle disease virus (NDV) against dual infection with highly pathogenic H5N1 and Velogenic NDV in Chickens Avian Diseases, 63(3),  474",seungeun.han,,4,,Egypt,2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1575s/2015, H5N1 clade 2.2.1.2",1,"Chickens (Gallus)",,0.33,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"256 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,10,10,5,"Other: specify","log2 titer",,,"There are 2 more study groups where animals were first challenged with HPAI and then challenged again with ND 3 days later or vice versa.  Data were not collected from those groups."
50324,"Said, M., Soliman, M.A., Mousa, S., Arafa, A., Hussein, H.A., Amarin, N., Mundt, E. (2019).  Efficacy of bivalent inactivated vaccine containing insect cell-expressed avian influenza H5 and egg-based newcastle disease virus (NDV) against dual infection with highly pathogenic H5N1 and Velogenic NDV in Chickens Avian Diseases, 63(3),  474",seungeun.han,,4,,Egypt,2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1575s/2015, H5N1 clade 2.2.1.2",2,"Chickens (Gallus)",,0.33,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,10,1,days,3,days,,,,,,,24,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct value of 40, then the results were experessed as the number of PCR copies/ml","Nucleic acid",,"Other (specify)","tracheal swab",10,10,6.5,"Other: specify","log10 PCR copies",,,"There are 2 more study groups where animals were first challenged with HPAI and then challenged again with ND 3 days later or vice versa.  Data were not collected from those groups."
50324,"Said, M., Soliman, M.A., Mousa, S., Arafa, A., Hussein, H.A., Amarin, N., Mundt, E. (2019).  Efficacy of bivalent inactivated vaccine containing insect cell-expressed avian influenza H5 and egg-based newcastle disease virus (NDV) against dual infection with highly pathogenic H5N1 and Velogenic NDV in Chickens Avian Diseases, 63(3),  474",seungeun.han,,4,,Egypt,2019,"Newcastle Disease virus",genotype,,"NDV-B7-RLQP-CH-EG-12, genotype VII",3,"Chickens (Gallus)",,0.33,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"128 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,24,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct value of 40, then the results were experessed as the number of PCR copies/ml","Nucleic acid",,"Other (specify)","tracheal swab",10,3,4.3,"Other: specify","log10 PCR copies",,,"There are 2 more study groups where animals were first challenged with HPAI and then challenged again with ND 3 days later or vice versa.  Data were not collected from those groups."
50324,"Said, M., Soliman, M.A., Mousa, S., Arafa, A., Hussein, H.A., Amarin, N., Mundt, E. (2019).  Efficacy of bivalent inactivated vaccine containing insect cell-expressed avian influenza H5 and egg-based newcastle disease virus (NDV) against dual infection with highly pathogenic H5N1 and Velogenic NDV in Chickens Avian Diseases, 63(3),  474",seungeun.han,,4,,Egypt,2019,"Newcastle Disease virus",genotype,,"NDV-B7-RLQP-CH-EG-12, genotype VII",3,"Chickens (Gallus)",,0.33,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"128 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,26,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct value of 40, then the results were experessed as the number of PCR copies/ml","Nucleic acid",,"Other (specify)","tracheal swab",10,3,3.2,"Other: specify","log10 PCR copies",,,"There are 2 more study groups where animals were first challenged with HPAI and then challenged again with ND 3 days later or vice versa.  Data were not collected from those groups."
50324,"Said, M., Soliman, M.A., Mousa, S., Arafa, A., Hussein, H.A., Amarin, N., Mundt, E. (2019).  Efficacy of bivalent inactivated vaccine containing insect cell-expressed avian influenza H5 and egg-based newcastle disease virus (NDV) against dual infection with highly pathogenic H5N1 and Velogenic NDV in Chickens Avian Diseases, 63(3),  474",seungeun.han,,4,,Egypt,2019,"Newcastle Disease virus",genotype,,"NDV-B7-RLQP-CH-EG-12, genotype VII",3,"Chickens (Gallus)",,0.33,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"128 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,28,"After challenge","Haemagglutination inhibition test (HIT)","Against the reference strain LaSota antigen",Antibody,,"Blood serum (as part-nature)",,10,10,10,"Other: specify","log2 titer",,,"There are 2 more study groups where animals were first challenged with HPAI and then challenged again with ND 3 days later or vice versa.  Data were not collected from those groups."
50324,"Said, M., Soliman, M.A., Mousa, S., Arafa, A., Hussein, H.A., Amarin, N., Mundt, E. (2019).  Efficacy of bivalent inactivated vaccine containing insect cell-expressed avian influenza H5 and egg-based newcastle disease virus (NDV) against dual infection with highly pathogenic H5N1 and Velogenic NDV in Chickens Avian Diseases, 63(3),  474",seungeun.han,,4,,Egypt,2019,"Newcastle Disease virus",genotype,,"NDV-B7-RLQP-CH-EG-12, genotype VII",3,"Chickens (Gallus)",,0.33,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"128 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against the reference strain LaSota antigen",Antibody,,"Blood serum (as part-nature)",,10,10,10,"Other: specify","log2 titer",,,"There are 2 more study groups where animals were first challenged with HPAI and then challenged again with ND 3 days later or vice versa.  Data were not collected from those groups."
50324,"Said, M., Soliman, M.A., Mousa, S., Arafa, A., Hussein, H.A., Amarin, N., Mundt, E. (2019).  Efficacy of bivalent inactivated vaccine containing insect cell-expressed avian influenza H5 and egg-based newcastle disease virus (NDV) against dual infection with highly pathogenic H5N1 and Velogenic NDV in Chickens Avian Diseases, 63(3),  474",seungeun.han,,4,,Egypt,2019,"Newcastle Disease virus",genotype,,"NDV-B7-RLQP-CH-EG-12, genotype VII",4,"Chickens (Gallus)",,0.33,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,10,3,days,7,days,,,,,,,24,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct value of 40, then the results were experessed as the number of PCR copies/ml","Nucleic acid",,"Other (specify)","tracheal swab",10,10,5.7,"Other: specify","log10 PCR copies",,,"There are 2 more study groups where animals were first challenged with HPAI and then challenged again with ND 3 days later or vice versa.  Data were not collected from those groups."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",1,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 functional particles/0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",42,0,,,,,,,,,,,44,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",25,23,2.2,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",1,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 functional particles/0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",42,0,,,,,,,,,,,46,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",25,21,1.8,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",1,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 functional particles/0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",42,0,,,,,,,,,,,49,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",25,5,1.5,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",1,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 functional particles/0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",42,0,,,,,,,,,,,44,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,25,2,1.2,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",1,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 functional particles/0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",42,0,,,,,,,,,,,46,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,25,9,1.4,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",2,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",42,25,2,days,3,days,,,,,,,44,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",25,25,6,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",2,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",42,25,2,days,3,days,,,,,,,44,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,25,25,3.5,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",3,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 functional particles/0.5ml dose",42,"10^7 functional particles/0.5ml dose",,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",119,0,,,,,,,,,,,121,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",25,10,1.8,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",3,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 functional particles/0.5ml dose",42,"10^7 functional particles/0.5ml dose",,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",119,0,,,,,,,,,,,123,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",25,9,1.8,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",3,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 functional particles/0.5ml dose",42,"10^7 functional particles/0.5ml dose",,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",119,0,,,,,,,,,,,126,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",25,8,1.4,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",3,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 functional particles/0.5ml dose",42,"10^7 functional particles/0.5ml dose",,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",119,0,,,,,,,,,,,121,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,25,1,1.2,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",3,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 functional particles/0.5ml dose",42,"10^7 functional particles/0.5ml dose",,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",119,0,,,,,,,,,,,123,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,25,4,1.4,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",3,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 functional particles/0.5ml dose",42,"10^7 functional particles/0.5ml dose",,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",119,0,,,,,,,,,,,126,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,25,3,1.2,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",4,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",119,25,3,days,4,days,,,,,,,121,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",25,25,4,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",4,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",119,25,3,days,4,days,,,,,,,123,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",7,7,5.2,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",4,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",119,25,3,days,4,days,,,,,,,121,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,25,25,3.2,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",4,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",119,25,3,days,4,days,,,,,,,123,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,7,7,3.4,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",5,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 functional particles/0.5ml dose",42,"10^7 functional particles/0.5ml dose",119,"10^7 functional particles/0.5ml dose","Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",245,0,,,,,,,,,,,247,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",25,5,1.2,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",5,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 functional particles/0.5ml dose",42,"10^7 functional particles/0.5ml dose",119,"10^7 functional particles/0.5ml dose","Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",245,0,,,,,,,,,,,249,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",25,6,1.2,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",5,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 functional particles/0.5ml dose",42,"10^7 functional particles/0.5ml dose",119,"10^7 functional particles/0.5ml dose","Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",245,0,,,,,,,,,,,252,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",25,2,1.2,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",5,"Chickens (Gallus)",,0.25,animal,,25,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7 functional particles/0.5ml dose",42,"10^7 functional particles/0.5ml dose",119,"10^7 functional particles/0.5ml dose","Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",245,0,,,,,,,,,,,252,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,25,1,1.2,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",6,"Chickens (Gallus)",,0.25,animal,,24,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",245,24,2,days,4,,,,,,,,247,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",24,24,4.8,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",6,"Chickens (Gallus)",,0.25,animal,,24,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",245,24,2,days,4,,,,,,,,249,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",4,3,3.8,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",6,"Chickens (Gallus)",,0.25,animal,,24,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",245,24,2,days,4,,,,,,,,247,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,24,24,3.7,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50327,"Ladman, B.S., Gelb, J., Jr., Sauble, L.A., Murphy, M.V., Spackman, E. (2019).  Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination Avian Pathology, 48(4),  371",seungeun.han,,4,,"United States",2019,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/MN/12582/2015, H5N2 clade 2.3.4.4",6,"Chickens (Gallus)",,0.25,animal,,24,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intrachoanal,,"10^6 EID50",245,24,2,days,4,,,,,,,,249,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,4,4,2.8,"Other: specify","log10 EID50/0.1 ml",,,"The results of RT-PCR test were presented by visual graphs, so the result values of RT-PCR were visually estimated to report on Question 45 test Value."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,1,-1,,-1,,,,,,,,10,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3.5,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,1,-1,,-1,,,,,,,,17,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3.33,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,1,-1,,-1,,,,,,,,31,"Challenge day","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,4,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,1,-1,,-1,,,,,,,,38,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,4.28,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,1,-1,,-1,,,,,,,,34,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.5 EID50/ml","Nucleic acid",,"Other (specify)","tracheal swab",10,5,0.9,"Other: specify","log10 EID50/ml",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,1,-1,,-1,,,,,,,,36,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.5 EID50/ml","Nucleic acid",,"Other (specify)","tracheal swab",9,2,1.84,"Other: specify","log10 EID50/ml",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,4,-1,,-1,,,,,,,,10,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3.5,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,4,-1,,-1,,,,,,,,17,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3.3,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,4,-1,,-1,,,,,,,,24,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,0,0,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,4,-1,,-1,,,,,,,,36,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.5 EID50/ml","Nucleic acid",,"Other (specify)","tracheal swab",10,10,2.51,"Other: specify","log10 EID50/ml",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,4,-1,,-1,,,,,,,,38,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.5 EID50/ml","Nucleic acid",,"Other (specify)","tracheal swab",7,7,1.46,"Other: specify","log10 EID50/ml",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,4,-1,,-1,,,,,,,,34,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.5 EID50/ml","Nucleic acid",,"Other (specify)","tracheal swab",10,10,1.86,"Other: specify","log10 EID50/ml",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",3,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,0,,,,,,,,,,,10,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3.5,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",3,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,0,,,,,,,,,,,17,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3.25,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",3,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,0,,,,,,,,,,,31,"Challenge day","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,4.4,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",3,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,0,,,,,,,,,,,38,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,5.71,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",4,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,SUBCUTANEOUS,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,0,,,,,,,,,,,10,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3.5,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",4,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,SUBCUTANEOUS,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,0,,,,,,,,,,,17,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",4,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,SUBCUTANEOUS,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,0,,,,,,,,,,,24,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,0,0,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",4,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,SUBCUTANEOUS,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,0,,,,,,,,,,,34,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.5 EID50/ml","Nucleic acid",,"Other (specify)","tracheal swab",10,10,1.1,"Other: specify","log10 EID50/ml",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",4,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,SUBCUTANEOUS,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,0,,,,,,,,,,,36,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.5 EID50/ml","Nucleic acid",,"Other (specify)","tracheal swab",10,10,1.35,"Other: specify","log10 EID50/ml",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",4,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,SUBCUTANEOUS,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,0,,,,,,,,,,,38,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.5 EID50/ml","Nucleic acid",,"Other (specify)","tracheal swab",7,7,2.85,"Other: specify","log10 EID50/ml",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",28,"128 HA units of 0.5ml dose",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,0,,,,,,,,,,,10,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3.5,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",28,"128 HA units of 0.5ml dose",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,0,,,,,,,,,,,17,"Between vaccination doses","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3.33,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",28,"128 HA units of 0.5ml dose",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,0,,,,,,,,,,,31,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,4.2,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",28,"128 HA units of 0.5ml dose",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,0,,,,,,,,,,,49,"Challenge day","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,4.3,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",28,"128 HA units of 0.5ml dose",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,0,,,,,,,,,,,56,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,5.77,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",6,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,6,-1,,-1,,,,,,,,10,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3.5,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",6,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,6,-1,,-1,,,,,,,,17,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3.2,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",6,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,6,-1,,-1,,,,,,,,24,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,0,0,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",6,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,6,-1,,-1,,,,,,,,52,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.5 EID50/ml","Nucleic acid",,"Other (specify)","tracheal swab",10,10,1.46,"Other: specify","log10 EID50/ml",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",6,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,6,-1,,-1,,,,,,,,54,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.5 EID50/ml","Nucleic acid",,"Other (specify)","tracheal swab",7,7,2.43,"Other: specify","log10 EID50/ml",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",6,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,6,-1,,-1,,,,,,,,56,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.5 EID50/ml","Nucleic acid",,"Other (specify)","tracheal swab",7,7,2.21,"Other: specify","log10 EID50/ml",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",7,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",28,"128 HA units of 0.5ml dose",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,0,,,,,,,,,,,10,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3.5,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",7,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",28,"128 HA units of 0.5ml dose",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,0,,,,,,,,,,,17,"Between vaccination doses","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3.25,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",7,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",28,"128 HA units of 0.5ml dose",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,0,,,,,,,,,,,31,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,5,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",7,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",28,"128 HA units of 0.5ml dose",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,0,,,,,,,,,,,49,"Challenge day","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,4.9,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",7,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Volvac B.E.S.T AI+ND",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"128 HA units of 0.5ml dose",28,"128 HA units of 0.5ml dose",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,0,,,,,,,,,,,56,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,7.2,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",8,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,4,-1,,-1,,,,,,,,10,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3.5,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",8,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,4,-1,,-1,,,,,,,,17,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",8,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,4,-1,,-1,,,,,,,,24,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,0,0,"Other: specify","log2 titer",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",8,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,4,-1,,-1,,,,,,,,52,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.5 EID50/ml","Nucleic acid",,"Other (specify)","tracheal swab",10,10,1.46,"Other: specify","log10 EID50/ml",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",8,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,4,-1,,-1,,,,,,,,54,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.5 EID50/ml","Nucleic acid",,"Other (specify)","tracheal swab",10,10,2.36,"Other: specify","log10 EID50/ml",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50331,"Sultan, H.A., Arafa, A.-E., Talaat, S., Gaballa, A.A., Kilany, W.H., Elfeil, W.K., Shehata, A.A., Amarin, N. (2019).  Efficacy of Clade 2.3.2 H5-Recombinant Baculovirus Vaccine in Protecting Muscovy and Pekin Ducks from Clade 2.3.4.4 H5N8 Highly Pathogenic Avian Influenza Infection Avian diseases, 63(sp1),  219",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Common-coot/Egypt/CA285/2016, H5N8 clade 2.3.4.4b",8,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",49,4,-1,,-1,,,,,,,,56,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 0.5 EID50/ml","Nucleic acid",,"Other (specify)","tracheal swab",7,7,2.21,"Other: specify","log10 EID50/ml",,,"Animals had maternal antibodies (MDA) against H5 AI when they were vaccinated. Only protection % (survival %) was given, min/max or mean mortality days were not provided. The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. Ducks in studyID 1, 2, 5, 6 were Muscovy. Ducks in studyID 3, 4, 7, 8 were Pekin ducks."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,SirraVax,,"Other (specify):","Recombinant alphavirus replicon-based vaccine",SUBCUTANEOUS,,2,"10^7 particles/0.2ml dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,7,"Other: specify","log2 titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,SirraVax,,"Other (specify):","Recombinant alphavirus replicon-based vaccine",SUBCUTANEOUS,,2,"10^7 particles/0.2ml dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,3,4.8,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,SirraVax,,"Other (specify):","Recombinant alphavirus replicon-based vaccine",SUBCUTANEOUS,,2,"10^7 particles/0.2ml dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,37,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,5,3.3,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,SirraVax,,"Other (specify):","Recombinant alphavirus replicon-based vaccine",SUBCUTANEOUS,,2,"10^7 particles/0.2ml dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,39,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,4,3.1,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,SirraVax,,"Other (specify):","Recombinant alphavirus replicon-based vaccine",SUBCUTANEOUS,,2,"10^7 particles/0.2ml dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,1,2.7,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,SirraVax,,"Other (specify):","Recombinant alphavirus replicon-based vaccine",SUBCUTANEOUS,,2,"10^7 particles/0.2ml dose",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,37,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,3,2.2,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Other: specify","A/gyrfalcon/Washington/41088/2014 (H5N8)","Other (specify):","Recombinant inactivated",SUBCUTANEOUS,,2,"512 HAU",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,9,5.5,"Other: specify","log2 titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Other: specify","A/gyrfalcon/Washington/41088/2014 (H5N8)","Other (specify):","Recombinant inactivated",SUBCUTANEOUS,,2,"512 HAU",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",8,2,4.4,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Other: specify","A/gyrfalcon/Washington/41088/2014 (H5N8)","Other (specify):","Recombinant inactivated",SUBCUTANEOUS,,2,"512 HAU",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,37,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,3,2.8,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Other: specify","A/gyrfalcon/Washington/41088/2014 (H5N8)","Other (specify):","Recombinant inactivated",SUBCUTANEOUS,,2,"512 HAU",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,39,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,1,2.6,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Other: specify","A/gyrfalcon/Washington/41088/2014 (H5N8)","Other (specify):","Recombinant inactivated",SUBCUTANEOUS,,2,"512 HAU",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,42,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,1,2.8,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Other: specify","A/gyrfalcon/Washington/41088/2014 (H5N8)","Other (specify):","Recombinant inactivated",SUBCUTANEOUS,,2,"512 HAU",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,37,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,2,2.6,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",3,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,SirraVax,,"Other (specify):","Recombinant alphavirus replicon-based vaccine",SUBCUTANEOUS,,2,"10^7 particles/0.2ml dose",15,"10^7 particles/0.2ml dose",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,32,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,8,5,"Other: specify","log2 titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",3,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,SirraVax,,"Other (specify):","Recombinant alphavirus replicon-based vaccine",SUBCUTANEOUS,,2,"10^7 particles/0.2ml dose",15,"10^7 particles/0.2ml dose",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,8,5.5,"Other: specify","log2 titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",3,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,SirraVax,,"Other (specify):","Recombinant alphavirus replicon-based vaccine",SUBCUTANEOUS,,2,"10^7 particles/0.2ml dose",15,"10^7 particles/0.2ml dose",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,1,2.3,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",3,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,SirraVax,,"Other (specify):","Recombinant alphavirus replicon-based vaccine",SUBCUTANEOUS,,2,"10^7 particles/0.2ml dose",15,"10^7 particles/0.2ml dose",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,39,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,1,3.4,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",3,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,SirraVax,,"Other (specify):","Recombinant alphavirus replicon-based vaccine",SUBCUTANEOUS,,2,"10^7 particles/0.2ml dose",15,"10^7 particles/0.2ml dose",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,1,2.3,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",4,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Other: specify","A/gyrfalcon/Washington/41088/2014 (H5N8)","Other (specify):","Recombinant inactivated",SUBCUTANEOUS,,2,"512 HAU",15,"512 HAU",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,32,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,5,4,"Other: specify","log2 titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",4,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Other: specify","A/gyrfalcon/Washington/41088/2014 (H5N8)","Other (specify):","Recombinant inactivated",SUBCUTANEOUS,,2,"512 HAU",15,"512 HAU",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,0,,,,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,9,6,4.5,"Other: specify","log2 titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,1,4,days,4,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,9,4,4.5,"Other: specify","log2 titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,1,4,days,4,days,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,5.8,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,1,4,days,4,days,,,,,,,37,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",9,7,4.3,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,1,4,days,4,days,,,,,,,39,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",9,9,3.1,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,1,4,days,4,days,,,,,,,42,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",9,9,3.4,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,1,4,days,4,days,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,8,3.6,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,1,4,days,4,days,,,,,,,37,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,9,6,3.6,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,1,4,days,4,days,,,,,,,39,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,9,3,3.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50335,"Pantin-Jackwood, M.J., DeJesus, E., Costa-Hurtado, M., Smith, D., Chrzastek, K., Kapczynski, D.R., Suarez, D.L. (2019).  Efficacy of Two Licensed Avian Influenza H5 Vaccines Against Challenge with a 2015 U.S. H5N2 clade 2.3.4.4 Highly Pathogenic Avian Influenza Virus in Domestic Ducks Avian diseases, 63(1),  90",seungeun.han,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",32,1,4,days,4,days,,,,,,,42,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit was 2 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,9,3,2.8,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50344,"Bakeer, A.M., Khattab, M.S., Aly, M.M., Arafa, A.-S., Amer, F., Hafez, H.M., Afify, M.M.H. (2019).  Estimation of pathological and molecular findings in vaccinated and non-vaccinated chickens challenged with highly pathogenic avian influenza H5N1 virus Pakistan Veterinary Journal, 39(1),  31",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128S/2012, H5N1, clade 2.2.1",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,1,2,days,2,days,,,,,,,33,"After challenge","Reverse-transcription PCR (RT-PCR)","Not provided","Nucleic acid",,"Other (specify)","organ tissue (not spedified)",1,1,"1.7 x 10^5","Not reported",,,,"Antibody test was not conducted. Virus was not detected from any swab samples from vaccinated animals. Interpretation of RT-PCR results was not described in detail."
50344,"Bakeer, A.M., Khattab, M.S., Aly, M.M., Arafa, A.-S., Amer, F., Hafez, H.M., Afify, M.M.H. (2019).  Estimation of pathological and molecular findings in vaccinated and non-vaccinated chickens challenged with highly pathogenic avian influenza H5N1 virus Pakistan Veterinary Journal, 39(1),  31",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128S/2012, H5N1, clade 2.2.1",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,10,-1,,2,days,,,,,,,33,"After challenge","Reverse-transcription PCR (RT-PCR)","Not provided","Nucleic acid",,"Other (specify)","lung tissue",7,7,4391.428,titer,,,,"Antibody test was not conducted. Virus was not detected from any swab samples from vaccinated animals. Interpretation of RT-PCR results was not described in detail."
50344,"Bakeer, A.M., Khattab, M.S., Aly, M.M., Arafa, A.-S., Amer, F., Hafez, H.M., Afify, M.M.H. (2019).  Estimation of pathological and molecular findings in vaccinated and non-vaccinated chickens challenged with highly pathogenic avian influenza H5N1 virus Pakistan Veterinary Journal, 39(1),  31",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128S/2012, H5N1, clade 2.2.1",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,10,-1,,2,days,,,,,,,33,"After challenge","Reverse-transcription PCR (RT-PCR)","Not provided","Nucleic acid",,"Other (specify)","spleen tissue",7,7,948.571,titer,,,,"Antibody test was not conducted. Virus was not detected from any swab samples from vaccinated animals. Interpretation of RT-PCR results was not described in detail."
50344,"Bakeer, A.M., Khattab, M.S., Aly, M.M., Arafa, A.-S., Amer, F., Hafez, H.M., Afify, M.M.H. (2019).  Estimation of pathological and molecular findings in vaccinated and non-vaccinated chickens challenged with highly pathogenic avian influenza H5N1 virus Pakistan Veterinary Journal, 39(1),  31",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128S/2012, H5N1, clade 2.2.1",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,10,-1,,2,days,,,,,,,33,"After challenge","Reverse-transcription PCR (RT-PCR)","Not provided","Nucleic acid",,"Other (specify)","Bursa Fabricius tissue",7,7,2425.714,titer,,,,"Antibody test was not conducted. Virus was not detected from any swab samples from vaccinated animals. Interpretation of RT-PCR results was not described in detail."
50344,"Bakeer, A.M., Khattab, M.S., Aly, M.M., Arafa, A.-S., Amer, F., Hafez, H.M., Afify, M.M.H. (2019).  Estimation of pathological and molecular findings in vaccinated and non-vaccinated chickens challenged with highly pathogenic avian influenza H5N1 virus Pakistan Veterinary Journal, 39(1),  31",seungeun.han,,4,,Egypt,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128S/2012, H5N1, clade 2.2.1",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",31,10,-1,,2,days,,,,,,,33,"After challenge","Reverse-transcription PCR (RT-PCR)","Not provided","Nucleic acid",,"Brain (as part-nature)",,7,7,347.857,titer,,,,"Antibody test was not conducted. Virus was not detected from any swab samples from vaccinated animals. Interpretation of RT-PCR results was not described in detail."
50347,"Li, J., Hou, G., Wang, Y., Wang, S., Cheng, S., Peng, C., Jiang, W. (2018).  Protective efficacy of an inactivated chimeric H5 avian influenza vaccine against H5 highly pathogenic avian influenza virus clades 2.3.4.4 and 2.3.2.1 Journal of General Virology, 99(12),  1600",seungeun.han,,4,,China,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/China/QH/2017, H5N6 clade 2.3.4.4",1,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"H5 Re-8",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",14,"0.3 ml",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,12,3,days,5,days,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,20,20,3.5,"Other: specify","log2 titier",,,"The results of virus isolation were presented by visual graphs, so the result values of VI were visually estimated to report on Question 45 test Value."
50347,"Li, J., Hou, G., Wang, Y., Wang, S., Cheng, S., Peng, C., Jiang, W. (2018).  Protective efficacy of an inactivated chimeric H5 avian influenza vaccine against H5 highly pathogenic avian influenza virus clades 2.3.4.4 and 2.3.2.1 Journal of General Virology, 99(12),  1600",seungeun.han,,4,,China,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/China/QH/2017, H5N6 clade 2.3.4.4",1,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"H5 Re-8",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",14,"0.3 ml",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,12,3,days,5,days,,,,,,,31,"After challenge","Virus Isolation (VI)","Detection limit was 0.7 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",-1,-1,2.2,"Other: specify","log10 EID50/ml",,,"The results of virus isolation were presented by visual graphs, so the result values of VI were visually estimated to report on Question 45 test Value. The number of animals shedding the virus was not given."
50347,"Li, J., Hou, G., Wang, Y., Wang, S., Cheng, S., Peng, C., Jiang, W. (2018).  Protective efficacy of an inactivated chimeric H5 avian influenza vaccine against H5 highly pathogenic avian influenza virus clades 2.3.4.4 and 2.3.2.1 Journal of General Virology, 99(12),  1600",seungeun.han,,4,,China,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/China/QH/2017, H5N6 clade 2.3.4.4",1,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"H5 Re-8",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",14,"0.3 ml",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,12,3,days,5,days,,,,,,,33,"After challenge","Virus Isolation (VI)","Detection limit was 0.7 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",-1,-1,1.7,"Other: specify","log10 EID50/ml",,,"The results of virus isolation were presented by visual graphs, so the result values of VI were visually estimated to report on Question 45 test Value. The number of animals shedding the virus was not given."
50347,"Li, J., Hou, G., Wang, Y., Wang, S., Cheng, S., Peng, C., Jiang, W. (2018).  Protective efficacy of an inactivated chimeric H5 avian influenza vaccine against H5 highly pathogenic avian influenza virus clades 2.3.4.4 and 2.3.2.1 Journal of General Virology, 99(12),  1600",seungeun.han,,4,,China,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/China/QH/2017, H5N6 clade 2.3.4.4",1,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"H5 Re-8",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",14,"0.3 ml",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,12,3,days,5,days,,,,,,,31,"After challenge","Virus Isolation (VI)","Detection limit was 0.7 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,-1,-1,2.5,"Other: specify","log10 EID50/ml",,,"The results of virus isolation were presented by visual graphs, so the result values of VI were visually estimated to report on Question 45 test Value. The number of animals shedding the virus was not given."
50347,"Li, J., Hou, G., Wang, Y., Wang, S., Cheng, S., Peng, C., Jiang, W. (2018).  Protective efficacy of an inactivated chimeric H5 avian influenza vaccine against H5 highly pathogenic avian influenza virus clades 2.3.4.4 and 2.3.2.1 Journal of General Virology, 99(12),  1600",seungeun.han,,4,,China,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/China/QH/2017, H5N6 clade 2.3.4.4",1,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"H5 Re-8",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",14,"0.3 ml",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,12,3,days,5,days,,,,,,,33,"After challenge","Virus Isolation (VI)","Detection limit was 0.7 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,-1,-1,2,"Other: specify","log10 EID50/ml",,,"The results of virus isolation were presented by visual graphs, so the result values of VI were visually estimated to report on Question 45 test Value. The number of animals shedding the virus was not given."
50347,"Li, J., Hou, G., Wang, Y., Wang, S., Cheng, S., Peng, C., Jiang, W. (2018).  Protective efficacy of an inactivated chimeric H5 avian influenza vaccine against H5 highly pathogenic avian influenza virus clades 2.3.4.4 and 2.3.2.1 Journal of General Virology, 99(12),  1600",seungeun.han,,4,,China,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/China/QH/2017, H5N6 clade 2.3.4.4",2,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,20,2,days,5,days,,,,,,,31,"After challenge","Virus Isolation (VI)","Detection limit was 0.7 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",-1,-1,3.4,"Other: specify","log10 EID50/ml",,,"The results of virus isolation were presented by visual graphs, so the result values of VI were visually estimated to report on Question 45 test Value. The number of animals shedding the virus was not given."
50347,"Li, J., Hou, G., Wang, Y., Wang, S., Cheng, S., Peng, C., Jiang, W. (2018).  Protective efficacy of an inactivated chimeric H5 avian influenza vaccine against H5 highly pathogenic avian influenza virus clades 2.3.4.4 and 2.3.2.1 Journal of General Virology, 99(12),  1600",seungeun.han,,4,,China,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/China/QH/2017, H5N6 clade 2.3.4.4",2,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,20,2,days,5,days,,,,,,,31,"After challenge","Virus Isolation (VI)","Detection limit was 0.7 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,-1,-1,3.4,"Other: specify","log10 EID50/ml",,,"The results of virus isolation were presented by visual graphs, so the result values of VI were visually estimated to report on Question 45 test Value. The number of animals shedding the virus was not given."
50347,"Li, J., Hou, G., Wang, Y., Wang, S., Cheng, S., Peng, C., Jiang, W. (2018).  Protective efficacy of an inactivated chimeric H5 avian influenza vaccine against H5 highly pathogenic avian influenza virus clades 2.3.4.4 and 2.3.2.1 Journal of General Virology, 99(12),  1600",seungeun.han,,4,,China,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/China/KJ/2017, H5N1 clade 2.3.2.1",3,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"H5 Re-8",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",14,"0.3 ml",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,20,2,days,5,days,,,,,,,31,"After challenge","Virus Isolation (VI)","Detection limit was 0.7 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",-1,-1,3.4,"Other: specify","log10 EID50/ml",,,"The results of virus isolation were presented by visual graphs, so the result values of VI were visually estimated to report on Question 45 test Value. The number of animals shedding the virus was not given."
50347,"Li, J., Hou, G., Wang, Y., Wang, S., Cheng, S., Peng, C., Jiang, W. (2018).  Protective efficacy of an inactivated chimeric H5 avian influenza vaccine against H5 highly pathogenic avian influenza virus clades 2.3.4.4 and 2.3.2.1 Journal of General Virology, 99(12),  1600",seungeun.han,,4,,China,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/China/KJ/2017, H5N1 clade 2.3.2.1",3,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"H5 Re-8",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",14,"0.3 ml",,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,20,2,days,5,days,,,,,,,31,"After challenge","Virus Isolation (VI)","Detection limit was 0.7 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,-1,-1,3.4,"Other: specify","log10 EID50/ml",,,"The results of virus isolation were presented by visual graphs, so the result values of VI were visually estimated to report on Question 45 test Value. The number of animals shedding the virus was not given."
50347,"Li, J., Hou, G., Wang, Y., Wang, S., Cheng, S., Peng, C., Jiang, W. (2018).  Protective efficacy of an inactivated chimeric H5 avian influenza vaccine against H5 highly pathogenic avian influenza virus clades 2.3.4.4 and 2.3.2.1 Journal of General Virology, 99(12),  1600",seungeun.han,,4,,China,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/China/KJ/2017, H5N1 clade 2.3.2.1",4,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,20,2,days,5,days,,,,,,,31,"After challenge","Virus Isolation (VI)","Detection limit was 0.7 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",-1,-1,3.2,"Other: specify","log10 EID50/ml",,,"The results of virus isolation were presented by visual graphs, so the result values of VI were visually estimated to report on Question 45 test Value. The number of animals shedding the virus was not given."
50347,"Li, J., Hou, G., Wang, Y., Wang, S., Cheng, S., Peng, C., Jiang, W. (2018).  Protective efficacy of an inactivated chimeric H5 avian influenza vaccine against H5 highly pathogenic avian influenza virus clades 2.3.4.4 and 2.3.2.1 Journal of General Virology, 99(12),  1600",seungeun.han,,4,,China,2018,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/China/KJ/2017, H5N1 clade 2.3.2.1",4,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,20,2,days,5,days,,,,,,,31,"After challenge","Virus Isolation (VI)","Detection limit was 0.7 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,-1,-1,3.5,"Other: specify","log10 EID50/ml",,,"The results of virus isolation were presented by visual graphs, so the result values of VI were visually estimated to report on Question 45 test Value. The number of animals shedding the virus was not given."
50368,"Jang, H., Elaish, M., Mahesh, K.C., Abundo, M.C., Ghorbani, A., Ngunjiri, J.M., Lee, C.-W. (2018).  Efficacy and synergy of live-attenuated and inactivated influenza vaccines in young chickens PLoS ONE, 13(4),  #Pages#",e.royall,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Lineage,"H7N3 North American H7 lineage",1,"Chickens (Gallus)",,0.03,animal,,13,SPF,,"Other: specify","A/TK/OR/71 (TK/OR/71) (H7N3)","Other (specify):",Inactivated,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,A/CK/NJ/150383-7/02(CK/NJ/02)(H7N2),"1x10^6 EID50 in 200 ul",14,0,,,,,,,,,,,19,"After challenge","Real-Time PCR (qualitative or quantitative)","One-tube RRT-PCR with Qiagen one-step RT-PCR kit. SmartCycler (Cepheid, Sunnyvale, CA)  a three-step cycling protocol was used for H5 and H7 specific primer sets: 95 °C for 10 s, 54 °C for 30 s, and 72 °C for 10 s for 40 cycles. For quantification, swab samples were run together with known amounts of control viral RNA. Control RNAs were titrated using ECE and RNA extracted from serially diluted viruses (101.0–106.0 EID50/ml). Generated standard curves. Amount of RNA in samples converted into EID50/ml by interpolation.","Nucleic acid",,"Other (specify)",tracheal,7,5,10^3.96,"Other: specify","log base 10 EID50 Equivalent/ml",,,"TK/OR/71 vaccine was delivered at a titre of 2^9 haemagglutinating units with Montanide ISA 70 adjuvant (Seppic, France) (3:7 V/V)"
50368,"Jang, H., Elaish, M., Mahesh, K.C., Abundo, M.C., Ghorbani, A., Ngunjiri, J.M., Lee, C.-W. (2018).  Efficacy and synergy of live-attenuated and inactivated influenza vaccines in young chickens PLoS ONE, 13(4),  #Pages#",e.royall,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Lineage,"H7N3 North American H7 lineage",1,"Chickens (Gallus)",,0.03,animal,,13,SPF,,"Other: specify","A/TK/OR/71 (TK/OR/71) (H7N3)","Other (specify):",Inactivated,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,A/CK/NJ/150383-7/02(CK/NJ/02)(H7N2),"1x10^6 EID50 in 200 ul",14,0,,,,,,,,,,,17,"After challenge","Real-Time PCR (qualitative or quantitative)","One-tube RRT-PCR with Qiagen one-step RT-PCR kit. SmartCycler (Cepheid, Sunnyvale, CA)  a three-step cycling protocol was used for H5 and H7 specific primer sets: 95 °C for 10 s, 54 °C for 30 s, and 72 °C for 10 s for 40 cycles. For quantification, swab samples were run together with known amounts of control viral RNA. Control RNAs were titrated using ECE and RNA extracted from serially diluted viruses (101.0–106.0 EID50/ml). Generated standard curves. Amount of RNA in samples converted into EID50/ml by interpolation.","Nucleic acid",,"Other (specify)",tracheal,6,1,4,"Other: specify","log base 10 EID50 /ml",,,"TK/OR/71 vaccine was delivered at a titre of 2^9 haemagglutinating units with Montanide ISA 70 adjuvant (Seppic, France) (3:7 V/V)"
50368,"Jang, H., Elaish, M., Mahesh, K.C., Abundo, M.C., Ghorbani, A., Ngunjiri, J.M., Lee, C.-W. (2018).  Efficacy and synergy of live-attenuated and inactivated influenza vaccines in young chickens PLoS ONE, 13(4),  #Pages#",e.royall,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Lineage,"H7N3 North American H7 lineage",2,"Chickens (Gallus)",,0.03,animal,,13,SPF,,"Unvaccinated control",,"Other (specify):",,SUBCUTANEOUS,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,A/CK/NJ/150383-7/02(CK/NJ/02)(H7N2),"1x10^6 EID50 in 200 ul",14,0,,,,,,,,,,,17,"After challenge","Real-Time PCR (qualitative or quantitative)","One-tube RRT-PCR with Qiagen one-step RT-PCR kit. SmartCycler (Cepheid, Sunnyvale, CA)  a three-step cycling protocol was used for H5 and H7 specific primer sets: 95 °C for 10 s, 54 °C for 30 s, and 72 °C for 10 s for 40 cycles. For quantification, swab samples were run together with known amounts of control viral RNA. Control RNAs were titrated using ECE and RNA extracted from serially diluted viruses (101.0–106.0 EID50/ml). Generated standard curves. Amount of RNA in samples converted into EID50/ml by interpolation.","Nucleic acid",,"Other (specify)",tracheal,6,5,10^4.69,"Other: specify","EID50 Equivalent/ml",,,"TK/OR/71 vaccine was delivered at a titre of 2^9 haemagglutinating units with Montanide ISA 70 adjuvant (Seppic, France) (3:7 V/V)"
50368,"Jang, H., Elaish, M., Mahesh, K.C., Abundo, M.C., Ghorbani, A., Ngunjiri, J.M., Lee, C.-W. (2018).  Efficacy and synergy of live-attenuated and inactivated influenza vaccines in young chickens PLoS ONE, 13(4),  #Pages#",e.royall,,4,,"United States",2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Lineage,"H7N3 North American H7 lineage",2,"Chickens (Gallus)",,0.03,animal,,13,SPF,,"Unvaccinated control",,"Other (specify):",,SUBCUTANEOUS,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,A/CK/NJ/150383-7/02(CK/NJ/02)(H7N2),"1x10^6 EID50 in 200 ul",14,0,,,,,,,,,,,19,"After challenge","Real-Time PCR (qualitative or quantitative)","One-tube RRT-PCR with Qiagen one-step RT-PCR kit. SmartCycler (Cepheid, Sunnyvale, CA)  a three-step cycling protocol was used for H5 and H7 specific primer sets: 95 °C for 10 s, 54 °C for 30 s, and 72 °C for 10 s for 40 cycles. For quantification, swab samples were run together with known amounts of control viral RNA. Control RNAs were titrated using ECE and RNA extracted from serially diluted viruses (101.0–106.0 EID50/ml). Generated standard curves. Amount of RNA in samples converted into EID50/ml by interpolation.","Nucleic acid",,"Other (specify)",tracheal,7,7,10^6.89,"Other: specify","EID50 Equivalent/ml",,,"TK/OR/71 vaccine was delivered at a titre of 2^9 haemagglutinating units with Montanide ISA 70 adjuvant (Seppic, France) (3:7 V/V)"
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,39,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,3,10^3,titer,,102.1,,"This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,40,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,3,10^3,titer,,102.1,,"This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,42,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",19,0,,titer,,102.1,,"Group 1 are broilers breed Ross 308. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,43,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",19,0,,titer,,102.1,,"Group 1 are broilers breed Ross 308. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,37,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,2,10^3,titer,,102.1,,"This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,38,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",19,0,,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,39,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",19,2,10^4,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,40,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",19,3,10^4.6,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,42,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",14,10,10^5,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,43,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",10,7,10^5.5,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,46,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",3,3,10^4,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",2,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,-1,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,1,days,,,,,,,,,38,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",20,16,10^4.5,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",2,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,-1,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,1,days,,,,,,,,,41,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",7,6,10^6,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",2,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,-1,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,1,days,,,,,,,,,40,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",10,7,10^6,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,50,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",18,0,,titer,,102.1,,"Group 1 are broilers breed Ross 308. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,41,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,2,10^3.5,titer,,102.1,,"Group 1 are broilers breed Ross 308. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,46,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",18,1,10^3,titer,,102.1,,"Group 1 are broilers breed Ross 308. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,38,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,2,10^3.5,titer,,102.1,,"This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,37,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",19,0,,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",2,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,-1,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,1,days,,,,,,,,,42,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",3,3,10^5,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,37,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",19,0,,titer,,,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",1,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,2,5,days,,,,90,,,,,41,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",18,13,10^5,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",2,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,-1,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,1,days,,,,,,,,,37,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",20,0,-1,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",2,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,-1,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,1,days,,,,,,,,,43,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",2,2,10^4,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,39,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,3,10^3.5,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,38,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,0,,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,41,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,0,,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,42,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,0,,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,46,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,0,,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,50,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,0,,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,37,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",20,0,,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,38,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",20,0,,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,41,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",20,0,,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,40,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",20,0,,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",4,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,4,days,,,,,,,,,38,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",20,18,10^4.25,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 4 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",4,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,4,days,,,,,,,,,39,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",20,19,10^4.5,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 4 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",4,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,4,days,,,,,,,,,40,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",20,19,10^5,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 4 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",4,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,4,days,,,,,,,,,41,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",15,15,10^5,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 4 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",4,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,4,days,,,,,,,,,37,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",20,3,10^3,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 4 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,43,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",20,0,,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,46,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",20,0,,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,50,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",20,0,,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",4,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,,,,,,42,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",5,5,10^4,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",4,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,,,,,,43,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",3,3,10^5,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",2,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,-1,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,1,days,,,,,,,,,39,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",18,15,10^6,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,37,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,1,10^4.5,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,39,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,1,10^4,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,40,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,1,10^3,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,43,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,0,,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",4,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,4,days,,,,,,,,,40,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,19,10^6,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 4 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",4,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,4,days,,,,,,,,,39,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",20,19,10^5.5,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 4 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",4,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,4,days,,,,,,,,,38,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",20,17,10^4.5,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 4 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",4,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,4,days,,,,,,,,,37,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,12,10^4,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 4 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",3,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,Live,,SUBCUTANEOUS,,0,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,0,,,,,,90,,,,,37,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","cloacal swab",20,0,,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 3 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",4,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,4,days,,,,,,,,,41,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",15,15,10^6.2,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 4 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",4,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,4,days,,,,,,,,,42,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",5,5,10^5.8,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 4 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",4,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,4,days,,,,,,,,,43,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",3,3,10^4.9,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 4 comprises layer chickens breed Tetra SL. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",2,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,-1,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,1,days,,,,,,,,,37,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,14,10^3.25,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. This paper also included contact groups exposed to infected groups to provide a measure of transmission. Group 2 are broilers breed Ross 308."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",2,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,-1,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,1,days,,,,,,,,,40,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",10,3,10^5.25,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. Group 2 are broilers breed Ross 308. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",2,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,-1,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,1,days,,,,,,,,,41,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",7,6,10^5.5,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml.  Group 2 are broilers breed Ross 308. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",2,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,-1,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,1,days,,,,,,,,,43,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",2,2,10^5.9,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. Group 2 are broilers breed Ross 308. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",2,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,-1,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,1,days,,,,,,,,,42,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",3,3,10^5.75,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. Group 2 are broilers breed Ross 308. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",2,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,-1,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,1,days,,,,,,,,,38,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",20,16,10^4.5,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. Group 2 are broilers breed Ross 308. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50376,"Palya, V., Tatár-Kis, T., Kovács, E.W., Kiss, I., Homonnay, Z., Gardin, Y., Kertész, K., Dán, Á. (2018).  Efficacy of a recombinant Turkey herpesvirus AI (H5) Vaccine in preventing transmission of heterologous highly pathogenic H5N8 Clade 2.3.4.4b challenge virus in commercial broilers and layer pullets Journal of Immunology Research, 2018(#issue#),  #Pages#",e.royall,,4,,Hungary,2018,"HPAI - Highly Pathogenic Avian Influenza","Other: specify",Clade,"A/goose/Hungary/1030/2017 H5N8 HPAIV HA clade 2.3.4.4b",2,"Chickens (Gallus)",,0.03,animal,,20,commercial,,"Unvaccinated control",,,,,,-1,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,H5N8,"10^6 ELD50/0.2 ml",36,20,1,days,,,,,,,,,39,"After challenge","Real-Time PCR (qualitative or quantitative)","Standard curve was established with viral RNA extracted from serial dilution of the titrated challenge virus suspension, and AIV load in ELD50/ml was calculated by extrapolationof Ct values of swab samples to this standard curve. The lowest limit of detection based on the swab samples from chickens was 102.1ELD50/ml.","Nucleic acid",,"Other (specify)","oronasal swab",19,19,10^5.5,titer,,102.1,,"All oronasal or cloaca swab samples which gave specific
signal were considered positive regardless the Ct value.
Standard curve was established with viral RNA extracted
from serial dilution of the titrated challenge virus suspension,
and AIV load in ELD50/ml was calculated by extrapolation
of Ct values of swab samples to this standard curve.
The lowest limit of detection based on the swab samples
from chickens was 102.1ELD50/ml. All negative samples
were included in the calculation of mean with a value of
101.5ELD50/ml. Group 2 are broilers breed Ross 308. This paper also included contact groups exposed to infected groups to provide a measure of transmission."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",28,1,8,days,8,,,,,,,,0,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against vaccine seed virus, titers as log2 GMT; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,0,3,"Other: specify","titer log2 GMT",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",28,1,8,days,8,,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against vaccine seed virus, titers as log2 GMT; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,4.5,"Other: specify","titer log2 GMT",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",28,1,8,days,8,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against vaccine seed virus, titers as log2 GMT; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,9,9,5.8,"Other: specify","titer log2 GMT",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",28,1,8,days,8,,,,,,,,0,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the callenge virus, titers as log2 GMT; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,0,3,"Other: specify","titer log2 GMT",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",28,1,8,days,8,,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the callenge virus, titers as log2 GMT; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,8,3.3,"Other: specify","titer log2 GMT",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",28,1,8,days,8,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the callenge virus, titers as log2 GMT; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,9,9,4.1,"Other: specify","titer log2 GMT",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",28,1,8,days,8,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 1.7 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,4,1.9,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",28,1,8,days,8,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 1.7 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,0,1.7,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",28,1,8,days,8,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 1.7 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,1,1.9,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",28,1,8,days,8,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 1.7 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,0,1.7,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",28,10,2,days,3,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 1.7 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,6.0,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",28,10,2,days,3,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 1.7 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,10,5.5,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",3,"Chickens (Gallus)",,15.25,animal,,20,SPF,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",INTRAMUSCULAR,,0,"10^7.0 RNA particle/bird",,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",21,1,5,days,5,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against vaccine seed virus, titers as log2 GMT; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,20,15,5.6,"Other: specify","titer log2 GMT",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",3,"Chickens (Gallus)",,15.25,animal,,20,SPF,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",INTRAMUSCULAR,,0,"10^7.0 RNA particle/bird",,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",21,1,5,days,5,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against vaccine seed virus, titers as log2 GMT; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,19,19,6.4,"Other: specify","titer log2 GMT",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",3,"Chickens (Gallus)",,15.25,animal,,20,SPF,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",INTRAMUSCULAR,,0,"10^7.0 RNA particle/bird",,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",21,1,5,days,5,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2 GMT; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,19,19,6.9,"Other: specify","titer log2 GMT",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",3,"Chickens (Gallus)",,15.25,animal,,20,SPF,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",INTRAMUSCULAR,,0,"10^7.0 RNA particle/bird",,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",21,1,5,days,5,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 1.7 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",20,16,3.1,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",3,"Chickens (Gallus)",,15.25,animal,,20,SPF,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",INTRAMUSCULAR,,0,"10^7.0 RNA particle/bird",,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",21,1,5,days,5,,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 1.7 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",20,16,3.5,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",4,"Chickens (Gallus)",,15.25,animal,,30,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",21,30,2,days,3,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 1.7 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",30,30,6.4,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50385,"Bertran, K., Balzli, C., Lee, D.-H., Suarez, D.L., Kapczynski, D.R., Swayne, D.E. (2017).  Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus Vaccine, 35(46),  6336",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2",4,"Chickens (Gallus)",,15.25,animal,,30,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",choanal,,"10^6.5 EID50 virus/0.1ml",21,30,2,days,3,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 1.7 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,20,15,7.0,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 40 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,4,2,days,4,,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against vaccine seed virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,10,10,4.7,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,4,2,days,4,,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,10,4,0.6,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,4,2,days,4,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,6,6,3.5,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,4,2,days,4,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,7,5.4,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,4,2,days,4,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,8,4.4,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,4,2,days,4,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",6,3,0.3,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,4,2,days,4,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,6,3,0.2,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,6,2,days,8,,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against vaccine seed virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,10,9,3.8,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,6,2,days,8,,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,10,1,0.1,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,6,2,days,8,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,4,4,8,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,6,2,days,8,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,5,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,6,2,days,8,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,6,3.9,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,6,2,days,8,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",9,9,5.6,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,6,2,days,8,,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,9,8,4.8,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",3,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-5,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,21,"Challenge day","Haemagglutination inhibition test (HIT)","Against vaccine seed virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,10,10,7.3,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",3,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-5,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,21,"Challenge day","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,10,6,1.2,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",3,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-5,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,10,10,2.4,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",3,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-5,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,0,,,,,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",3,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-5,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,0,,,,,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",3,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-5,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,0,,,,,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",4,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-6,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,21,"Challenge day","Haemagglutination inhibition test (HIT)","Against vaccine seed virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,10,10,7.3,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",4,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-6,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,21,"Challenge day","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,10,8,1.7,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",4,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-6,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,10,7,1.8,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",4,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-6,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,3,2.7,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",4,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-6,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,2,0.3,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",4,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-6,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,5,3.3,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",4,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-6,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,0,,,,,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",5,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,10,2,days,8,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,6.5,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",5,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,10,2,days,8,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,10,4.1,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",5,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,10,2,days,8,days,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",7,7,6.2,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/gryfalcon/Washington/40188-6/2014, H5N8 clade 2.3.4.4",5,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,10,2,days,8,days,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,7,7,4,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",6,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,4,3,days,8,days,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,10,10,2,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",6,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,4,3,days,8,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,6,6,4.8,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",6,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,4,3,days,8,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,5,5.4,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",6,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,4,3,days,8,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,4,4,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",6,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,4,3,days,8,days,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",7,1,1,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",6,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,4,3,days,8,days,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,7,1,0.8,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",7,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,3,4,days,8,days,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,10,10,1.2,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",7,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,3,4,days,8,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,7,7,4.9,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",7,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,3,4,days,8,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,4,6.3,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",7,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,3,4,days,8,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,2,1.3,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",7,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,3,4,days,8,days,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",9,6,5,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",7,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.1ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",28,3,4,days,8,days,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,9,3,4.6,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",8,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-5,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,21,"Challenge day","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,10,10,4,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",8,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-5,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,10,10,4.1,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",8,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-5,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,2,3.2,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",8,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-5,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,0,,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",8,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-5,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,8,6.9,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",8,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-5,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,0,,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",9,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-6,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,21,"Challenge day","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,10,10,2.8,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",9,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-6,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2",Antibody,,"Blood serum (as part-nature)",,10,10,4,"Other: specify","titer log2",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",9,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-6,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,6,5.3,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",9,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-6,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,0,,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",9,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-6,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,7,4.3,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",9,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify",RE-6,"Other (specify):",inactivated,SUBCUTANEOUS,,0,"512 HA units/0.5ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,0,,,,,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,1,0.4,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",10,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,10,2,days,9,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,9,7.2,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",10,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,10,2,days,9,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,8,5.5,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",10,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,10,2,days,9,days,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",6,6,6.9,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50386,"Kapczynski, D.R., Pantin-Jackwood, M.J., Spackman, E., Chrzastek, K., Suarez, D.L., Swayne, D.E. (2017).  Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses Vaccine, 35(46),  6345",seungeun.han,,4,,"United States",2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/northern pintail/Washington/40964/2014, H5N2 clade 2.3.4.4",10,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6.5 EID50 /bird",21,10,2,days,9,days,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,6,4,4.9,"Other: specify","log10 EID50/ml",,,"The results of HIT and RT-PCR tests were presented by visual graphs. The values  visually estimated from the result graphs were recoreded for Question 45 testValue."
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",1,"Turkeys (Meleagridis)",,0.033,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.2ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",28,5,4,days,8,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",20,18,4.18,"Other: specify","log10 EID50/ml",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",1,"Turkeys (Meleagridis)",,0.033,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.2ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",28,5,4,days,8,days,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",20,19,4.73,"Other: specify","log10 EID50/ml",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",1,"Turkeys (Meleagridis)",,0.033,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.2ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",28,5,4,days,8,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,20,4,3.05,"Other: specify","log10 EID50/ml",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",1,"Turkeys (Meleagridis)",,0.033,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.2ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",28,5,4,days,8,days,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,20,9,3.55,"Other: specify","log10 EID50/ml",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",1,"Turkeys (Meleagridis)",,0.033,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.2ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",28,5,4,days,8,days,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,20,5,1.8,"Other: specify","titer log2",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",1,"Turkeys (Meleagridis)",,0.033,animal,,20,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"0.2ml volume per the manufactureres recommendation",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",28,5,4,days,8,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,15,15,6.7,"Other: specify","titer log2",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",2,"Turkeys (Meleagridis)",,0.033,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",28,20,4,days,7,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",20,20,5.68,"Other: specify","log10 EID50/ml",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",2,"Turkeys (Meleagridis)",,0.033,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",28,20,4,days,7,days,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",13,13,6.25,"Other: specify","log10 EID50/ml",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",2,"Turkeys (Meleagridis)",,0.033,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",28,20,4,days,7,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,20,20,4.55,"Other: specify","log10 EID50/ml",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",2,"Turkeys (Meleagridis)",,0.033,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",28,20,4,days,7,days,,,,,,,32,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,13,13,5.12,"Other: specify","log10 EID50/ml",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",2,"Turkeys (Meleagridis)",,0.033,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",28,20,4,days,7,days,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,0,<3,"Other: specify","titer log2",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",3,"Turkeys (Meleagridis)",,0.75,animal,,20,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7.0 RNA particle/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",21,7,4,days,8,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",20,1,1.67,"Other: specify","log10 EID50/ml",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",3,"Turkeys (Meleagridis)",,0.75,animal,,20,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7.0 RNA particle/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",21,7,4,days,8,days,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",20,4,1.28,"Other: specify","log10 EID50/ml",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",3,"Turkeys (Meleagridis)",,0.75,animal,,20,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7.0 RNA particle/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",21,7,4,days,8,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,20,1,1.67,"Other: specify","log10 EID50/ml",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",3,"Turkeys (Meleagridis)",,0.75,animal,,20,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7.0 RNA particle/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",21,7,4,days,8,days,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,20,4,1.93,"Other: specify","log10 EID50/ml",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",3,"Turkeys (Meleagridis)",,0.75,animal,,20,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7.0 RNA particle/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",21,7,4,days,8,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,20,20,3.9,"Other: specify","titer log2",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",3,"Turkeys (Meleagridis)",,0.75,animal,,20,commercial,,"A/Gyrfalcon/Washington/40188-6/2014 (H5N8), Merck Animal Health",,"Other (specify):","RNA particle vaccine",SUBCUTANEOUS,,0,"10^7.0 RNA particle/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",21,7,4,days,8,days,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,13,13,7.11,"Other: specify","titer log2",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",4,"Turkeys (Meleagridis)",,0.75,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",21,20,1,days,3,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",11,11,3.68,"Other: specify","log10 EID50/ml",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",4,"Turkeys (Meleagridis)",,0.75,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",21,20,1,days,3,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off 0.9 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,11,11,3.68,"Other: specify","log10 EID50/ml",,,
50397,"Kapczynski, D.R., Sylte, M.J., Killian, M.L., Torchetti, M.K., Chrzastek, K., Suarez, D.L. (2017).  Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015 U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus Veterinary Immunology and Immunopathology, 191(#issue#),  74",seungeun.han,,4,,"United States",2017,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Minnesota/12582/2015, H5N2 clade 2.3.4.4",4,"Turkeys (Meleagridis)",,0.75,animal,,20,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"3 x 10^6 EID50 /bird",21,20,1,days,3,days,,,,,,,21,"Challenge day","Haemagglutination inhibition test (HIT)","Against challenge virus, titers as log2; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,20,20,<3,"Other: specify","titer log2",,,
50407,"Zhang, Z., Zhang, J., Zhang, J., Li, Q., Miao, P., Liu, J., Li, S., Huang, J., Liao, M., Fan, H. (2017).  Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus Veterinary Microbiology, 203(#issue#),  143",seungeun.han,,4,,China,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/goose/Guangdong/14079/2013, H5N1 clade 2.3.4.4",1,"Chickens (Gallus)",,0.75,animal,,12,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,300ul,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50/bird",21,6,8,days,12,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologous clade 2.3.2.1 antigen by OIE method",Antibody,,"Blood serum (as part-nature)",,12,12,7,"Other: specify","titer log2",,,
50407,"Zhang, Z., Zhang, J., Zhang, J., Li, Q., Miao, P., Liu, J., Li, S., Huang, J., Liao, M., Fan, H. (2017).  Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus Veterinary Microbiology, 203(#issue#),  143",seungeun.han,,4,,China,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/goose/Guangdong/14079/2013, H5N1 clade 2.3.4.4",1,"Chickens (Gallus)",,0.75,animal,,12,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,300ul,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50/bird",21,6,8,days,12,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against heterologous clade 2.3.4.4 antigen by OIE method",Antibody,,"Blood serum (as part-nature)",,12,12,3,"Other: specify","titer log2",,,
50407,"Zhang, Z., Zhang, J., Zhang, J., Li, Q., Miao, P., Liu, J., Li, S., Huang, J., Liao, M., Fan, H. (2017).  Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus Veterinary Microbiology, 203(#issue#),  143",seungeun.han,,4,,China,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/goose/Guangdong/14079/2013, H5N1 clade 2.3.4.4",1,"Chickens (Gallus)",,0.75,animal,,12,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,300ul,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50/bird",21,6,8,days,12,days,,,,,,,24,"After challenge","Virus Isolation (VI)","Inoculation on the allantoic cavity of embryonated chicken eggs",Virus,,"Other (specify)","oropharyngeal swab",12,0,,"Other: specify","log10 EID50/ml",,,
50407,"Zhang, Z., Zhang, J., Zhang, J., Li, Q., Miao, P., Liu, J., Li, S., Huang, J., Liao, M., Fan, H. (2017).  Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus Veterinary Microbiology, 203(#issue#),  143",seungeun.han,,4,,China,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/goose/Guangdong/14079/2013, H5N1 clade 2.3.4.4",1,"Chickens (Gallus)",,0.75,animal,,12,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,300ul,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50/bird",21,6,8,days,12,days,,,,,,,26,"After challenge","Virus Isolation (VI)","Inoculation on the allantoic cavity of embryonated chicken eggs",Virus,,"Other (specify)","oropharyngeal swab",12,1,3.2,"Other: specify","log10 EID50/ml",,,
50407,"Zhang, Z., Zhang, J., Zhang, J., Li, Q., Miao, P., Liu, J., Li, S., Huang, J., Liao, M., Fan, H. (2017).  Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus Veterinary Microbiology, 203(#issue#),  143",seungeun.han,,4,,China,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/goose/Guangdong/14079/2013, H5N1 clade 2.3.4.4",1,"Chickens (Gallus)",,0.75,animal,,12,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,300ul,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50/bird",21,6,8,days,12,days,,,,,,,28,"After challenge","Virus Isolation (VI)","Inoculation on the allantoic cavity of embryonated chicken eggs",Virus,,"Other (specify)","oropharyngeal swab",12,3,2.8,"Other: specify","log10 EID50/ml",,,
50407,"Zhang, Z., Zhang, J., Zhang, J., Li, Q., Miao, P., Liu, J., Li, S., Huang, J., Liao, M., Fan, H. (2017).  Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus Veterinary Microbiology, 203(#issue#),  143",seungeun.han,,4,,China,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/goose/Guangdong/14079/2013, H5N1 clade 2.3.4.4",1,"Chickens (Gallus)",,0.75,animal,,12,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,300ul,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50/bird",21,6,8,days,12,days,,,,,,,24,"After challenge","Virus Isolation (VI)","Inoculation on the allantoic cavity of embryonated chicken eggs",Virus,,"Rectum-anal swab (as part-nature)",,12,0,,"Other: specify","log10 EID50/ml",,,
50407,"Zhang, Z., Zhang, J., Zhang, J., Li, Q., Miao, P., Liu, J., Li, S., Huang, J., Liao, M., Fan, H. (2017).  Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus Veterinary Microbiology, 203(#issue#),  143",seungeun.han,,4,,China,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/goose/Guangdong/14079/2013, H5N1 clade 2.3.4.4",1,"Chickens (Gallus)",,0.75,animal,,12,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,300ul,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50/bird",21,6,8,days,12,days,,,,,,,26,"After challenge","Virus Isolation (VI)","Inoculation on the allantoic cavity of embryonated chicken eggs",Virus,,"Rectum-anal swab (as part-nature)",,12,1,2.7,"Other: specify","log10 EID50/ml",,,
50407,"Zhang, Z., Zhang, J., Zhang, J., Li, Q., Miao, P., Liu, J., Li, S., Huang, J., Liao, M., Fan, H. (2017).  Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus Veterinary Microbiology, 203(#issue#),  143",seungeun.han,,4,,China,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/goose/Guangdong/14079/2013, H5N1 clade 2.3.4.4",1,"Chickens (Gallus)",,0.75,animal,,12,SPF,,"H5N1 Re-6",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,300ul,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50/bird",21,6,8,days,12,days,,,,,,,28,"After challenge","Virus Isolation (VI)","Inoculation on the allantoic cavity of embryonated chicken eggs",Virus,,"Rectum-anal swab (as part-nature)",,12,3,2.6,"Other: specify","log10 EID50/ml",,,
50407,"Zhang, Z., Zhang, J., Zhang, J., Li, Q., Miao, P., Liu, J., Li, S., Huang, J., Liao, M., Fan, H. (2017).  Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus Veterinary Microbiology, 203(#issue#),  143",seungeun.han,,4,,China,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/goose/Guangdong/14079/2013, H5N1 clade 2.3.4.4",2,"Chickens (Gallus)",,0.75,animal,,12,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50/bird",21,12,3,days,6,days,,,,,,,21,"Challenge day","Haemagglutination inhibition test (HIT)","Against homologous clade 2.3.2.1 antigen by OIE method",Antibody,,"Blood serum (as part-nature)",,12,0,0,"Other: specify","titer log2",,,
50407,"Zhang, Z., Zhang, J., Zhang, J., Li, Q., Miao, P., Liu, J., Li, S., Huang, J., Liao, M., Fan, H. (2017).  Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus Veterinary Microbiology, 203(#issue#),  143",seungeun.han,,4,,China,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/goose/Guangdong/14079/2013, H5N1 clade 2.3.4.4",2,"Chickens (Gallus)",,0.75,animal,,12,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50/bird",21,12,3,days,6,days,,,,,,,21,"Challenge day","Haemagglutination inhibition test (HIT)","Against heterologous clade 2.3.4.4 antigen by OIE method",Antibody,,"Blood serum (as part-nature)",,12,0,0,"Other: specify","titer log2",,,
50407,"Zhang, Z., Zhang, J., Zhang, J., Li, Q., Miao, P., Liu, J., Li, S., Huang, J., Liao, M., Fan, H. (2017).  Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus Veterinary Microbiology, 203(#issue#),  143",seungeun.han,,4,,China,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/goose/Guangdong/14079/2013, H5N1 clade 2.3.4.4",2,"Chickens (Gallus)",,0.75,animal,,12,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50/bird",21,12,3,days,6,days,,,,,,,24,"After challenge","Virus Isolation (VI)","Inoculation on the allantoic cavity of embryonated chicken eggs",Virus,,"Other (specify)","oropharyngeal swab",12,5,2.0,"Other: specify","log10 EID50/ml",,,
50407,"Zhang, Z., Zhang, J., Zhang, J., Li, Q., Miao, P., Liu, J., Li, S., Huang, J., Liao, M., Fan, H. (2017).  Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus Veterinary Microbiology, 203(#issue#),  143",seungeun.han,,4,,China,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/goose/Guangdong/14079/2013, H5N1 clade 2.3.4.4",2,"Chickens (Gallus)",,0.75,animal,,12,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50/bird",21,12,3,days,6,days,,,,,,,26,"After challenge","Virus Isolation (VI)","Inoculation on the allantoic cavity of embryonated chicken eggs",Virus,,"Other (specify)","oropharyngeal swab",3,3,4.0,"Other: specify","log10 EID50/ml",,,
50407,"Zhang, Z., Zhang, J., Zhang, J., Li, Q., Miao, P., Liu, J., Li, S., Huang, J., Liao, M., Fan, H. (2017).  Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus Veterinary Microbiology, 203(#issue#),  143",seungeun.han,,4,,China,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/goose/Guangdong/14079/2013, H5N1 clade 2.3.4.4",2,"Chickens (Gallus)",,0.75,animal,,12,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50/bird",21,12,3,days,6,days,,,,,,,24,"After challenge","Virus Isolation (VI)","Inoculation on the allantoic cavity of embryonated chicken eggs",Virus,,"Rectum-anal swab (as part-nature)",,12,2,1.6,"Other: specify","log10 EID50/ml",,,
50407,"Zhang, Z., Zhang, J., Zhang, J., Li, Q., Miao, P., Liu, J., Li, S., Huang, J., Liao, M., Fan, H. (2017).  Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus Veterinary Microbiology, 203(#issue#),  143",seungeun.han,,4,,China,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/goose/Guangdong/14079/2013, H5N1 clade 2.3.4.4",2,"Chickens (Gallus)",,0.75,animal,,12,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50/bird",21,12,3,days,6,days,,,,,,,26,"After challenge","Virus Isolation (VI)","Inoculation on the allantoic cavity of embryonated chicken eggs",Virus,,"Rectum-anal swab (as part-nature)",,3,3,3.8,"Other: specify","log10 EID50/ml",,,
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"12450 pfu/0.3ml/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",21,2,8,days,,,,,,,,,24,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,8,4.1,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"12450 pfu/0.3ml/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",21,2,8,days,,,,,,,,,27,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,8,3.2,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"12450 pfu/0.3ml/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",21,2,8,days,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologous vaccinal antigen by using OIE method; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,1.5,"Other: specify","titer log2",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"12450 pfu/0.3ml/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",28,2,12,days,,,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,4,2.7,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"12450 pfu/0.3ml/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",28,2,12,days,,,,,,,,,34,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,4,3.2,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"12450 pfu/0.3ml/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",28,2,12,days,,,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologous vaccinal antigen by using OIE method; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,2,"Other: specify","titer log2",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",3,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"12450 pfu/0.3ml/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",35,1,14,days,14,days,,,,,,,38,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,4,3.6,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",3,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"12450 pfu/0.3ml/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",35,1,14,days,14,days,,,,,,,41,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,4,4.1,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",3,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"12450 pfu/0.3ml/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",35,1,14,days,14,days,,,,,,,44,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,4,4.2,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",3,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"12450 pfu/0.3ml/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",35,1,14,days,14,days,,,,,,,49,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,4,2.5,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",3,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"12450 pfu/0.3ml/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",35,1,14,days,14,days,,,,,,,35,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologous vaccinal antigen by using OIE method; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,2.5,"Other: specify","titer log2",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",4,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"12450 pfu/0.3ml/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",42,1,14,days,14,days,,,,,,,45,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,2,3.1,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",4,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"12450 pfu/0.3ml/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",42,1,14,days,14,days,,,,,,,48,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,2,2.0,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",4,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"12450 pfu/0.3ml/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",42,1,14,days,14,days,,,,,,,42,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologous vaccinal antigen by using OIE method; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,3.5,"Other: specify","titer log2",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",21,5,7.8,days,,,,,,,,,24,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,5,3.3,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",21,5,7.8,days,,,,,,,,,27,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,5,3.5,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",21,5,7.8,days,,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,5,3.3,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",5,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",21,5,7.8,days,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologous vaccinal antigen by using OIE method; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,2.8,"Other: specify","titer log2",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",6,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",28,3,9.3,days,,,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,8,3.6,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",6,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",28,3,9.3,days,,,,,,,,,34,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,8,3.2,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",6,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",28,3,9.3,days,,,,,,,,,37,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,8,4.5,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",6,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",28,3,9.3,days,,,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologous vaccinal antigen by using OIE method; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,4.5,"Other: specify","titer log2",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",7,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",35,2,10,days,,,,,,,,,38,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,8,3.9,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",7,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",35,2,10,days,,,,,,,,,41,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,8,3.1,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",7,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",35,2,10,days,,,,,,,,,44,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,8,4.5,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",7,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",35,2,10,days,,,,,,,,,35,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologous vaccinal antigen by using OIE method; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,5.2,"Other: specify","titer log2",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",8,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",42,1,14,days,14,days,,,,,,,45,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,2,3,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",8,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",42,1,14,days,14,days,,,,,,,48,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,2,2.4,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",8,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",42,1,14,days,14,days,,,,,,,51,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,2,3.7,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",8,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",42,1,14,days,14,days,,,,,,,56,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,2,3.9,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",8,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Mefluvac H5",,"Other (specify):",inactivated,INTRAMUSCULAR,,8,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",42,1,14,days,14,days,,,,,,,42,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologous vaccinal antigen by using OIE method; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,5.6,"Other: specify","titer log2",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",9,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",21,10,8.2,days,,,,,,,,,24,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,3.9,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",9,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",21,10,8.2,days,,,,,,,,,27,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,3.6,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",9,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",21,10,8.2,days,,,,,,,,,21,"Challenge day","Haemagglutination inhibition test (HIT)","Against homologous vaccinal antigen by using OIE method; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,0.1,"Other: specify","titer log2",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",10,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",28,10,8,days,,,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,3.5,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",10,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",28,10,8,days,,,,,,,,,34,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,3.6,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",10,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",28,10,8,days,,,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against homologous vaccinal antigen by using OIE method; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,0,"Other: specify","titer log2",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",11,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",35,10,9.8,days,,,,,,,,,38,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,4.4,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",11,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",35,10,9.8,days,,,,,,,,,41,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,4.1,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",11,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",35,10,9.8,days,,,,,,,,,35,"Challenge day","Haemagglutination inhibition test (HIT)","Against homologous vaccinal antigen by using OIE method; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,0,"Other: specify","titer log2",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",12,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",42,10,12.8,days,,,,,,,,,45,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,3,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",12,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",42,10,12.8,days,,,,,,,,,48,"After challenge","Reverse-transcription PCR (RT-PCR)","The detection limit is 2.3 copies","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,3.5,"Other: specify","log10 PCR copies",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50434,"Kilany, W.H., Safwat, M., Mohammed, S.M., Salim, A., Fasina, F.O., Fasanmi, O.G., Shalaby, A.G., Dauphin, G., Hassan, M.K., Lubroth, J., Jobre, Y.M. (2016).  Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus PLoS ONE, 11(6),  #Pages#",seungeun.han,,4,,Egypt,2016,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/128s/2012, H5N1",12,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50/bird",42,10,12.8,days,,,,,,,,,42,"Challenge day","Haemagglutination inhibition test (HIT)","Against homologous vaccinal antigen by using OIE method; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,0,"Other: specify","titer log2",,,"Mortality date was given as the mean death time. Mean death time was recorded at Question27 mortality Time minimum."
50435,"Kapczynski, D.R., Dorsey, K., Chrzastek, K., Moraes, M., Jackwood, M., Hilt, D., Gardin, Y. (2016).  Vaccine Protection of Turkeys Against H5N1 Highly Pathogenic Avian Influenza Virus with a Recombinant Turkey Herpesvirus Expressing the Hemagglutinin Gene of Avian Influenza Avian Diseases, 60(2),  413",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/L244/2005, H5N1 clade 2.2",1,"Turkeys (Meleagridis)",,0.033,animal,,50,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"2 x 10^6 EID50",28,2,6,days,14,days,,,,,,,30,"After challenge","Virus Isolation (VI)","Injected into the chorioallantoic sac of embryonated SPF chicken egg",Virus,,"Other (specify)","oropharyngeal swab",50,21,1,"Other: specify","log10 EID50/ml",,,
50435,"Kapczynski, D.R., Dorsey, K., Chrzastek, K., Moraes, M., Jackwood, M., Hilt, D., Gardin, Y. (2016).  Vaccine Protection of Turkeys Against H5N1 Highly Pathogenic Avian Influenza Virus with a Recombinant Turkey Herpesvirus Expressing the Hemagglutinin Gene of Avian Influenza Avian Diseases, 60(2),  413",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/L244/2005, H5N1 clade 2.2",1,"Turkeys (Meleagridis)",,0.033,animal,,50,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"2 x 10^6 EID50",28,2,6,days,14,days,,,,,,,32,"After challenge","Virus Isolation (VI)","Injected into the chorioallantoic sac of embryonated SPF chicken egg",Virus,,"Other (specify)","oropharyngeal swab",50,10,0.5,"Other: specify","log10 EID50/ml",,,
50435,"Kapczynski, D.R., Dorsey, K., Chrzastek, K., Moraes, M., Jackwood, M., Hilt, D., Gardin, Y. (2016).  Vaccine Protection of Turkeys Against H5N1 Highly Pathogenic Avian Influenza Virus with a Recombinant Turkey Herpesvirus Expressing the Hemagglutinin Gene of Avian Influenza Avian Diseases, 60(2),  413",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/L244/2005, H5N1 clade 2.2",1,"Turkeys (Meleagridis)",,0.033,animal,,50,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"2 x 10^6 EID50",28,2,6,days,14,days,,,,,,,30,"After challenge","Virus Isolation (VI)","Injected into the chorioallantoic sac of embryonated SPF chicken egg",Virus,,"Rectum-anal swab (as part-nature)",,50,4,1,"Other: specify","log10 EID50/ml",,,
50435,"Kapczynski, D.R., Dorsey, K., Chrzastek, K., Moraes, M., Jackwood, M., Hilt, D., Gardin, Y. (2016).  Vaccine Protection of Turkeys Against H5N1 Highly Pathogenic Avian Influenza Virus with a Recombinant Turkey Herpesvirus Expressing the Hemagglutinin Gene of Avian Influenza Avian Diseases, 60(2),  413",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/L244/2005, H5N1 clade 2.2",1,"Turkeys (Meleagridis)",,0.033,animal,,50,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"2 x 10^6 EID50",28,2,6,days,14,days,,,,,,,32,"After challenge","Virus Isolation (VI)","Injected into the chorioallantoic sac of embryonated SPF chicken egg",Virus,,"Rectum-anal swab (as part-nature)",,50,2,1.5,"Other: specify","log10 EID50/ml",,,
50435,"Kapczynski, D.R., Dorsey, K., Chrzastek, K., Moraes, M., Jackwood, M., Hilt, D., Gardin, Y. (2016).  Vaccine Protection of Turkeys Against H5N1 Highly Pathogenic Avian Influenza Virus with a Recombinant Turkey Herpesvirus Expressing the Hemagglutinin Gene of Avian Influenza Avian Diseases, 60(2),  413",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/L244/2005, H5N1 clade 2.2",1,"Turkeys (Meleagridis)",,0.033,animal,,50,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"2 x 10^6 EID50",28,2,6,days,14,days,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against challenge virus antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,50,23,4.5,"Other: specify","titer log2",,,
50435,"Kapczynski, D.R., Dorsey, K., Chrzastek, K., Moraes, M., Jackwood, M., Hilt, D., Gardin, Y. (2016).  Vaccine Protection of Turkeys Against H5N1 Highly Pathogenic Avian Influenza Virus with a Recombinant Turkey Herpesvirus Expressing the Hemagglutinin Gene of Avian Influenza Avian Diseases, 60(2),  413",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/L244/2005, H5N1 clade 2.2",1,"Turkeys (Meleagridis)",,0.033,animal,,50,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"2 x 10^6 EID50",28,2,6,days,14,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,48,48,6.2,"Other: specify","titer log2",,,
50435,"Kapczynski, D.R., Dorsey, K., Chrzastek, K., Moraes, M., Jackwood, M., Hilt, D., Gardin, Y. (2016).  Vaccine Protection of Turkeys Against H5N1 Highly Pathogenic Avian Influenza Virus with a Recombinant Turkey Herpesvirus Expressing the Hemagglutinin Gene of Avian Influenza Avian Diseases, 60(2),  413",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/L244/2005, H5N1 clade 2.2",2,"Turkeys (Meleagridis)",,0.033,animal,,50,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"2 x 10^6 EID50",28,10,2,days,3,days,,,,,,,30,"After challenge","Virus Isolation (VI)","Injected into the chorioallantoic sac of embryonated SPF chicken egg",Virus,,"Other (specify)","oropharyngeal swab",2,2,7.5,"Other: specify","log10 EID50/ml",,,
50435,"Kapczynski, D.R., Dorsey, K., Chrzastek, K., Moraes, M., Jackwood, M., Hilt, D., Gardin, Y. (2016).  Vaccine Protection of Turkeys Against H5N1 Highly Pathogenic Avian Influenza Virus with a Recombinant Turkey Herpesvirus Expressing the Hemagglutinin Gene of Avian Influenza Avian Diseases, 60(2),  413",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/L244/2005, H5N1 clade 2.2",2,"Turkeys (Meleagridis)",,0.033,animal,,50,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"2 x 10^6 EID50",28,10,2,days,3,days,,,,,,,30,"After challenge","Virus Isolation (VI)","Injected into the chorioallantoic sac of embryonated SPF chicken egg",Virus,,"Rectum-anal swab (as part-nature)",,2,2,7,"Other: specify","log10 EID50/ml",,,
50435,"Kapczynski, D.R., Dorsey, K., Chrzastek, K., Moraes, M., Jackwood, M., Hilt, D., Gardin, Y. (2016).  Vaccine Protection of Turkeys Against H5N1 Highly Pathogenic Avian Influenza Virus with a Recombinant Turkey Herpesvirus Expressing the Hemagglutinin Gene of Avian Influenza Avian Diseases, 60(2),  413",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/L244/2005, H5N1 clade 2.2",2,"Turkeys (Meleagridis)",,0.033,animal,,50,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"2 x 10^6 EID50",28,10,2,days,3,days,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against challenge virus antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,0,1.5,"Other: specify","titer log2",,,
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^5 EID50",28,0,,,,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,1,2.83,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^5 EID50",28,0,,,,,,,,,,,33,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,1,2.04,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^5 EID50",28,0,,,,,,,,,,,33,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,1,2.07,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^5 EID50",28,0,,,,,,,,,,,27,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologuous vaccinal antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,8,4.5,"Other: specify","titier log2",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^5 EID50",28,0,,,,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against homologuous vaccinal antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,7.5,"Other: specify","titier log2",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^5 EID50",28,0,,,,,,,,,,,27,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against challenge virus antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,1,1.2,"Other: specify","titier log2",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^5 EID50",28,0,,,,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,6,3,"Other: specify","titier log2",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^6 EID50",28,0,,,,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,9,2.57,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^6 EID50",28,0,,,,,,,,,,,33,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,5,2.21,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^6 EID50",28,0,,,,,,,,,,,37,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,1,2.00,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^6 EID50",28,0,,,,,,,,,,,42,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,2,1.29,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^6 EID50",28,0,,,,,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,3,2.23,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^6 EID50",28,0,,,,,,,,,,,37,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,1,2.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^6 EID50",28,0,,,,,,,,,,,27,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologuous vaccinal antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,4.5,"Other: specify","titer log2",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^6 EID50",28,0,,,,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against homologuous vaccinal antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,10,8,"Other: specify","titer log2",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^6 EID50",28,0,,,,,,,,,,,27,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against challenge virus antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,2,1.5,"Other: specify","titer log2",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Vectormune AI (rHVT-H5)",,"Other (specify):","live recombinant vectored vaccine",SUBCUTANEOUS,,0,"4000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^6 EID50",28,0,,,,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,10,6,4,"Other: specify","titer log2",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^5 EID50",28,9,2,days,9,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,4.67,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^5 EID50",28,9,2,days,9,days,,,,,,,33,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",3,3,3.08,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^5 EID50",28,9,2,days,9,days,,,,,,,37,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",1,1,2.26,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^5 EID50",28,9,2,days,9,days,,,,,,,42,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",1,1,1.75,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^5 EID50",28,9,2,days,9,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,10,3.8,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^5 EID50",28,9,2,days,9,days,,,,,,,33,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,3,3,2.59,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^5 EID50",28,9,2,days,9,days,,,,,,,42,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,1,1,2.38,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",4,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^6 EID50",28,10,2,days,4,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",9,9,5.66,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50440,"Steensels, M., Rauw, F., Van Den Berg, Th., Marché, S., Gardin, Y., Palya, V., Lambrecht, B. (2016).  Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 european highly pathogenic H5N8 avian influenza strain Avian Diseases, 60(1),  202",seungeun.han,,4,,Belgium,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Germany-MV/R2472/2014, H5N8 clade 2.3.4.4",4,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","oculo nasal",,"10^6 EID50",28,10,2,days,4,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 0.66 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,9,9,3.71,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test were presented by visual graphs, so the HI assay result values were visually estimated to report on Question 45 test Value. The results of RT-PCR from swab samples were given in tables."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-2721/2013, H5N1 clade 1.1.2",1,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,3,days,9,days,,,,,,,29,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,6.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-2721/2013, H5N1 clade 1.1.2",1,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,3,days,9,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",8,8,7,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-2721/2013, H5N1 clade 1.1.2",1,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,3,days,9,days,,,,,,,34,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",5,5,5.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-2721/2013, H5N1 clade 1.1.2",1,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,3,days,9,days,,,,,,,36,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",3,3,4.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-2721/2013, H5N1 clade 1.1.2",1,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,3,days,9,days,,,,,,,29,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.5 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,10,3.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-2721/2013, H5N1 clade 1.1.2",1,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,3,days,9,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.5 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,8,8,4,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-2721/2013, H5N1 clade 1.1.2",1,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,3,days,9,days,,,,,,,34,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.5 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,5,5,4,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-2721/2013, H5N1 clade 1.1.2",1,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,3,days,9,days,,,,,,,36,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.5 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,3,3,3.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-2721/2013, H5N1 clade 1.1.2",1,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,3,days,9,days,,,,,,,36,"After challenge","Haemagglutination inhibition test (HIT)","Against homologous vaccinal antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,3,3,3.5,"Other: specify","titer log2",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-2721/2013, H5N1 clade 1.1.2",1,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,3,days,9,days,,,,,,,36,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,3,3,4.5,"Other: specify","titer log2",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-2721/2013, H5N1 clade 1.1.2",2,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,10,3,days,5,days,,,,,,,29,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,7,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-2721/2013, H5N1 clade 1.1.2",2,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,10,3,days,5,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.5 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",4,4,7.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-2721/2013, H5N1 clade 1.1.2",2,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,10,3,days,5,days,,,,,,,29,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.5 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,10,4.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-2721/2013, H5N1 clade 1.1.2",2,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,10,3,days,5,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.5 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,4,4,5.2,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-1584/2012, H5N1 clade 2.3.2.1",3,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,2,days,5,days,,,,,,,29,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",8,8,6.2,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-1584/2012, H5N1 clade 2.3.2.1",3,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,2,days,5,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",4,4,6.5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-1584/2012, H5N1 clade 2.3.2.1",3,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,2,days,5,days,,,,,,,36,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",3,3,3,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-1584/2012, H5N1 clade 2.3.2.1",3,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,2,days,5,days,,,,,,,29,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.2 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,8,8,5,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-1584/2012, H5N1 clade 2.3.2.1",3,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,2,days,5,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.2 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,4,4,3,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-1584/2012, H5N1 clade 2.3.2.1",3,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,2,days,5,days,,,,,,,36,"After challenge","Haemagglutination inhibition test (HIT)","Against homologous vaccinal antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,3,3,6,"Other: specify","titer log2",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-1584/2012, H5N1 clade 2.3.2.1",3,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Vectormune HVT-AIV",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"9820 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,7,2,days,5,days,,,,,,,36,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus antigen; cut-off 3 log2",Antibody,,"Blood serum (as part-nature)",,3,3,5.5,"Other: specify","titer log2",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-1584/2012, H5N1 clade 2.3.2.1",4,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,10,1,days,5,days,,,,,,,29,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",6,6,6.2,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-1584/2012, H5N1 clade 2.3.2.1",4,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,10,1,days,5,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.2 log10 EID50/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",3,3,7.2,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-1584/2012, H5N1 clade 2.3.2.1",4,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,10,1,days,5,days,,,,,,,29,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.2 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,6,6,4.8,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50447,"Pantin-Jackwood, M.J., Kapczynski, D.R., Dejesus, E., Costa-Hurtado, M., Dauphin, G., Tripodi, A., Dunn, J.R., Swayne, D.E. (2016).  Efficacy of a recombinant Turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1.2 and 2.3.2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) Avian Diseases, 60(1),  22",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/NCVD-1584/2012, H5N1 clade 2.3.2.1",4,"Ducks (Anatidae)",,0.1,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",27,10,1,days,5,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit of 2.2 log10 EID50/ml","Nucleic acid",,"Rectum-anal swab (as part-nature)",,3,3,3,"Other: specify","log10 EID50/ml",,,"The results of HI antibody test and RT-PCR were presented by visual graphs, so the result values of HIT and RT-PCR were visually estimated to report on Question 45 test Value."
50450,"Gamoh, K., Nakamizo, M., Okamatsu, M., Sakoda, Y., Kida, H., Suzuki, S. (2016).  Protective efficacy of stockpiled vaccine against H5N8 highly pathogenic avian influenza virus isolated from a chicken in kumamoto prefecture, japan, in 2014 Journal of Veterinary Medical Science, 78(1),  139",seungeun.han,,4,,Japan,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Kumamoto/1-7/2014, H5N8",1,"Chickens (Gallus)",,1.75,animal,,10,commercial,,"A/duck/Hokkaido/Vac-1/2004 (H5N1) strain, by Kaketsuken",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.5ml/bird according to the manufacturer's recommendation",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^7.8 EID50",35,0,,,,,,,,,,,35,"Challenge day","Haemagglutination inhibition test (HIT)","Cut-off 1:4 titer",Antibody,,"Blood serum (as part-nature)",,10,10,1:256~512,titer,,,,"All the vaccinated chickens were completely protected from disease and the challenge virus was not recovered from any of the swabs from vaccinated chickens. Detailed descriptions of HI assay regarding result interpretation or cut-off limit were missing."
50450,"Gamoh, K., Nakamizo, M., Okamatsu, M., Sakoda, Y., Kida, H., Suzuki, S. (2016).  Protective efficacy of stockpiled vaccine against H5N8 highly pathogenic avian influenza virus isolated from a chicken in kumamoto prefecture, japan, in 2014 Journal of Veterinary Medical Science, 78(1),  139",seungeun.han,,4,,Japan,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Kumamoto/1-7/2014, H5N8",2,"Chickens (Gallus)",,1.75,animal,,3,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^7.8 EID50",35,3,4,days,5,days,,,,,,,35,"Challenge day","Haemagglutination inhibition test (HIT)","Cut-off 1:4 titer",Antibody,,"Blood serum (as part-nature)",,3,0,,,,,,"All the vaccinated chickens were completely protected from disease and the challenge virus was not recovered from any of the swabs from vaccinated chickens. Detailed descriptions of HI assay regarding result interpretation or cut-off limit were missing."
50450,"Gamoh, K., Nakamizo, M., Okamatsu, M., Sakoda, Y., Kida, H., Suzuki, S. (2016).  Protective efficacy of stockpiled vaccine against H5N8 highly pathogenic avian influenza virus isolated from a chicken in kumamoto prefecture, japan, in 2014 Journal of Veterinary Medical Science, 78(1),  139",seungeun.han,,4,,Japan,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Kumamoto/1-7/2014, H5N8",2,"Chickens (Gallus)",,1.75,animal,,3,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^7.8 EID50",35,3,4,days,5,days,,,,,,,37,"After challenge","Virus Isolation (VI)","Swab solutions were inoculated into an allantoic cavity of SPF embryonated chicken egg",Virus,,"Rectum-anal swab (as part-nature)",,3,3,3.1,"Other: specify","log10 EID50/ml",,,"All the vaccinated chickens were completely protected from disease and the challenge virus was not recovered from any of the swabs from vaccinated chickens. Detailed descriptions of HI assay regarding result interpretation or cut-off limit were missing."
50450,"Gamoh, K., Nakamizo, M., Okamatsu, M., Sakoda, Y., Kida, H., Suzuki, S. (2016).  Protective efficacy of stockpiled vaccine against H5N8 highly pathogenic avian influenza virus isolated from a chicken in kumamoto prefecture, japan, in 2014 Journal of Veterinary Medical Science, 78(1),  139",seungeun.han,,4,,Japan,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Kumamoto/1-7/2014, H5N8",2,"Chickens (Gallus)",,1.75,animal,,3,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^7.8 EID50",35,3,4,days,5,days,,,,,,,41,"After challenge","Virus Isolation (VI)","Swab solutions were inoculated into an allantoic cavity of SPF embryonated chicken egg",Virus,,"Rectum-anal swab (as part-nature)",,2,2,6.3,"Other: specify","log10 EID50/ml",,,"All the vaccinated chickens were completely protected from disease and the challenge virus was not recovered from any of the swabs from vaccinated chickens. Detailed descriptions of HI assay regarding result interpretation or cut-off limit were missing."
50450,"Gamoh, K., Nakamizo, M., Okamatsu, M., Sakoda, Y., Kida, H., Suzuki, S. (2016).  Protective efficacy of stockpiled vaccine against H5N8 highly pathogenic avian influenza virus isolated from a chicken in kumamoto prefecture, japan, in 2014 Journal of Veterinary Medical Science, 78(1),  139",seungeun.han,,4,,Japan,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Kumamoto/1-7/2014, H5N8",2,"Chickens (Gallus)",,1.75,animal,,3,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^7.8 EID50",35,3,4,days,5,days,,,,,,,41,"After challenge","Virus Isolation (VI)","Swab solutions were inoculated into an allantoic cavity of SPF embryonated chicken egg",Virus,,"Other (specify)","oropharyngeal swab",3,3,3.3,"Other: specify","log10 EID50/ml",,,"All the vaccinated chickens were completely protected from disease and the challenge virus was not recovered from any of the swabs from vaccinated chickens. Detailed descriptions of HI assay regarding result interpretation or cut-off limit were missing."
50456,"Jiao, P., Song, H., Liu, X., Song, Y., Cui, J., Wu, S., Ye, J., Qu, N., Zhang, T., Liao, M. (2016).  Pathogenicity, transmission and antigenic variation of H5N1 highly pathogenic avian influenza viruses Frontiers in Microbiology, 7(MAY),  #Pages#",seungeun.han,,4,,China,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Duck/China/G3/2012, H5N1 clade 2.3.2.1",1,"Chickens (Gallus)",,0.75,animal,,9,SPF,,"Other: specify",Re-4,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,0.3ml,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,3,6,days,-1,,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against homologuous vaccinal antigen",Antibody,,"Blood serum (as part-nature)",,9,9,9.4,"Other: specify","titer log2",,,"Only the first day of the mortality was given. Cut-off value of HI assay was not given. Oropharyngeal and cloacal swabs were collected on 3, 5, 7, 9, and 11 PCD for virus isolation, but only the virus shedding proportion of all swab samples from each group was given.  No virus shedding or death was found from D7 vaccinated group."
50456,"Jiao, P., Song, H., Liu, X., Song, Y., Cui, J., Wu, S., Ye, J., Qu, N., Zhang, T., Liao, M. (2016).  Pathogenicity, transmission and antigenic variation of H5N1 highly pathogenic avian influenza viruses Frontiers in Microbiology, 7(MAY),  #Pages#",seungeun.han,,4,,China,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Duck/China/G3/2012, H5N1 clade 2.3.2.1",1,"Chickens (Gallus)",,0.75,animal,,9,SPF,,"Other: specify",Re-4,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,0.3ml,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,3,6,days,-1,,,,,,,,31,"After challenge","Virus Isolation (VI)","Swab solutions were inoculated into embryonated chicken eggs",Virus,,"Other (specify)","Oropharyngeal and cloacal swabs",,,88.9,"Other: specify",%,,,"Only the first day of the mortality was given. Cut-off value of HI assay was not given. Oropharyngeal and cloacal swabs were collected on 3, 5, 7, 9, and 11 PCD for virus isolation, but only the virus shedding proportion of all swab samples from each group was given.  No virus shedding or death was found from D7 vaccinated group."
50456,"Jiao, P., Song, H., Liu, X., Song, Y., Cui, J., Wu, S., Ye, J., Qu, N., Zhang, T., Liao, M. (2016).  Pathogenicity, transmission and antigenic variation of H5N1 highly pathogenic avian influenza viruses Frontiers in Microbiology, 7(MAY),  #Pages#",seungeun.han,,4,,China,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Duck/China/G3/2012, H5N1 clade 2.3.2.1",2,"Chickens (Gallus)",,0.75,animal,,9,SPF,,"Other: specify",Re-6,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,0.3ml,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,1,6,days,6,days,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against homologuous vaccinal antigen",Antibody,,"Blood serum (as part-nature)",,9,9,7.2,"Other: specify","titer log2",,,"Only the first day of the mortality was given. Cut-off value of HI assay was not given. Oropharyngeal and cloacal swabs were collected on 3, 5, 7, 9, and 11 PCD for virus isolation, but only the virus shedding proportion of all swab samples from each group was given.  No virus shedding or death was found from D7 vaccinated group."
50456,"Jiao, P., Song, H., Liu, X., Song, Y., Cui, J., Wu, S., Ye, J., Qu, N., Zhang, T., Liao, M. (2016).  Pathogenicity, transmission and antigenic variation of H5N1 highly pathogenic avian influenza viruses Frontiers in Microbiology, 7(MAY),  #Pages#",seungeun.han,,4,,China,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Duck/China/G3/2012, H5N1 clade 2.3.2.1",2,"Chickens (Gallus)",,0.75,animal,,9,SPF,,"Other: specify",Re-6,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,0.3ml,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,1,6,days,6,days,,,,,,,31,"After challenge","Virus Isolation (VI)","Swab solutions were inoculated into embryonated chicken eggs",Virus,,"Other (specify)","Oropharyngeal and cloacal swabs",,,44.4,"Other: specify",%,,,"Only the first day of the mortality was given. Cut-off value of HI assay was not given. Oropharyngeal and cloacal swabs were collected on 3, 5, 7, 9, and 11 PCD for virus isolation, but only the virus shedding proportion of all swab samples from each group was given.  No virus shedding or death was found from D7 vaccinated group."
50456,"Jiao, P., Song, H., Liu, X., Song, Y., Cui, J., Wu, S., Ye, J., Qu, N., Zhang, T., Liao, M. (2016).  Pathogenicity, transmission and antigenic variation of H5N1 highly pathogenic avian influenza viruses Frontiers in Microbiology, 7(MAY),  #Pages#",seungeun.han,,4,,China,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Duck/China/G3/2012, H5N1 clade 2.3.2.1",3,"Chickens (Gallus)",,0.75,animal,,9,SPF,,D7,,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,0.3ml,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,0,,,,,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against homologuous vaccinal antigen",Antibody,,"Blood serum (as part-nature)",,9,9,7.5,"Other: specify","titer log2",,,"Only the first day of the mortality was given. Cut-off value of HI assay was not given. Oropharyngeal and cloacal swabs were collected on 3, 5, 7, 9, and 11 PCD for virus isolation, but only the virus shedding proportion of all swab samples from each group was given.  No virus shedding or death was found from D7 vaccinated group."
50456,"Jiao, P., Song, H., Liu, X., Song, Y., Cui, J., Wu, S., Ye, J., Qu, N., Zhang, T., Liao, M. (2016).  Pathogenicity, transmission and antigenic variation of H5N1 highly pathogenic avian influenza viruses Frontiers in Microbiology, 7(MAY),  #Pages#",seungeun.han,,4,,China,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Duck/China/G3/2012, H5N1 clade 2.3.2.1",4,"Chickens (Gallus)",,0.75,animal,,9,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,9,-1,,-1,,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against homologuous vaccinal antigen",Antibody,,"Blood serum (as part-nature)",,9,0,,,,,,"Only the first day of the mortality was given. Cut-off value of HI assay was not given. Oropharyngeal and cloacal swabs were collected on 3, 5, 7, 9, and 11 PCD for virus isolation, but only the virus shedding proportion of all swab samples from each group was given.  No virus shedding or death was found from D7 vaccinated group."
50456,"Jiao, P., Song, H., Liu, X., Song, Y., Cui, J., Wu, S., Ye, J., Qu, N., Zhang, T., Liao, M. (2016).  Pathogenicity, transmission and antigenic variation of H5N1 highly pathogenic avian influenza viruses Frontiers in Microbiology, 7(MAY),  #Pages#",seungeun.han,,4,,China,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Duck/China/G3/2012, H5N1 clade 2.3.2.1",4,"Chickens (Gallus)",,0.75,animal,,9,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,9,-1,,-1,,,,,,,,31,"After challenge","Virus Isolation (VI)","Swab solutions were inoculated into embryonated chicken eggs",Virus,,"Other (specify)","Oropharyngeal and cloacal swabs",,,100,"Other: specify",%,,,"Only the first day of the mortality was given. Cut-off value of HI assay was not given. Oropharyngeal and cloacal swabs were collected on 3, 5, 7, 9, and 11 PCD for virus isolation, but only the virus shedding proportion of all swab samples from each group was given.  No virus shedding or death was found from D7 vaccinated group."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/3/2005; H5N1 clade 2.2",1,"Chickens (Gallus)",,0.033,animal,,30,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",42,0,,,,,,,,,,,35,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologuous vaccinal antigen",Antibody,,"Blood serum (as part-nature)",,30,30,6.4,"Other: specify","titer log2",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/3/2005; H5N1 clade 2.2",1,"Chickens (Gallus)",,0.033,animal,,30,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",42,0,,,,,,,,,,,56,"After challenge","Haemagglutination inhibition test (HIT)","Against homologuous vaccinal antigen",Antibody,,"Blood serum (as part-nature)",,30,30,5.6,"Other: specify","titer log2",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/3/2005; H5N1 clade 2.2",1,"Chickens (Gallus)",,0.033,animal,,30,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",42,0,,,,,,,,,,,44,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",30,4,2,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/3/2005; H5N1 clade 2.2",2,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-free form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",42,0,,,,,,,,,,,35,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologuous vaccinal antigen",Antibody,,"Blood serum (as part-nature)",,20,20,5.1,"Other: specify","titer log2",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/3/2005; H5N1 clade 2.2",2,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-free form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",42,0,,,,,,,,,,,56,"After challenge","Haemagglutination inhibition test (HIT)","Against homologuous vaccinal antigen",Antibody,,"Blood serum (as part-nature)",,20,20,6.4,"Other: specify","titer log2",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/3/2005; H5N1 clade 2.2",2,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-free form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",42,0,,,,,,,,,,,44,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",20,3,2,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/3/2005; H5N1 clade 2.2",2,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-free form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",42,0,,,,,,,,,,,46,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",20,1,-1,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/3/2005; H5N1 clade 2.2",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",42,10,2,days,3,days,,,,,,,44,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",6,6,6,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Whooper Swan/Mongolia/3/2005; H5N1 clade 2.2",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",42,10,2,days,3,days,,,,,,,44,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,6,6,3.5,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",4,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,4,6,days,8,days,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against homologuous vaccinal antigen",Antibody,,"Blood serum (as part-nature)",,20,20,5,"Other: specify","titer log2",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",4,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,4,6,days,8,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against homologuous vaccinal antigen",Antibody,,"Blood serum (as part-nature)",,16,16,8,"Other: specify","titer log2",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",4,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,4,6,days,8,days,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against challenge virus antigen",Antibody,,"Blood serum (as part-nature)",,20,18,1.5,"Other: specify","titer log2",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",4,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,4,6,days,8,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus antigen",Antibody,,"Blood serum (as part-nature)",,16,16,6,"Other: specify","titer log2",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",4,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,4,6,days,8,days,,,,,,,30,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",20,13,3,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",4,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,4,6,days,8,days,,,,,,,32,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",20,8,3,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",4,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,4,6,days,8,days,,,,,,,30,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,20,1,3.5,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",4,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"2000 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,4,6,days,8,days,,,,,,,32,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,20,4,4,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",5,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"CEVAC Flu-Kem H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"Not given",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,19,3,days,10,days,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against homologuous vaccinal antigen",Antibody,,"Blood serum (as part-nature)",,20,20,2,"Other: specify","titer log2",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",5,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"CEVAC Flu-Kem H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"Not given",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,19,3,days,10,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against homologuous vaccinal antigen",Antibody,,"Blood serum (as part-nature)",,1,1,5,"Other: specify","titer log2",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",5,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"CEVAC Flu-Kem H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"Not given",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,19,3,days,10,days,,,,,,,28,"Challenge day","Haemagglutination inhibition test (HIT)","Against challenge virus antigen",Antibody,,"Blood serum (as part-nature)",,20,3,1,"Other: specify","titer log2",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",5,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"CEVAC Flu-Kem H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"Not given",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,19,3,days,10,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus antigen",Antibody,,"Blood serum (as part-nature)",,1,1,7,"Other: specify","titer log2",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",5,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"CEVAC Flu-Kem H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"Not given",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,19,3,days,10,days,,,,,,,30,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",20,19,4,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",5,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"CEVAC Flu-Kem H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"Not given",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,19,3,days,10,days,,,,,,,32,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",14,14,4.5,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",5,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"CEVAC Flu-Kem H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"Not given",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,19,3,days,10,days,,,,,,,30,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,20,12,2,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",5,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"CEVAC Flu-Kem H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"Not given",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,19,3,days,10,days,,,,,,,32,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,14,12,3.8,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",6,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,10,2,days,2,days,,,,,,,30,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",10,10,6,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java Sbg/29/2007, H5N1 clade 2.1.3",6,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,10,2,days,2,days,,,,,,,30,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,10,10,6,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Queretaro/14588-19/95, H5N2",7,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,1,3,days,3,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against challenge virus antigen",Antibody,,"Blood serum (as part-nature)",,20,20,3,"Other: specify","titer log2",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Queretaro/14588-19/95, H5N2",7,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,1,3,days,3,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus antigen",Antibody,,"Blood serum (as part-nature)",,19,19,7.5,"Other: specify","titer log2",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Queretaro/14588-19/95, H5N2",7,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,1,3,days,3,days,,,,,,,31,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",19,2,2,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Queretaro/14588-19/95, H5N2",7,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,1,3,days,3,days,,,,,,,31,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,19,1,3.2,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Queretaro/14588-19/95, H5N2",7,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/Swan/Hungary/4999/2006 H5N1","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,1,3,days,3,days,,,,,,,34,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,19,1,2,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Queretaro/14588-19/95, H5N2",8,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/turkey/Wisconsin/68, H5N9","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against challenge virus antigen",Antibody,,"Blood serum (as part-nature)",,20,20,4.5,"Other: specify","titer log2",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Queretaro/14588-19/95, H5N2",8,"Chickens (Gallus)",,0.033,animal,,20,SPF,,"Other: specify","Vectormune AI rHVT-AI using cell-associated form of HVT vector with HA gene of HPAI A/turkey/Wisconsin/68, H5N9","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"1500 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,0,,,,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against challenge virus antigen",Antibody,,"Blood serum (as part-nature)",,20,20,7.5,"Other: specify","titer log2",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Queretaro/14588-19/95, H5N2",9,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,10,3,days,6,days,,,,,,,31,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",7,6,2.9,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Queretaro/14588-19/95, H5N2",9,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,10,3,days,6,days,,,,,,,34,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",1,1,2,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Queretaro/14588-19/95, H5N2",9,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,10,3,days,6,days,,,,,,,31,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,7,1,1.2,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50472,"Kapczynski, D.R., Esaki, M., Dorsey, K.M., Jiang, H., Jackwood, M., Moraes, M., Gardin, Y. (2015).  Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus Vaccine, 33(9),  1197",seungeun.han,,4,,"United States",2013,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Queretaro/14588-19/95, H5N2",9,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",28,10,3,days,6,days,,,,,,,34,"After challenge","Virus Isolation (VI)","Detection limit of 0.9 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,1,1,0.9,"Other: specify","log10 EID50/ml",,,"The results of virus isolation from swab samples were presented in visual graphs, so the value of virus isolation for the question45 was visually estimated from the result graphs."
50477,"Kilany, W.H., Hassan, M.K., Safwat, M., Mohammed, S., Selim, A., VonDobschuetz, S., Dauphin, G., Lubroth, J., Jobre, Y. (2015).  Comparison of the effectiveness of rHVT-H5, inactivated H5 and rHVT-H5 with inactivated H5 prime/boost vaccination regimes in commercial broiler chickens carrying MDAs against HPAI H5N1 clade 2.2.1 virus Avian Pathology, 44(5),  333",seungeun.han,,4,,Egypt,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128S/2012, H5N1",1,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryo-preserved cell-associated)","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"3.8x10^3 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,2,-1,,-1,,,,,,,,37,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit is 2.3 M gene copies/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,2,2.5,"Other: specify","log10 PCR copies",,,"All chickens carry high maternally delivered AI antibody levels when the experiment started. Mortality day or mean death time were not provided, only mortality rate was given. The total number of virus shedder birds was given for each group, the number of birds shedding virus on each test day was not provided."
50477,"Kilany, W.H., Hassan, M.K., Safwat, M., Mohammed, S., Selim, A., VonDobschuetz, S., Dauphin, G., Lubroth, J., Jobre, Y. (2015).  Comparison of the effectiveness of rHVT-H5, inactivated H5 and rHVT-H5 with inactivated H5 prime/boost vaccination regimes in commercial broiler chickens carrying MDAs against HPAI H5N1 clade 2.2.1 virus Avian Pathology, 44(5),  333",seungeun.han,,4,,Egypt,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128S/2012, H5N1",2,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Other: specify","Vectormune AI rHVT-H5 (cryo-preserved cell-associated)","Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"3.8x10^3 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",35,1,-1,,-1,,,,,,,,44,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit is 2.3 M gene copies/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,1,1.9,"Other: specify","log10 PCR copies",,,"All chickens carry high maternally delivered AI antibody levels when the experiment started. Mortality day or mean death time were not provided, only mortality rate was given. The total number of virus shedder birds was given for each group, the number of birds shedding virus on each test day was not provided."
50477,"Kilany, W.H., Hassan, M.K., Safwat, M., Mohammed, S., Selim, A., VonDobschuetz, S., Dauphin, G., Lubroth, J., Jobre, Y. (2015).  Comparison of the effectiveness of rHVT-H5, inactivated H5 and rHVT-H5 with inactivated H5 prime/boost vaccination regimes in commercial broiler chickens carrying MDAs against HPAI H5N1 clade 2.2.1 virus Avian Pathology, 44(5),  333",seungeun.han,,4,,Egypt,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128S/2012, H5N1",3,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,INTRAMUSCULAR,,8,0.5ml,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,7,-1,,-1,,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit is 2.3 M gene copies/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,9,2.1,"Other: specify","log10 PCR copies",,,"All chickens carry high maternally delivered AI antibody levels when the experiment started. Mortality day or mean death time were not provided, only mortality rate was given. The total number of virus shedder birds was given for each group, the number of birds shedding virus on each test day was not provided."
50477,"Kilany, W.H., Hassan, M.K., Safwat, M., Mohammed, S., Selim, A., VonDobschuetz, S., Dauphin, G., Lubroth, J., Jobre, Y. (2015).  Comparison of the effectiveness of rHVT-H5, inactivated H5 and rHVT-H5 with inactivated H5 prime/boost vaccination regimes in commercial broiler chickens carrying MDAs against HPAI H5N1 clade 2.2.1 virus Avian Pathology, 44(5),  333",seungeun.han,,4,,Egypt,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128S/2012, H5N1",3,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,INTRAMUSCULAR,,8,0.5ml,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,7,-1,,-1,,,,,,,,34,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit is 2.3 M gene copies/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,9,2.4,"Other: specify","log10 PCR copies",,,"All chickens carry high maternally delivered AI antibody levels when the experiment started. Mortality day or mean death time were not provided, only mortality rate was given. The total number of virus shedder birds was given for each group, the number of birds shedding virus on each test day was not provided."
50477,"Kilany, W.H., Hassan, M.K., Safwat, M., Mohammed, S., Selim, A., VonDobschuetz, S., Dauphin, G., Lubroth, J., Jobre, Y. (2015).  Comparison of the effectiveness of rHVT-H5, inactivated H5 and rHVT-H5 with inactivated H5 prime/boost vaccination regimes in commercial broiler chickens carrying MDAs against HPAI H5N1 clade 2.2.1 virus Avian Pathology, 44(5),  333",seungeun.han,,4,,Egypt,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128S/2012, H5N1",3,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,INTRAMUSCULAR,,8,0.5ml,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,7,-1,,-1,,,,,,,,37,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit is 2.3 M gene copies/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,9,3.1,"Other: specify","log10 PCR copies",,,"All chickens carry high maternally delivered AI antibody levels when the experiment started. Mortality day or mean death time were not provided, only mortality rate was given. The total number of virus shedder birds was given for each group, the number of birds shedding virus on each test day was not provided."
50477,"Kilany, W.H., Hassan, M.K., Safwat, M., Mohammed, S., Selim, A., VonDobschuetz, S., Dauphin, G., Lubroth, J., Jobre, Y. (2015).  Comparison of the effectiveness of rHVT-H5, inactivated H5 and rHVT-H5 with inactivated H5 prime/boost vaccination regimes in commercial broiler chickens carrying MDAs against HPAI H5N1 clade 2.2.1 virus Avian Pathology, 44(5),  333",seungeun.han,,4,,Egypt,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128S/2012, H5N1",4,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,INTRAMUSCULAR,,8,0.5ml,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",35,7,-1,,-1,,,,,,,,38,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit is 2.3 M gene copies/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,8,2,"Other: specify","log10 PCR copies",,,"All chickens carry high maternally delivered AI antibody levels when the experiment started. Mortality day or mean death time were not provided, only mortality rate was given. The total number of virus shedder birds was given for each group, the number of birds shedding virus on each test day was not provided."
50477,"Kilany, W.H., Hassan, M.K., Safwat, M., Mohammed, S., Selim, A., VonDobschuetz, S., Dauphin, G., Lubroth, J., Jobre, Y. (2015).  Comparison of the effectiveness of rHVT-H5, inactivated H5 and rHVT-H5 with inactivated H5 prime/boost vaccination regimes in commercial broiler chickens carrying MDAs against HPAI H5N1 clade 2.2.1 virus Avian Pathology, 44(5),  333",seungeun.han,,4,,Egypt,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128S/2012, H5N1",4,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,INTRAMUSCULAR,,8,0.5ml,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",35,7,-1,,-1,,,,,,,,41,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit is 2.3 M gene copies/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,8,3.3,"Other: specify","log10 PCR copies",,,"All chickens carry high maternally delivered AI antibody levels when the experiment started. Mortality day or mean death time were not provided, only mortality rate was given. The total number of virus shedder birds was given for each group, the number of birds shedding virus on each test day was not provided."
50477,"Kilany, W.H., Hassan, M.K., Safwat, M., Mohammed, S., Selim, A., VonDobschuetz, S., Dauphin, G., Lubroth, J., Jobre, Y. (2015).  Comparison of the effectiveness of rHVT-H5, inactivated H5 and rHVT-H5 with inactivated H5 prime/boost vaccination regimes in commercial broiler chickens carrying MDAs against HPAI H5N1 clade 2.2.1 virus Avian Pathology, 44(5),  333",seungeun.han,,4,,Egypt,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128S/2012, H5N1",4,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,INTRAMUSCULAR,,8,0.5ml,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",35,7,-1,,-1,,,,,,,,44,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit is 2.3 M gene copies/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,8,3.7,"Other: specify","log10 PCR copies",,,"All chickens carry high maternally delivered AI antibody levels when the experiment started. Mortality day or mean death time were not provided, only mortality rate was given. The total number of virus shedder birds was given for each group, the number of birds shedding virus on each test day was not provided."
50477,"Kilany, W.H., Hassan, M.K., Safwat, M., Mohammed, S., Selim, A., VonDobschuetz, S., Dauphin, G., Lubroth, J., Jobre, Y. (2015).  Comparison of the effectiveness of rHVT-H5, inactivated H5 and rHVT-H5 with inactivated H5 prime/boost vaccination regimes in commercial broiler chickens carrying MDAs against HPAI H5N1 clade 2.2.1 virus Avian Pathology, 44(5),  333",seungeun.han,,4,,Egypt,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128S/2012, H5N1",5,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,10,-1,,-1,,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit is 2.3 M gene copies/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,2.9,"Other: specify","log10 PCR copies",,,"All chickens carry high maternally delivered AI antibody levels when the experiment started. Mortality day or mean death time were not provided, only mortality rate was given. The total number of virus shedder birds was given for each group, the number of birds shedding virus on each test day was not provided."
50477,"Kilany, W.H., Hassan, M.K., Safwat, M., Mohammed, S., Selim, A., VonDobschuetz, S., Dauphin, G., Lubroth, J., Jobre, Y. (2015).  Comparison of the effectiveness of rHVT-H5, inactivated H5 and rHVT-H5 with inactivated H5 prime/boost vaccination regimes in commercial broiler chickens carrying MDAs against HPAI H5N1 clade 2.2.1 virus Avian Pathology, 44(5),  333",seungeun.han,,4,,Egypt,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128S/2012, H5N1",5,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",28,10,-1,,-1,,,,,,,,34,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit is 2.3 M gene copies/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,4.1,"Other: specify","log10 PCR copies",,,"All chickens carry high maternally delivered AI antibody levels when the experiment started. Mortality day or mean death time were not provided, only mortality rate was given. The total number of virus shedder birds was given for each group, the number of birds shedding virus on each test day was not provided."
50477,"Kilany, W.H., Hassan, M.K., Safwat, M., Mohammed, S., Selim, A., VonDobschuetz, S., Dauphin, G., Lubroth, J., Jobre, Y. (2015).  Comparison of the effectiveness of rHVT-H5, inactivated H5 and rHVT-H5 with inactivated H5 prime/boost vaccination regimes in commercial broiler chickens carrying MDAs against HPAI H5N1 clade 2.2.1 virus Avian Pathology, 44(5),  333",seungeun.han,,4,,Egypt,2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128S/2012, H5N1",6,"Chickens (Gallus)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-nasal,,"10^6 EID50",35,10,-1,,-1,,,,,,,,38,"After challenge","Reverse-transcription PCR (RT-PCR)","Detection limit is 2.3 M gene copies/ml","Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,4.4,"Other: specify","log10 PCR copies",,,"All chickens carry high maternally delivered AI antibody levels when the experiment started. Mortality day or mean death time were not provided, only mortality rate was given. The total number of virus shedder birds was given for each group, the number of birds shedding virus on each test day was not provided."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java/SMI-HAMD/06, H5N1 clade 2.1.1",1,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"A/chicken/Legok/2003 (H5N1), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,1,2,days,2,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologuous vaccinial antigen",Antibody,,"Blood serum (as part-nature)",,10,10,50,titer,,,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java/SMI-HAMD/06, H5N1 clade 2.1.1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"rg-generated A/duck/Vietnam/2004 (H5N3), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologuous vaccinial antigen",Antibody,,"Blood serum (as part-nature)",,10,10,70,titer,,,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java/SMI-HAMD/06, H5N1 clade 2.1.1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"rg-generated A/duck/Vietnam/2004 (H5N3), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,1,4,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java/SMI-HAMD/06, H5N1 clade 2.1.1",3,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"A/goose/Guangdong/1/1996 (H5N1), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologuous vaccinial antigen",Antibody,,"Blood serum (as part-nature)",,10,10,70,titer,,,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java/SMI-HAMD/06, H5N1 clade 2.1.1",4,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"A/turkey/England/N28/1973 (H5N2), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,5,2,days,6,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologuous vaccinial antigen",Antibody,,"Blood serum (as part-nature)",,10,10,170,titer,,,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java/SMI-HAMD/06, H5N1 clade 2.1.1",4,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"A/turkey/England/N28/1973 (H5N2), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,5,2,days,6,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,1,4,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java/SMI-HAMD/06, H5N1 clade 2.1.1",5,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"A/chicken/Mexico/232/1994 (H5N2), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologuous vaccinial antigen",Antibody,,"Blood serum (as part-nature)",,10,10,620,titer,,,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java/SMI-HAMD/06, H5N1 clade 2.1.1",5,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"A/chicken/Mexico/232/1994 (H5N2), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,1,4,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java/SMI-HAMD/06, H5N1 clade 2.1.1",6,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"A/turkey/Wisconsin/1968 (H5N9), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against homologuous vaccinial antigen",Antibody,,"Blood serum (as part-nature)",,10,10,830,titer,,,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java/SMI-HAMD/06, H5N1 clade 2.1.1",7,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,10,2,days,2,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,7.1,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Papua/TA5/2006, H5N1 clade 2.1.3.1",8,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"A/chicken/Legok/2003 (H5N1), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,0,,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Papua/TA5/2006, H5N1 clade 2.1.3.1",9,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"rg-generated A/duck/Vietnam/2004 (H5N3), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,1,10,days,10,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,0,,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Papua/TA5/2006, H5N1 clade 2.1.3.1",10,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"A/goose/Guangdong/1/1996 (H5N1), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,2,5,days,6,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,0,,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Papua/TA5/2006, H5N1 clade 2.1.3.1",11,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"A/turkey/England/N28/1973 (H5N2), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,5,2,days,7,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,3,5.1,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Papua/TA5/2006, H5N1 clade 2.1.3.1",12,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"A/chicken/Mexico/232/1994 (H5N2), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,0,,,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,2,4.8,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Papua/TA5/2006, H5N1 clade 2.1.3.1",13,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"A/turkey/Wisconsin/1968 (H5N9), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,3,1,days,9,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,1,4.9,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Papua/TA5/2006, H5N1 clade 2.1.3.1",14,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,10,1,days,2,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",1,1,7.1,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java/PWT-WIJ/2006, H5N1 clade 2.1.3.2",15,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"A/chicken/Legok/2003 (H5N1), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,5,2,days,11,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,1,5.68,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java/PWT-WIJ/2006, H5N1 clade 2.1.3.2",16,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"rg-generated A/duck/Vietnam/2004 (H5N3), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,5,2,days,7,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,2,4.5,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java/PWT-WIJ/2006, H5N1 clade 2.1.3.2",17,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"A/turkey/England/N28/1973 (H5N2), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,10,2,days,6,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,8,6.13,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java/PWT-WIJ/2006, H5N1 clade 2.1.3.2",18,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"A/chicken/Mexico/232/1994 (H5N2), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,8,4,days,11,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,0,,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java/PWT-WIJ/2006, H5N1 clade 2.1.3.2",19,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"A/turkey/Wisconsin/1968 (H5N9), licensed in Indonesia",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"Manufacturere's recommended dose",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,10,3,days,5,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,4,5.4,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50482,"Swayne, D.E., Suarez, D.L., Spackman, E., Jadhao, S., Dauphin, G., Kim-Torchetti, M., McGrane, J., Weaver, J., Daniels, P., Wong, F., Selleck, P., Wiyono, A., Indriani, R., Yupiana, Y., Siregar, E.S., Prajitno, T., Smith, D., Fouchier, R. (2015).  Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia Journal of Virology, 89(7),  3746",seungeun.han,,4,,"United States",2015,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/West Java/PWT-WIJ/2006, H5N1 clade 2.1.3.2",20,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,10,1,days,2,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,10,6.3,"Other: specify","log10 virus titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value."
50489,"Kilany, W., Dauphin, G., Selim, A., Tripodi, A., Samy, M., Sobhy, H., VonDobschuetz, S., Safwat, M., Saad, M., Erfan, A., Hassan, M., Lubroth, J., Jobre, Y. (2014).  Protection conferred by recombinant turkey herpesvirus avian influenza (rHVT-H5) vaccine in the rearing period in two commercial layer chicken breeds in Egypt Avian Pathology, 43(6),  514",seungeun.han,,4,,Egypt,2014,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128s/2012, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.033,animal,,15,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"3.8 x 10^3 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",133,4,7,days,10,days,,,,,,,139,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off value of 40 Ct","Nucleic acid",,"Other (specify)","tracheal swab",15,1,3.5,"Other: specify","log10 PCR copies",,,
50489,"Kilany, W., Dauphin, G., Selim, A., Tripodi, A., Samy, M., Sobhy, H., VonDobschuetz, S., Safwat, M., Saad, M., Erfan, A., Hassan, M., Lubroth, J., Jobre, Y. (2014).  Protection conferred by recombinant turkey herpesvirus avian influenza (rHVT-H5) vaccine in the rearing period in two commercial layer chicken breeds in Egypt Avian Pathology, 43(6),  514",seungeun.han,,4,,Egypt,2014,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128s/2012, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.033,animal,,15,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"3.8 x 10^3 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",133,4,7,days,10,days,,,,,,,141,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off value of 40 Ct","Nucleic acid",,"Other (specify)","tracheal swab",14,2,2,"Other: specify","log10 PCR copies",,,
50489,"Kilany, W., Dauphin, G., Selim, A., Tripodi, A., Samy, M., Sobhy, H., VonDobschuetz, S., Safwat, M., Saad, M., Erfan, A., Hassan, M., Lubroth, J., Jobre, Y. (2014).  Protection conferred by recombinant turkey herpesvirus avian influenza (rHVT-H5) vaccine in the rearing period in two commercial layer chicken breeds in Egypt Avian Pathology, 43(6),  514",seungeun.han,,4,,Egypt,2014,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128s/2012, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.033,animal,,15,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"3.8 x 10^3 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",133,4,7,days,10,days,,,,,,,142,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off value of 40 Ct","Nucleic acid",,"Other (specify)","tracheal swab",12,1,2.5,"Other: specify","log10 PCR copies",,,
50489,"Kilany, W., Dauphin, G., Selim, A., Tripodi, A., Samy, M., Sobhy, H., VonDobschuetz, S., Safwat, M., Saad, M., Erfan, A., Hassan, M., Lubroth, J., Jobre, Y. (2014).  Protection conferred by recombinant turkey herpesvirus avian influenza (rHVT-H5) vaccine in the rearing period in two commercial layer chicken breeds in Egypt Avian Pathology, 43(6),  514",seungeun.han,,4,,Egypt,2014,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128s/2012, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.033,animal,,15,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"3.8 x 10^3 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",133,6,5,days,11,days,,,,,,,136,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off value of 40 Ct","Nucleic acid",,"Other (specify)","tracheal swab",15,1,4.5,"Other: specify","log10 PCR copies",,,
50489,"Kilany, W., Dauphin, G., Selim, A., Tripodi, A., Samy, M., Sobhy, H., VonDobschuetz, S., Safwat, M., Saad, M., Erfan, A., Hassan, M., Lubroth, J., Jobre, Y. (2014).  Protection conferred by recombinant turkey herpesvirus avian influenza (rHVT-H5) vaccine in the rearing period in two commercial layer chicken breeds in Egypt Avian Pathology, 43(6),  514",seungeun.han,,4,,Egypt,2014,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128s/2012, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.033,animal,,15,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"3.8 x 10^3 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",133,6,5,days,11,days,,,,,,,137,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off value of 40 Ct","Nucleic acid",,"Other (specify)","tracheal swab",15,1,3.2,"Other: specify","log10 PCR copies",,,
50489,"Kilany, W., Dauphin, G., Selim, A., Tripodi, A., Samy, M., Sobhy, H., VonDobschuetz, S., Safwat, M., Saad, M., Erfan, A., Hassan, M., Lubroth, J., Jobre, Y. (2014).  Protection conferred by recombinant turkey herpesvirus avian influenza (rHVT-H5) vaccine in the rearing period in two commercial layer chicken breeds in Egypt Avian Pathology, 43(6),  514",seungeun.han,,4,,Egypt,2014,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128s/2012, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.033,animal,,15,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"3.8 x 10^3 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",133,6,5,days,11,days,,,,,,,138,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off value of 40 Ct","Nucleic acid",,"Other (specify)","tracheal swab",14,1,2.7,"Other: specify","log10 PCR copies",,,
50489,"Kilany, W., Dauphin, G., Selim, A., Tripodi, A., Samy, M., Sobhy, H., VonDobschuetz, S., Safwat, M., Saad, M., Erfan, A., Hassan, M., Lubroth, J., Jobre, Y. (2014).  Protection conferred by recombinant turkey herpesvirus avian influenza (rHVT-H5) vaccine in the rearing period in two commercial layer chicken breeds in Egypt Avian Pathology, 43(6),  514",seungeun.han,,4,,Egypt,2014,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128s/2012, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.033,animal,,15,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"3.8 x 10^3 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",133,6,5,days,11,days,,,,,,,139,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off value of 40 Ct","Nucleic acid",,"Other (specify)","tracheal swab",13,2,2.9,"Other: specify","log10 PCR copies",,,
50489,"Kilany, W., Dauphin, G., Selim, A., Tripodi, A., Samy, M., Sobhy, H., VonDobschuetz, S., Safwat, M., Saad, M., Erfan, A., Hassan, M., Lubroth, J., Jobre, Y. (2014).  Protection conferred by recombinant turkey herpesvirus avian influenza (rHVT-H5) vaccine in the rearing period in two commercial layer chicken breeds in Egypt Avian Pathology, 43(6),  514",seungeun.han,,4,,Egypt,2014,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128s/2012, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.033,animal,,15,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"3.8 x 10^3 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",133,6,5,days,11,days,,,,,,,142,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off value of 40 Ct","Nucleic acid",,"Other (specify)","tracheal swab",11,1,4.8,"Other: specify","log10 PCR copies",,,
50489,"Kilany, W., Dauphin, G., Selim, A., Tripodi, A., Samy, M., Sobhy, H., VonDobschuetz, S., Safwat, M., Saad, M., Erfan, A., Hassan, M., Lubroth, J., Jobre, Y. (2014).  Protection conferred by recombinant turkey herpesvirus avian influenza (rHVT-H5) vaccine in the rearing period in two commercial layer chicken breeds in Egypt Avian Pathology, 43(6),  514",seungeun.han,,4,,Egypt,2014,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128s/2012, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.033,animal,,15,commercial,,"Vectormune AI (rHVT-H5)",,"Other (specify):","Live recombinant vector vaccine",SUBCUTANEOUS,,0,"3.8 x 10^3 pfu/bird",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",133,6,5,days,11,days,,,,,,,143,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off value of 40 Ct","Nucleic acid",,"Other (specify)","tracheal swab",10,1,2.6,"Other: specify","log10 PCR copies",,,
50489,"Kilany, W., Dauphin, G., Selim, A., Tripodi, A., Samy, M., Sobhy, H., VonDobschuetz, S., Safwat, M., Saad, M., Erfan, A., Hassan, M., Lubroth, J., Jobre, Y. (2014).  Protection conferred by recombinant turkey herpesvirus avian influenza (rHVT-H5) vaccine in the rearing period in two commercial layer chicken breeds in Egypt Avian Pathology, 43(6),  514",seungeun.han,,4,,Egypt,2014,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128s/2012, H5N1 clade 2.2.1",3,"Chickens (Gallus)",,0.033,animal,,15,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",133,10,3,days,5,days,,,,,,,136,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off value of 40 Ct","Nucleic acid",,"Other (specify)","tracheal swab",10,10,3.7,"Other: specify","log10 PCR copies",,,
50489,"Kilany, W., Dauphin, G., Selim, A., Tripodi, A., Samy, M., Sobhy, H., VonDobschuetz, S., Safwat, M., Saad, M., Erfan, A., Hassan, M., Lubroth, J., Jobre, Y. (2014).  Protection conferred by recombinant turkey herpesvirus avian influenza (rHVT-H5) vaccine in the rearing period in two commercial layer chicken breeds in Egypt Avian Pathology, 43(6),  514",seungeun.han,,4,,Egypt,2014,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128s/2012, H5N1 clade 2.2.1",3,"Chickens (Gallus)",,0.033,animal,,15,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",133,10,3,days,5,days,,,,,,,137,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off value of 40 Ct","Nucleic acid",,"Other (specify)","tracheal swab",4,4,4.1,"Other: specify","log10 PCR copies",,,
50489,"Kilany, W., Dauphin, G., Selim, A., Tripodi, A., Samy, M., Sobhy, H., VonDobschuetz, S., Safwat, M., Saad, M., Erfan, A., Hassan, M., Lubroth, J., Jobre, Y. (2014).  Protection conferred by recombinant turkey herpesvirus avian influenza (rHVT-H5) vaccine in the rearing period in two commercial layer chicken breeds in Egypt Avian Pathology, 43(6),  514",seungeun.han,,4,,Egypt,2014,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Egypt/128s/2012, H5N1 clade 2.2.1",3,"Chickens (Gallus)",,0.033,animal,,15,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",133,10,3,days,5,days,,,,,,,138,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off value of 40 Ct","Nucleic acid",,"Other (specify)","tracheal swab",1,1,4.5,"Other: specify","log10 PCR copies",,,
50511,"Kilany, W.H., Abdelwhab, E.M., Arafa, A.-S., Selim, A., Safwat, M., Nawar, A.A., Erfan, A.M., Hassan, M.K., Aly, M.M., Hafez, H.M. (2014).  Corrigendum to Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus [Vet. Microbiol., 150, (2011), 28-34] Veterinary Microbiology, 170(1-2),  178",seungeun.han,,4,,Egypt,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/086Q-NLQP/2008, H5N1 clade 2.2.1",1,"Turkeys (Meleagridis)",,0.25,animal,,10,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,10,4,days,8,days,,,,,,,14,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,-1,-1,2.3,titer,,,,"The number of animals tested and positive by HI assay was not provided."
50511,"Kilany, W.H., Abdelwhab, E.M., Arafa, A.-S., Selim, A., Safwat, M., Nawar, A.A., Erfan, A.M., Hassan, M.K., Aly, M.M., Hafez, H.M. (2014).  Corrigendum to Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus [Vet. Microbiol., 150, (2011), 28-34] Veterinary Microbiology, 170(1-2),  178",seungeun.han,,4,,Egypt,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/086Q-NLQP/2008, H5N1 clade 2.2.1",1,"Turkeys (Meleagridis)",,0.25,animal,,10,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,10,4,days,8,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,-1,-1,3.8,titer,,,,"The number of animals tested and positive by HI assay was not provided."
50511,"Kilany, W.H., Abdelwhab, E.M., Arafa, A.-S., Selim, A., Safwat, M., Nawar, A.A., Erfan, A.M., Hassan, M.K., Aly, M.M., Hafez, H.M. (2014).  Corrigendum to Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus [Vet. Microbiol., 150, (2011), 28-34] Veterinary Microbiology, 170(1-2),  178",seungeun.han,,4,,Egypt,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/086Q-NLQP/2008, H5N1 clade 2.2.1",1,"Turkeys (Meleagridis)",,0.25,animal,,10,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,10,4,days,8,days,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,-1,-1,4.2,titer,,,,"The number of animals tested and positive by HI assay was not provided."
50511,"Kilany, W.H., Abdelwhab, E.M., Arafa, A.-S., Selim, A., Safwat, M., Nawar, A.A., Erfan, A.M., Hassan, M.K., Aly, M.M., Hafez, H.M. (2014).  Corrigendum to Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus [Vet. Microbiol., 150, (2011), 28-34] Veterinary Microbiology, 170(1-2),  178",seungeun.han,,4,,Egypt,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/086Q-NLQP/2008, H5N1 clade 2.2.1",1,"Turkeys (Meleagridis)",,0.25,animal,,10,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,10,4,days,8,days,,,,,,,29,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal and cloacal swab",10,6,10^3.1,"Other: specify",EID50/ml,,,"The number of animals tested and positive by HI assay was not provided."
50511,"Kilany, W.H., Abdelwhab, E.M., Arafa, A.-S., Selim, A., Safwat, M., Nawar, A.A., Erfan, A.M., Hassan, M.K., Aly, M.M., Hafez, H.M. (2014).  Corrigendum to Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus [Vet. Microbiol., 150, (2011), 28-34] Veterinary Microbiology, 170(1-2),  178",seungeun.han,,4,,Egypt,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/086Q-NLQP/2008, H5N1 clade 2.2.1",1,"Turkeys (Meleagridis)",,0.25,animal,,10,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,10,4,days,8,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal and cloacal swab",10,10,10^3.7,"Other: specify",EID50/ml,,,"The number of animals tested and positive by HI assay was not provided."
50511,"Kilany, W.H., Abdelwhab, E.M., Arafa, A.-S., Selim, A., Safwat, M., Nawar, A.A., Erfan, A.M., Hassan, M.K., Aly, M.M., Hafez, H.M. (2014).  Corrigendum to Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus [Vet. Microbiol., 150, (2011), 28-34] Veterinary Microbiology, 170(1-2),  178",seungeun.han,,4,,Egypt,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/086Q-NLQP/2008, H5N1 clade 2.2.1",1,"Turkeys (Meleagridis)",,0.25,animal,,10,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,10,4,days,8,days,,,,,,,34,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal and cloacal swab",3,3,10^5.5,"Other: specify",EID50/ml,,,"The number of animals tested and positive by HI assay was not provided."
50511,"Kilany, W.H., Abdelwhab, E.M., Arafa, A.-S., Selim, A., Safwat, M., Nawar, A.A., Erfan, A.M., Hassan, M.K., Aly, M.M., Hafez, H.M. (2014).  Corrigendum to Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus [Vet. Microbiol., 150, (2011), 28-34] Veterinary Microbiology, 170(1-2),  178",seungeun.han,,4,,Egypt,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/086Q-NLQP/2008, H5N1 clade 2.2.1",2,"Turkeys (Meleagridis)",,0.25,animal,,10,commercial,,Re-1,,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,4,5,days,7,days,,,,,,,14,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,-1,-1,3.5,titer,,,,"The number of animals tested and positive by HI assay was not provided."
50511,"Kilany, W.H., Abdelwhab, E.M., Arafa, A.-S., Selim, A., Safwat, M., Nawar, A.A., Erfan, A.M., Hassan, M.K., Aly, M.M., Hafez, H.M. (2014).  Corrigendum to Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus [Vet. Microbiol., 150, (2011), 28-34] Veterinary Microbiology, 170(1-2),  178",seungeun.han,,4,,Egypt,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/086Q-NLQP/2008, H5N1 clade 2.2.1",2,"Turkeys (Meleagridis)",,0.25,animal,,10,commercial,,Re-1,,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,4,5,days,7,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,-1,-1,4.7,titer,,,,"The number of animals tested and positive by HI assay was not provided."
50511,"Kilany, W.H., Abdelwhab, E.M., Arafa, A.-S., Selim, A., Safwat, M., Nawar, A.A., Erfan, A.M., Hassan, M.K., Aly, M.M., Hafez, H.M. (2014).  Corrigendum to Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus [Vet. Microbiol., 150, (2011), 28-34] Veterinary Microbiology, 170(1-2),  178",seungeun.han,,4,,Egypt,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/086Q-NLQP/2008, H5N1 clade 2.2.1",2,"Turkeys (Meleagridis)",,0.25,animal,,10,commercial,,Re-1,,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,4,5,days,7,days,,,,,,,28,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,-1,-1,6.8,titer,,,,"The number of animals tested and positive by HI assay was not provided."
50511,"Kilany, W.H., Abdelwhab, E.M., Arafa, A.-S., Selim, A., Safwat, M., Nawar, A.A., Erfan, A.M., Hassan, M.K., Aly, M.M., Hafez, H.M. (2014).  Corrigendum to Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus [Vet. Microbiol., 150, (2011), 28-34] Veterinary Microbiology, 170(1-2),  178",seungeun.han,,4,,Egypt,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/086Q-NLQP/2008, H5N1 clade 2.2.1",2,"Turkeys (Meleagridis)",,0.25,animal,,10,commercial,,Re-1,,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,4,5,days,7,days,,,,,,,29,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal and cloacal swab",10,1,10^3.6,"Other: specify",EID50/ml,,,"The number of animals tested and positive by HI assay was not provided."
50511,"Kilany, W.H., Abdelwhab, E.M., Arafa, A.-S., Selim, A., Safwat, M., Nawar, A.A., Erfan, A.M., Hassan, M.K., Aly, M.M., Hafez, H.M. (2014).  Corrigendum to Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus [Vet. Microbiol., 150, (2011), 28-34] Veterinary Microbiology, 170(1-2),  178",seungeun.han,,4,,Egypt,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/086Q-NLQP/2008, H5N1 clade 2.2.1",2,"Turkeys (Meleagridis)",,0.25,animal,,10,commercial,,Re-1,,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,4,5,days,7,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal and cloacal swab",10,5,10^3.4,"Other: specify",EID50/ml,,,"The number of animals tested and positive by HI assay was not provided."
50511,"Kilany, W.H., Abdelwhab, E.M., Arafa, A.-S., Selim, A., Safwat, M., Nawar, A.A., Erfan, A.M., Hassan, M.K., Aly, M.M., Hafez, H.M. (2014).  Corrigendum to Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus [Vet. Microbiol., 150, (2011), 28-34] Veterinary Microbiology, 170(1-2),  178",seungeun.han,,4,,Egypt,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/086Q-NLQP/2008, H5N1 clade 2.2.1",2,"Turkeys (Meleagridis)",,0.25,animal,,10,commercial,,Re-1,,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,4,5,days,7,days,,,,,,,34,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal and cloacal swab",6,2,10^3.4,"Other: specify",EID50/ml,,,"The number of animals tested and positive by HI assay was not provided."
50511,"Kilany, W.H., Abdelwhab, E.M., Arafa, A.-S., Selim, A., Safwat, M., Nawar, A.A., Erfan, A.M., Hassan, M.K., Aly, M.M., Hafez, H.M. (2014).  Corrigendum to Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus [Vet. Microbiol., 150, (2011), 28-34] Veterinary Microbiology, 170(1-2),  178",seungeun.han,,4,,Egypt,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/086Q-NLQP/2008, H5N1 clade 2.2.1",3,"Turkeys (Meleagridis)",,0.25,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,10,2,days,4,days,,,,,,,29,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal and cloacal swab",10,4,10^3.8,"Other: specify",EID50/ml,,,"The number of animals tested and positive by HI assay was not provided."
50511,"Kilany, W.H., Abdelwhab, E.M., Arafa, A.-S., Selim, A., Safwat, M., Nawar, A.A., Erfan, A.M., Hassan, M.K., Aly, M.M., Hafez, H.M. (2014).  Corrigendum to Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus [Vet. Microbiol., 150, (2011), 28-34] Veterinary Microbiology, 170(1-2),  178",seungeun.han,,4,,Egypt,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/086Q-NLQP/2008, H5N1 clade 2.2.1",3,"Turkeys (Meleagridis)",,0.25,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,10,2,days,4,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal and cloacal swab",7,7,10^5.6,"Other: specify",EID50/ml,,,"The number of animals tested and positive by HI assay was not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",1,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,24,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",47,0,,,,,,,,,,,24,"Not vaccinated/Before vaccination","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,18,18,0.31,"Other: specify","log2 titer",,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",1,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,24,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",47,0,,,,,,,,,,,31,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,16,9,0.81,"Other: specify","log2 titer",,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",1,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,24,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",47,0,,,,,,,,,,,38,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,14,14,3.07,"Other: specify","log2 titer",,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",1,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,24,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",47,0,,,,,,,,,,,45,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,12,12,4.08,"Other: specify","log2 titer",,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",1,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,24,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",47,0,,,,,,,,,,,50,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",10,5,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",1,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,24,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",47,0,,,,,,,,,,,52,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",10,5,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",1,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,24,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",47,0,,,,,,,,,,,54,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",10,3,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",1,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,24,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",47,0,,,,,,,,,,,50,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,10,3,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",1,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,24,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",47,0,,,,,,,,,,,52,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,10,2,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",1,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,24,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",47,0,,,,,,,,,,,54,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,10,1,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",2,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",47,18,-1,,-1,,,,,,,,50,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",11,11,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",2,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",47,18,-1,,-1,,,,,,,,52,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",7,7,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",2,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",47,18,-1,,-1,,,,,,,,50,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,11,7,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",2,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",47,18,-1,,-1,,,,,,,,52,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,7,7,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",3,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",31,0,,,,,,,,,,,17,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,18,12,1,"Other: specify","log2 titer",,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",3,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",31,0,,,,,,,,,,,24,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,16,16,3.5,"Other: specify","log2 titer",,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",3,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",31,0,,,,,,,,,,,31,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,14,14,4.64,"Other: specify","log2 titer",,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",3,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",31,0,,,,,,,,,,,34,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",10,5,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",3,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",31,0,,,,,,,,,,,36,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",10,4,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",3,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",31,0,,,,,,,,,,,38,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",10,2,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",3,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",31,0,,,,,,,,,,,34,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,10,3,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",3,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"H5N1 Re-5",,"Other (specify):",Inactivated,SUBCUTANEOUS,,10,"0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",31,0,,,,,,,,,,,36,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,10,1,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",4,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",31,18,-1,,-1,,,,,,,,34,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",12,12,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",4,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",31,18,-1,,-1,,,,,,,,36,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",2,2,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",4,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",31,18,-1,,-1,,,,,,,,34,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",12,10,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50567,"Qian, C., Chen, S., Ding, P., Chai, M., Xu, C., Gan, J., Peng, D., Liu, X. (2012).  The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks Vaccine, 30(44),  6279",seungeun.han,,4,,China,2012,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/mallard/Huadong/SY/2005, H5N1 clade 2.3.4",4,"Ducks (Anatidae)",,0.033,animal,,18,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","nose/eye drop",,"10^5.75 EID50",31,18,-1,,-1,,,,,,,,36,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",2,2,pos,"Other: specify",pos/neg,,,"Ducks in studyID 1, 2 were Gaoyou ducks. Ducks in studyID 3, 4 were cherry valley ducks. Mortality days were not provided."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",1,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",161,2,5,days,5,days,,,,,,,164,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",8,8,31.43,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",1,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",161,2,5,days,5,days,,,,,,,168,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",6,5,27.43,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",1,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",161,2,5,days,5,days,,,,,,,171,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",6,5,33.59,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",1,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",161,2,5,days,5,days,,,,,,,164,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",8,3,163,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",1,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",161,2,5,days,5,days,,,,,,,168,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",5,2,126,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",4,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",189,0,,,,,,,,,,,192,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",8,4,34.95,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",4,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",189,0,,,,,,,,,,,196,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",8,3,33.73,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",4,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",189,0,,,,,,,,,,,199,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",8,1,33.73,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",2,"Chickens (Gallus)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","direct contact with studyID 1",,,161,5,4,days,4,days,,,,,,,164,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",5,3,35.25,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",3,"Chickens (Gallus)",,0.033,animal,,3,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",161,3,4,days,5,days,,,,,,,164,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",3,3,27.18,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",3,"Chickens (Gallus)",,0.033,animal,,3,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",161,3,4,days,5,days,,,,,,,164,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",3,3,1570,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",5,"Chickens (Gallus)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","direct contact with studyID 4",,,189,5,3,days,6,days,,,,,,,192,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",5,2,26.36,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",5,"Chickens (Gallus)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","direct contact with studyID 4",,,189,5,3,days,6,days,,,,,,,192,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",2,2,218,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",6,"Chickens (Gallus)",,0.033,animal,,3,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",189,3,3,days,3,days,,,,,,,192,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",3,3,25.62,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",6,"Chickens (Gallus)",,0.033,animal,,3,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",189,3,3,days,3,days,,,,,,,192,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",3,3,903,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",7,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",336,2,6,days,7,days,,,,,,,339,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",8,7,32.11,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",7,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",336,2,6,days,7,days,,,,,,,343,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",7,7,28.37,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",7,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",336,2,6,days,7,days,,,,,,,346,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",5,3,36.25,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",7,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",336,2,6,days,7,days,,,,,,,339,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",7,2,381,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",7,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",336,2,6,days,7,days,,,,,,,343,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",7,5,510,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",8,"Chickens (Gallus)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","direct contact with studyID 7",,,336,5,3,days,7,days,,,,,,,339,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",5,1,34.89,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",8,"Chickens (Gallus)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","direct contact with studyID 7",,,336,5,3,days,7,days,,,,,,,343,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",2,2,23.79,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",8,"Chickens (Gallus)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","direct contact with studyID 7",,,336,5,3,days,7,days,,,,,,,343,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",2,2,504,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",9,"Chickens (Gallus)",,0.033,animal,,3,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EId50",336,3,3,days,4,days,,,,,,,339,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",3,3,31.76,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",9,"Chickens (Gallus)",,0.033,animal,,3,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EId50",336,3,3,days,4,days,,,,,,,339,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",3,3,296,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",10,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EId50",518,3,4,days,6,days,,,,,,,521,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",8,8,33.19,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",10,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EId50",518,3,4,days,6,days,,,,,,,525,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",7,7,31.53,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",10,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EId50",518,3,4,days,6,days,,,,,,,521,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",8,2,178,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",10,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EId50",518,3,4,days,6,days,,,,,,,525,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",7,2,715,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",11,"Chickens (Gallus)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","direct contact with studyID 10",,,518,0,,,,,,,,,,,521,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",5,5,37.92,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",11,"Chickens (Gallus)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","direct contact with studyID 10",,,518,0,,,,,,,,,,,525,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",5,4,33.2,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",11,"Chickens (Gallus)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","direct contact with studyID 10",,,518,0,,,,,,,,,,,528,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",5,3,33.75,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",11,"Chickens (Gallus)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","direct contact with studyID 10",,,518,0,,,,,,,,,,,525,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",4,2,225,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",12,"Chickens (Gallus)",,0.033,animal,,3,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",518,3,2,days,4,days,,,,,,,521,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",1,1,31.1,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",12,"Chickens (Gallus)",,0.033,animal,,3,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",518,3,2,days,4,days,,,,,,,521,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",1,1,398,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",13,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",336,"0.5 ml","Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",518,1,8,days,8,days,,,,,,,521,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",8,6,34.99,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",13,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",336,"0.5 ml","Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",518,1,8,days,8,days,,,,,,,525,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",8,5,35.43,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",13,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",336,"0.5 ml","Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",518,1,8,days,8,days,,,,,,,521,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",6,2,103,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",14,"Chickens (Gallus)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","direct contact with studyID 13",,,518,0,,,,,,,,,,,521,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",5,3,37.99,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",15,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",707,5,6,days,10,days,,,,,,,710,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",8,8,28.8,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",15,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",707,5,6,days,10,days,,,,,,,714,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",8,8,31.53,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",15,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",707,5,6,days,10,days,,,,,,,717,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",3,2,33.73,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",15,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",707,5,6,days,10,days,,,,,,,710,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",8,4,47100,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",15,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"10^6 EID50",707,5,6,days,10,days,,,,,,,714,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",8,3,44300,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",16,"Chickens (Gallus)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","direct contact with studyID 15",,,707,2,7,days,10,days,,,,,,,710,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",5,2,35.89,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",16,"Chickens (Gallus)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","direct contact with studyID 15",,,707,2,7,days,10,days,,,,,,,714,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",5,5,25.83,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",16,"Chickens (Gallus)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","direct contact with studyID 15",,,707,2,7,days,10,days,,,,,,,717,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",4,4,31.03,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",16,"Chickens (Gallus)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","direct contact with studyID 15",,,707,2,7,days,10,days,,,,,,,714,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",5,5,11500,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",17,"Chickens (Gallus)",,0.033,animal,,3,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"1066 EID50",707,3,3,days,6,days,,,,,,,710,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",3,3,27.12,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",17,"Chickens (Gallus)",,0.033,animal,,3,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"1066 EID50",707,3,3,days,6,days,,,,,,,714,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",1,1,28.95,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",17,"Chickens (Gallus)",,0.033,animal,,3,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"1066 EID50",707,3,3,days,6,days,,,,,,,714,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal/cloacal swabs",1,1,126,titer,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",18,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",336,"0.5 ml","Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"1066 EID50",707,0,,,,,,,,,,,710,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",8,6,34.38,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",18,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",336,"0.5 ml","Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"1066 EID50",707,0,,,,,,,,,,,714,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",8,5,33.23,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",18,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,INTRAMUSCULAR,,140,"0.5 ml",161,"0.5 ml",336,"0.5 ml","Challenged with the pathogen","OTHER: specify",oculo-oronasal,,"1066 EID50",707,0,,,,,,,,,,,717,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",8,1,37.74,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50611,"Rudolf, M., Pöppel, M., Fröhlich, A., Breithaupt, A., Teifke, J., Blohm, U., Mettenleiter, T., Beer, M., Harder, T. (2010).  Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens Vaccine, 28(42),  6832",seungeun.han,,4,,Germany,2010,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Cygnus cygnus/Germany/R65/06, H5N1 clade 2.2",19,"Chickens (Gallus)",,0.033,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","direct contact with studyID 18",,,707,0,,,,,,,,,,,714,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct 40","Nucleic acid",,"Other (specify)","oropharyngeal/cloacal swabs",5,2,34.81,Cq/Ct,,,,"A free-range flock of 3,600 chickens was vaccinated at the field condition. Challenge experiments were conducted in a laboratory condition with the selected number of chickens from each vaccination group."
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify","Volvac AI KV","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,2,5,days,7,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,10,10,11.3,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify","Volvac AI KV","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,2,5,days,7,days,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,9,9,13.11,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify","Volvac AI KV","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,2,5,days,7,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,8,8,9.5,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify","Volvac AI KV","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,2,5,days,7,days,,,,,,,49,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,8,8,9.75,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify","Volvac AI KV","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,2,5,days,7,days,,,,,,,56,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,8,8,10.5,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify","Volvac AI KV","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,2,5,days,7,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,10,2,0.3,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify","Volvac AI KV","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,2,5,days,7,days,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,9,5,1.22,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify","Volvac AI KV","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,2,5,days,7,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,8,5,1.5,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify","Volvac AI KV","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,2,5,days,7,days,,,,,,,49,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,8,5,1.88,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify","Volvac AI KV","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,2,5,days,7,days,,,,,,,56,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,8,5,1.75,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify","Volvac AI KV","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,2,5,days,7,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct value was 35","Nucleic acid",,"Other (specify)","tracheal/cloacal swab",10,2,pos,"Other: specify",pos/neg,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",1,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Other: specify","Volvac AI KV","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,2,5,days,7,days,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct value was 35","Nucleic acid",,"Other (specify)","tracheal/cloacal swab",9,1,pos,"Other: specify",pos/neg,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Volvac AI + ND KV",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,1,5,days,5,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,10,10,11.3,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Volvac AI + ND KV",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,1,5,days,5,days,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,9,9,11.33,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Volvac AI + ND KV",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,1,5,days,5,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,9,9,10.22,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Volvac AI + ND KV",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,1,5,days,5,days,,,,,,,49,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,9,9,8.78,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Volvac AI + ND KV",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,1,5,days,5,days,,,,,,,56,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,9,9,8.56,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Volvac AI + ND KV",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,1,5,days,5,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen",Antibody,,"Blood serum (as part-nature)",,10,1,0.4,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Volvac AI + ND KV",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,1,5,days,5,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,10,1,0.4,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Volvac AI + ND KV",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,1,5,days,5,days,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,9,5,1.11,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Volvac AI + ND KV",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,1,5,days,5,days,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,9,7,1.22,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Volvac AI + ND KV",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,1,5,days,5,days,,,,,,,49,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,9,7,1.56,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Volvac AI + ND KV",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,1,5,days,5,days,,,,,,,56,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen",Antibody,,"Blood serum (as part-nature)",,9,7,1.11,titer,,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Volvac AI + ND KV",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"10^8.5 EID50/0.5 ml",,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,1,5,days,5,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct value was 35","Nucleic acid",,"Other (specify)","tracheal/cloacal swab",10,1,pos,"Other: specify",pos/neg,,,
50620,"Terregino, C., Toffan, A., Cilloni, F., Monne, I., Bertoli, E., Castellanos, L., Amarin, N., Mancin, M., Capua, I. (2010).  Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests Avian Pathology, 39(3),  215",seungeun.han,,4,,Egypt,2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/chicken/Egypt/1709-6/08, H5N1 clade 2.2.1",3,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",28,10,3,days,5,days,,,,,,,31,"After challenge","Reverse-transcription PCR (RT-PCR)","Cut-off Ct value was 35","Nucleic acid",,"Other (specify)","tracheal/cloacal swab",10,10,pos,"Other: specify",pos/neg,,,
50629,"Bublot, M., Manvell, R.J., Shell, W., Brown, I.H. (2010).  High level of protection induced by two fowlpox vector vaccines against a highly pathogenic avian influenza H5N1 challenge in specific-pathogen-free chickens Avian Diseases, 54(SUPPL. 1),  257",seungeun.han,,4,,"United Kingdom",2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Turkey/1/2005, H5N1 clade 2.2",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","Recombinant fowpox vectored vaccine",SUBCUTANEOUS,,0,"3 log10 TCID50/0.2ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",21,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 2 log2",Antibody,,"Blood serum (as part-nature)",,-1,-1,3.5,"Other: specify","log2 titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. The number of seroconverted birds was not given. Swabs were collected from the challenge day through the experiment and tested by PCR. The result showed only the total number of positive birds. It was not described when the positive swabs were collected. The animals in studyID2 were challenged by direct contact with studyID 1. StudyID 4 was challenged by contact with studyID 3."
50629,"Bublot, M., Manvell, R.J., Shell, W., Brown, I.H. (2010).  High level of protection induced by two fowlpox vector vaccines against a highly pathogenic avian influenza H5N1 challenge in specific-pathogen-free chickens Avian Diseases, 54(SUPPL. 1),  257",seungeun.han,,4,,"United Kingdom",2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Turkey/1/2005, H5N1 clade 2.2",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","Recombinant fowpox vectored vaccine",SUBCUTANEOUS,,0,"3 log10 TCID50/0.2ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",21,0,,,,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 2 log2",Antibody,,"Blood serum (as part-nature)",,-1,-1,5.1,"Other: specify","log2 titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. The number of seroconverted birds was not given. Swabs were collected from the challenge day through the experiment and tested by PCR. The result showed only the total number of positive birds. It was not described when the positive swabs were collected. The animals in studyID2 were challenged by direct contact with studyID 1. StudyID 4 was challenged by contact with studyID 3."
50629,"Bublot, M., Manvell, R.J., Shell, W., Brown, I.H. (2010).  High level of protection induced by two fowlpox vector vaccines against a highly pathogenic avian influenza H5N1 challenge in specific-pathogen-free chickens Avian Diseases, 54(SUPPL. 1),  257",seungeun.han,,4,,"United Kingdom",2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Turkey/1/2005, H5N1 clade 2.2",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","Recombinant fowpox vectored vaccine",SUBCUTANEOUS,,0,"3 log10 TCID50/0.2ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",21,0,,,,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen; cut-off 2 log2",Antibody,,"Blood serum (as part-nature)",,-1,-1,2.5,"Other: specify","log2 titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. The number of seroconverted birds was not given. Swabs were collected from the challenge day through the experiment and tested by PCR. The result showed only the total number of positive birds. It was not described when the positive swabs were collected. The animals in studyID2 were challenged by direct contact with studyID 1. StudyID 4 was challenged by contact with studyID 3."
50629,"Bublot, M., Manvell, R.J., Shell, W., Brown, I.H. (2010).  High level of protection induced by two fowlpox vector vaccines against a highly pathogenic avian influenza H5N1 challenge in specific-pathogen-free chickens Avian Diseases, 54(SUPPL. 1),  257",seungeun.han,,4,,"United Kingdom",2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Turkey/1/2005, H5N1 clade 2.2",1,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","Recombinant fowpox vectored vaccine",SUBCUTANEOUS,,0,"3 log10 TCID50/0.2ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",21,0,,,,,,,,,,,-1,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,3,pos,"Other: specify",pos/neg,,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. The number of seroconverted birds was not given. Swabs were collected from the challenge day through the experiment and tested by PCR. The result showed only the total number of positive birds. It was not described when the positive swabs were collected. The animals in studyID2 were challenged by direct contact with studyID 1. StudyID 4 was challenged by contact with studyID 3."
50629,"Bublot, M., Manvell, R.J., Shell, W., Brown, I.H. (2010).  High level of protection induced by two fowlpox vector vaccines against a highly pathogenic avian influenza H5N1 challenge in specific-pathogen-free chickens Avian Diseases, 54(SUPPL. 1),  257",seungeun.han,,4,,"United Kingdom",2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Turkey/1/2005, H5N1 clade 2.2",2,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"TROVAC AIV-H5 (recombinant)",,"Other (specify):","Recombinant fowpox vectored vaccine",SUBCUTANEOUS,,0,"3 log10 TCID50/0.2ml",,,,,"Challenged with the pathogen","OTHER: specify","Direct contact",,,22,0,,,,,,,,,,,42,"After challenge","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 2 log2",Antibody,,"Blood serum (as part-nature)",,-1,-1,3.8,"Other: specify","log2 titer",,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. The number of seroconverted birds was not given. Swabs were collected from the challenge day through the experiment and tested by PCR. The result showed only the total number of positive birds. It was not described when the positive swabs were collected. The animals in studyID2 were challenged by direct contact with studyID 1. StudyID 4 was challenged by contact with studyID 3."
50629,"Bublot, M., Manvell, R.J., Shell, W., Brown, I.H. (2010).  High level of protection induced by two fowlpox vector vaccines against a highly pathogenic avian influenza H5N1 challenge in specific-pathogen-free chickens Avian Diseases, 54(SUPPL. 1),  257",seungeun.han,,4,,"United Kingdom",2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Turkey/1/2005, H5N1 clade 2.2",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,10,2,days,3,days,,,,,,,-1,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",3,3,pos,"Other: specify",pos/neg,,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. The number of seroconverted birds was not given. Swabs were collected from the challenge day through the experiment and tested by PCR. The result showed only the total number of positive birds. It was not described when the positive swabs were collected. The animals in studyID2 were challenged by direct contact with studyID 1. StudyID 4 was challenged by contact with studyID 3."
50629,"Bublot, M., Manvell, R.J., Shell, W., Brown, I.H. (2010).  High level of protection induced by two fowlpox vector vaccines against a highly pathogenic avian influenza H5N1 challenge in specific-pathogen-free chickens Avian Diseases, 54(SUPPL. 1),  257",seungeun.han,,4,,"United Kingdom",2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Turkey/1/2005, H5N1 clade 2.2",3,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID50",21,10,2,days,3,days,,,,,,,-1,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,3,3,pos,"Other: specify",pos/neg,,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. The number of seroconverted birds was not given. Swabs were collected from the challenge day through the experiment and tested by PCR. The result showed only the total number of positive birds. It was not described when the positive swabs were collected. The animals in studyID2 were challenged by direct contact with studyID 1. StudyID 4 was challenged by contact with studyID 3."
50629,"Bublot, M., Manvell, R.J., Shell, W., Brown, I.H. (2010).  High level of protection induced by two fowlpox vector vaccines against a highly pathogenic avian influenza H5N1 challenge in specific-pathogen-free chickens Avian Diseases, 54(SUPPL. 1),  257",seungeun.han,,4,,"United Kingdom",2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Turkey/1/2005, H5N1 clade 2.2",4,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Direct contact",,,22,9,4,days,9,days,,,,,,,-1,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","oropharyngeal swab",10,8,pos,"Other: specify",pos/neg,,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. The number of seroconverted birds was not given. Swabs were collected from the challenge day through the experiment and tested by PCR. The result showed only the total number of positive birds. It was not described when the positive swabs were collected. The animals in studyID2 were challenged by direct contact with studyID 1. StudyID 4 was challenged by contact with studyID 3."
50629,"Bublot, M., Manvell, R.J., Shell, W., Brown, I.H. (2010).  High level of protection induced by two fowlpox vector vaccines against a highly pathogenic avian influenza H5N1 challenge in specific-pathogen-free chickens Avian Diseases, 54(SUPPL. 1),  257",seungeun.han,,4,,"United Kingdom",2009,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/turkey/Turkey/1/2005, H5N1 clade 2.2",4,"Chickens (Gallus)",,0.033,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Direct contact",,,22,9,4,days,9,days,,,,,,,-1,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,8,pos,"Other: specify",pos/neg,,,"The results of HI antibody test were presented by visual graphs, so the result values of HIT were visually estimated to report on Question 45 test Value. The number of seroconverted birds was not given. Swabs were collected from the challenge day through the experiment and tested by PCR. The result showed only the total number of positive birds. It was not described when the positive swabs were collected. The animals in studyID2 were challenged by direct contact with studyID 1. StudyID 4 was challenged by contact with studyID 3."
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",28,"1 ml",,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,0,,,,,,,,,,,54,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,2,pos,"Other: specify",pos/neg,,,
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",28,"1 ml",,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,0,,,,,,,,,,,56,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,1,pos,"Other: specify",pos/neg,,,
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",28,"1 ml",,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,0,,,,,,,,,,,58,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,2,pos,"Other: specify",pos/neg,,,
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",28,"1 ml",,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,0,,,,,,,,,,,61,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,1,pos,"Other: specify",pos/neg,,,
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",1,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",28,"1 ml",,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,0,,,,,,,,,,,54,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,1,pos,"Other: specify",pos/neg,,,
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,7,3,days,7,days,,,,,,,54,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",10,9,pos,"Other: specify",pos/neg,,,
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,7,3,days,7,days,,,,,,,56,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",5,2,pos,"Other: specify",pos/neg,,,
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,7,3,days,7,days,,,,,,,58,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",4,2,pos,"Other: specify",pos/neg,,,
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,7,3,days,7,days,,,,,,,61,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Other (specify)","tracheal swab",3,1,pos,"Other: specify",pos/neg,,,
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,7,3,days,7,days,,,,,,,54,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,10,2,pos,"Other: specify",pos/neg,,,
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,7,3,days,7,days,,,,,,,58,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,4,1,pos,"Other: specify",pos/neg,,,
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,7,3,days,7,days,,,,,,,61,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Rectum-anal swab (as part-nature)",,3,2,pos,"Other: specify",pos/neg,,,
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,7,3,days,7,days,,,,,,,54,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","tracheal swab",10,9,pos,"Other: specify",pos/neg,,,
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",2,"Ducks (Anatidae)",,0.033,animal,,10,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,7,3,days,7,days,,,,,,,54,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,10,4,pos,"Other: specify",pos/neg,,,
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",3,"Ducks (Anatidae)",,0.033,animal,,5,commercial,,"Nobilis Influenza H5N2",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"0.5 ml",28,"1 ml",,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,,,,,,,,,,,,54,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","Organ tissues",5,0,,"Other: specify",pos/neg,,,"Virus was not isolated from any of the organ tissues (breast, thigh, intestine, liver, lung, blood) tested 3 or 6 DPC from vaccinated ducks in studyID 3."
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",4,"Ducks (Anatidae)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,1,4,days,4,days,,,,,,,54,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)",breast,2,2,pos,"Other: specify",pos/neg,,,"Virus was not isolated from any of the organ tissues (breast, thigh, intestine, liver, lung, blood) tested 3 or 6 DPC from vaccinated ducks in studyID 3."
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",4,"Ducks (Anatidae)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,1,4,days,4,days,,,,,,,54,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)",thigh,2,2,pos,"Other: specify",pos/neg,,,"Virus was not isolated from any of the organ tissues (breast, thigh, intestine, liver, lung, blood) tested 3 or 6 DPC from vaccinated ducks in studyID 3."
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",4,"Ducks (Anatidae)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,1,4,days,4,days,,,,,,,54,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)",intestine,2,2,pos,"Other: specify",pos/neg,,,"Virus was not isolated from any of the organ tissues (breast, thigh, intestine, liver, lung, blood) tested 3 or 6 DPC from vaccinated ducks in studyID 3."
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",4,"Ducks (Anatidae)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,1,4,days,4,days,,,,,,,54,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)",liver,2,2,pos,"Other: specify",pos/neg,,,"Virus was not isolated from any of the organ tissues (breast, thigh, intestine, liver, lung, blood) tested 3 or 6 DPC from vaccinated ducks in studyID 3."
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",4,"Ducks (Anatidae)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,1,4,days,4,days,,,,,,,54,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)",lung,2,2,pos,"Other: specify",pos/neg,,,"Virus was not isolated from any of the organ tissues (breast, thigh, intestine, liver, lung, blood) tested 3 or 6 DPC from vaccinated ducks in studyID 3."
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",4,"Ducks (Anatidae)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,1,4,days,4,days,,,,,,,54,"After challenge","Virus Isolation (VI)",,Virus,,"Animal blood",,2,2,pos,"Other: specify",pos/neg,,,"Virus was not isolated from any of the organ tissues (breast, thigh, intestine, liver, lung, blood) tested 3 or 6 DPC from vaccinated ducks in studyID 3."
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",4,"Ducks (Anatidae)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,1,4,days,4,days,,,,,,,55,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)",breast,1,1,pos,"Other: specify",pos/neg,,,"Virus was not isolated from any of the organ tissues (breast, thigh, intestine, liver, lung, blood) tested 3 or 6 DPC from vaccinated ducks in studyID 3."
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",4,"Ducks (Anatidae)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,1,4,days,4,days,,,,,,,55,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)",intestine,1,1,pos,"Other: specify",pos/neg,,,"Virus was not isolated from any of the organ tissues (breast, thigh, intestine, liver, lung, blood) tested 3 or 6 DPC from vaccinated ducks in studyID 3."
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",4,"Ducks (Anatidae)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,1,4,days,4,days,,,,,,,55,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)",liver,1,1,pos,"Other: specify",pos/neg,,,"Virus was not isolated from any of the organ tissues (breast, thigh, intestine, liver, lung, blood) tested 3 or 6 DPC from vaccinated ducks in studyID 3."
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",4,"Ducks (Anatidae)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,1,4,days,4,days,,,,,,,55,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)",lung,1,1,pos,"Other: specify",pos/neg,,,"Virus was not isolated from any of the organ tissues (breast, thigh, intestine, liver, lung, blood) tested 3 or 6 DPC from vaccinated ducks in studyID 3."
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",4,"Ducks (Anatidae)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,1,4,days,4,days,,,,,,,55,"After challenge","Virus Isolation (VI)",,Virus,,"Animal blood",,1,1,pos,"Other: specify",pos/neg,,,"Virus was not isolated from any of the organ tissues (breast, thigh, intestine, liver, lung, blood) tested 3 or 6 DPC from vaccinated ducks in studyID 3."
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",4,"Ducks (Anatidae)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,1,4,days,4,days,,,,,,,57,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)",breast,2,1,pos,"Other: specify",pos/neg,,,"Virus was not isolated from any of the organ tissues (breast, thigh, intestine, liver, lung, blood) tested 3 or 6 DPC from vaccinated ducks in studyID 3."
50715,"Beato, M.S., Toffan, A., De Nardi, R., Cristalli, A., Terregino, C., Cattoli, G., Capua, I. (2007).  A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 Vaccine, 25(20),  4064",seungeun.han,,4,,Italy,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/duck/Vietnam/12/05, H5N1",4,"Ducks (Anatidae)",,0.033,animal,,5,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intranasal and oral",,"10^7 EID50",51,1,4,days,4,days,,,,,,,57,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)",lung,2,1,pos,"Other: specify",pos/neg,,,"Virus was not isolated from any of the organ tissues (breast, thigh, intestine, liver, lung, blood) tested 3 or 6 DPC from vaccinated ducks in studyID 3."
50721,"Middleton, D., Bingham, J., Selleck, P., Lowther, S., Gleeson, L., Lehrbach, P., Robinson, S., Rodenberg, J., Kumar, M., Andrew, M. (2007).  Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks Virology, 359(1),  66",seungeun.han,,4,,Australia,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Muscovy duck/Vietnam/453/2004, H5N1",1,"Ducks (Anatidae)",,0.033,animal,,15,commercial,,"Other: specify","Poulvac i-AI H5N9 and H7N1 bivalent vaccine","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"200 ul",21,"500 ul",,,"Challenged with the pathogen","OTHER: specify","intraocular, intranasal, oral",,"10^4.7 EID50",42,0,,,,,,,,,,,46,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",15,2,pos,"Other: specify",pos/neg,,,"Min/max or mean mortality day was not given."
50721,"Middleton, D., Bingham, J., Selleck, P., Lowther, S., Gleeson, L., Lehrbach, P., Robinson, S., Rodenberg, J., Kumar, M., Andrew, M. (2007).  Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks Virology, 359(1),  66",seungeun.han,,4,,Australia,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Muscovy duck/Vietnam/453/2004, H5N1",1,"Ducks (Anatidae)",,0.033,animal,,15,commercial,,"Other: specify","Poulvac i-AI H5N9 and H7N1 bivalent vaccine","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"200 ul",21,"500 ul",,,"Challenged with the pathogen","OTHER: specify","intraocular, intranasal, oral",,"10^4.7 EID50",42,0,,,,,,,,,,,46,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,15,1,pos,"Other: specify",pos/neg,,,"Min/max or mean mortality day was not given."
50721,"Middleton, D., Bingham, J., Selleck, P., Lowther, S., Gleeson, L., Lehrbach, P., Robinson, S., Rodenberg, J., Kumar, M., Andrew, M. (2007).  Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks Virology, 359(1),  66",seungeun.han,,4,,Australia,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Muscovy duck/Vietnam/453/2004, H5N1",1,"Ducks (Anatidae)",,0.033,animal,,15,commercial,,"Other: specify","Poulvac i-AI H5N9 and H7N1 bivalent vaccine","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"200 ul",21,"500 ul",,,"Challenged with the pathogen","OTHER: specify","intraocular, intranasal, oral",,"10^4.7 EID50",42,0,,,,,,,,,,,41,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen; Cut off 4",Antibody,,"Blood serum (as part-nature)",,15,3,5.3,titer,,,,"Min/max or mean mortality day was not given."
50721,"Middleton, D., Bingham, J., Selleck, P., Lowther, S., Gleeson, L., Lehrbach, P., Robinson, S., Rodenberg, J., Kumar, M., Andrew, M. (2007).  Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks Virology, 359(1),  66",seungeun.han,,4,,Australia,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Muscovy duck/Vietnam/453/2004, H5N1",1,"Ducks (Anatidae)",,0.033,animal,,15,commercial,,"Other: specify","Poulvac i-AI H5N9 and H7N1 bivalent vaccine","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"200 ul",21,"500 ul",,,"Challenged with the pathogen","OTHER: specify","intraocular, intranasal, oral",,"10^4.7 EID50",42,0,,,,,,,,,,,53,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen; Cut off 4",Antibody,,"Blood serum (as part-nature)",,15,12,35,titer,,,,"Min/max or mean mortality day was not given."
50721,"Middleton, D., Bingham, J., Selleck, P., Lowther, S., Gleeson, L., Lehrbach, P., Robinson, S., Rodenberg, J., Kumar, M., Andrew, M. (2007).  Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks Virology, 359(1),  66",seungeun.han,,4,,Australia,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Muscovy duck/Vietnam/453/2004, H5N1",1,"Ducks (Anatidae)",,0.033,animal,,15,commercial,,"Other: specify","Poulvac i-AI H5N9 and H7N1 bivalent vaccine","Other (specify):",Inactivated,SUBCUTANEOUS,,0,"200 ul",21,"500 ul",,,"Challenged with the pathogen","OTHER: specify","intraocular, intranasal, oral",,"10^4.7 EID50",42,0,,,,,,,,,,,56,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen; Cut off 4",Antibody,,"Blood serum (as part-nature)",,15,15,55.5,titer,,,,"Min/max or mean mortality day was not given."
50721,"Middleton, D., Bingham, J., Selleck, P., Lowther, S., Gleeson, L., Lehrbach, P., Robinson, S., Rodenberg, J., Kumar, M., Andrew, M. (2007).  Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks Virology, 359(1),  66",seungeun.han,,4,,Australia,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Muscovy duck/Vietnam/453/2004, H5N1",2,"Ducks (Anatidae)",,0.033,animal,,15,commercial,,"Poulvac FluFend I AI H5N3 RG",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"200 ul",21,"500 ul",,,"Challenged with the pathogen","OTHER: specify","intraocular, intranasal, oral",,"10^4.7 EID50",42,0,,,,,,,,,,,41,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen; Cut off 4",Antibody,,"Blood serum (as part-nature)",,15,15,27.2,titer,,,,"Min/max or mean mortality day was not given."
50721,"Middleton, D., Bingham, J., Selleck, P., Lowther, S., Gleeson, L., Lehrbach, P., Robinson, S., Rodenberg, J., Kumar, M., Andrew, M. (2007).  Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks Virology, 359(1),  66",seungeun.han,,4,,Australia,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Muscovy duck/Vietnam/453/2004, H5N1",2,"Ducks (Anatidae)",,0.033,animal,,15,commercial,,"Poulvac FluFend I AI H5N3 RG",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"200 ul",21,"500 ul",,,"Challenged with the pathogen","OTHER: specify","intraocular, intranasal, oral",,"10^4.7 EID50",42,0,,,,,,,,,,,53,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen; Cut off 4",Antibody,,"Blood serum (as part-nature)",,15,15,31.5,titer,,,,"Min/max or mean mortality day was not given."
50721,"Middleton, D., Bingham, J., Selleck, P., Lowther, S., Gleeson, L., Lehrbach, P., Robinson, S., Rodenberg, J., Kumar, M., Andrew, M. (2007).  Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks Virology, 359(1),  66",seungeun.han,,4,,Australia,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Muscovy duck/Vietnam/453/2004, H5N1",2,"Ducks (Anatidae)",,0.033,animal,,15,commercial,,"Poulvac FluFend I AI H5N3 RG",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"200 ul",21,"500 ul",,,"Challenged with the pathogen","OTHER: specify","intraocular, intranasal, oral",,"10^4.7 EID50",42,0,,,,,,,,,,,56,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen; Cut off 4",Antibody,,"Blood serum (as part-nature)",,15,15,19.7,titer,,,,"Min/max or mean mortality day was not given."
50721,"Middleton, D., Bingham, J., Selleck, P., Lowther, S., Gleeson, L., Lehrbach, P., Robinson, S., Rodenberg, J., Kumar, M., Andrew, M. (2007).  Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks Virology, 359(1),  66",seungeun.han,,4,,Australia,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Muscovy duck/Vietnam/453/2004, H5N1",3,"Ducks (Anatidae)",,0.033,animal,,14,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intraocular, intranasal, oral",,"10^4.7 EID50",42,9,-1,,-1,,,,,,,,46,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",14,12,pos,"Other: specify",pos/neg,,,"Min/max or mean mortality day was not given."
50721,"Middleton, D., Bingham, J., Selleck, P., Lowther, S., Gleeson, L., Lehrbach, P., Robinson, S., Rodenberg, J., Kumar, M., Andrew, M. (2007).  Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks Virology, 359(1),  66",seungeun.han,,4,,Australia,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Muscovy duck/Vietnam/453/2004, H5N1",3,"Ducks (Anatidae)",,0.033,animal,,14,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intraocular, intranasal, oral",,"10^4.7 EID50",42,9,-1,,-1,,,,,,,,49,"After challenge","Virus Isolation (VI)",,Virus,,"Other (specify)","oropharyngeal swab",7,3,pos,"Other: specify",pos/neg,,,"Min/max or mean mortality day was not given."
50721,"Middleton, D., Bingham, J., Selleck, P., Lowther, S., Gleeson, L., Lehrbach, P., Robinson, S., Rodenberg, J., Kumar, M., Andrew, M. (2007).  Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks Virology, 359(1),  66",seungeun.han,,4,,Australia,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Muscovy duck/Vietnam/453/2004, H5N1",3,"Ducks (Anatidae)",,0.033,animal,,14,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intraocular, intranasal, oral",,"10^4.7 EID50",42,9,-1,,-1,,,,,,,,46,"After challenge","Virus Isolation (VI)",,Virus,,"Rectum-anal swab (as part-nature)",,14,2,pos,"Other: specify",pos/neg,,,"Min/max or mean mortality day was not given."
50721,"Middleton, D., Bingham, J., Selleck, P., Lowther, S., Gleeson, L., Lehrbach, P., Robinson, S., Rodenberg, J., Kumar, M., Andrew, M. (2007).  Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks Virology, 359(1),  66",seungeun.han,,4,,Australia,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Muscovy duck/Vietnam/453/2004, H5N1",3,"Ducks (Anatidae)",,0.033,animal,,14,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intraocular, intranasal, oral",,"10^4.7 EID50",42,9,-1,,-1,,,,,,,,53,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen; Cut off 4",Antibody,,"Blood serum (as part-nature)",,5,5,96,titer,,,,"Min/max or mean mortality day was not given."
50721,"Middleton, D., Bingham, J., Selleck, P., Lowther, S., Gleeson, L., Lehrbach, P., Robinson, S., Rodenberg, J., Kumar, M., Andrew, M. (2007).  Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks Virology, 359(1),  66",seungeun.han,,4,,Australia,2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Muscovy duck/Vietnam/453/2004, H5N1",3,"Ducks (Anatidae)",,0.033,animal,,14,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","intraocular, intranasal, oral",,"10^4.7 EID50",42,9,-1,,-1,,,,,,,,56,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen; Cut off 4",Antibody,,"Blood serum (as part-nature)",,5,5,115.2,titer,,,,"Min/max or mean mortality day was not given."
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",1,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"Gallimune Flu H5N9",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",21,1,5,days,5,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2 titer",Antibody,,"Blood serum (as part-nature)",,20,20,7.3,"Other: specify","log2 titer",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",1,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"Gallimune Flu H5N9",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",21,1,5,days,5,days,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen; Cut off 3 log2 titer",Antibody,,"Blood serum (as part-nature)",,20,7,2.5,"Other: specify","log2 titer",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",1,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"Gallimune Flu H5N9",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",21,1,5,days,5,days,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen; Cut off 3 log2 titer",Antibody,,"Blood serum (as part-nature)",,19,19,4.5,"Other: specify","log2 titer",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",1,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"Gallimune Flu H5N9",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",21,1,5,days,5,days,,,,,,,22,"After challenge","Virus Isolation (VI)","Cut-off 1 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",20,20,3.9,"Other: specify","log10 EID50/ml",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",1,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"Gallimune Flu H5N9",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",,,,,"Challenged with the pathogen","OTHER: specify",intranasal,,"10^6 EID50",21,1,5,days,5,days,,,,,,,22,"After challenge","Virus Isolation (VI)","Cut-off 1 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,20,3,0.9,"Other: specify","log10 EID50/ml",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Gallimune Flu H5N9",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",,,,,"Challenged with the pathogen","OTHER: specify","Direct contact with studyID 1",,,22,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2 titer",Antibody,,"Blood serum (as part-nature)",,10,10,7.3,"Other: specify","log2 titer",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Gallimune Flu H5N9",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",,,,,"Challenged with the pathogen","OTHER: specify","Direct contact with studyID 1",,,22,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen; Cut off 3 log2 titer",Antibody,,"Blood serum (as part-nature)",,10,3,2.5,"Other: specify","log2 titer",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Gallimune Flu H5N9",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",,,,,"Challenged with the pathogen","OTHER: specify","Direct contact with studyID 1",,,22,0,,,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen; Cut off 3 log2 titer",Antibody,,"Blood serum (as part-nature)",,10,2,0.9,"Other: specify","log2 titer",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",2,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Gallimune Flu H5N9",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",,,,,"Challenged with the pathogen","OTHER: specify","Direct contact with studyID 1",,,22,0,,,,,,,,,,,24,"After challenge","Virus Isolation (VI)","Cut-off 1 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,10,1,0.9,"Other: specify","log10 EID50/ml",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",3,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Direct contact with studyID 1",,,22,10,2,days,9,days,,,,,,,24,"After challenge","Virus Isolation (VI)","Cut-off 1 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",10,2,1.5,"Other: specify","log10 EID50/ml",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",3,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Direct contact with studyID 1",,,22,10,2,days,9,days,,,,,,,24,"After challenge","Virus Isolation (VI)","Cut-off 1 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,10,1,1.3,"Other: specify","log10 EID50/ml",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",4,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID 50",21,20,2,days,2,days,,,,,,,22,"After challenge","Virus Isolation (VI)","Cut-off 1 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",20,20,5.5,"Other: specify","log10 EID50/ml",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",4,"Chickens (Gallus)",,0.75,animal,,20,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify",Intranasal,,"10^6 EID 50",21,20,2,days,2,days,,,,,,,22,"After challenge","Virus Isolation (VI)","Cut-off 1 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,20,20,3.9,"Other: specify","log10 EID50/ml",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",5,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Gallimune Flu H5N9",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",,,,,"Challenged with the pathogen","OTHER: specify","Direct contact with studyID 4",,,22,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the vaccine homologous antigen; cut-off 3 log2 titer",Antibody,,"Blood serum (as part-nature)",,10,10,7.3,"Other: specify","log2 titer",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",5,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Gallimune Flu H5N9",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",,,,,"Challenged with the pathogen","OTHER: specify","Direct contact with studyID 4",,,22,0,,,,,,,,,,,21,"Vaccinated, not challenged","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen; Cut off 3 log2 titer",Antibody,,"Blood serum (as part-nature)",,10,3,2.5,"Other: specify","log2 titer",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",5,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Gallimune Flu H5N9",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",,,,,"Challenged with the pathogen","OTHER: specify","Direct contact with studyID 4",,,22,0,,,,,,,,,,,35,"After challenge","Haemagglutination inhibition test (HIT)","Against the challenge strain antigen; Cut off 3 log2 titer",Antibody,,"Blood serum (as part-nature)",,9,6,2,"Other: specify","log2 titer",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",5,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Gallimune Flu H5N9",,"Other (specify):",Inactivated,INTRAMUSCULAR,,0,"0.3 ml",,,,,"Challenged with the pathogen","OTHER: specify","Direct contact with studyID 4",,,22,0,,,,,,,,,,,24,"After challenge","Virus Isolation (VI)","Cut-off 1 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",10,8,2,"Other: specify","log10 EID50/ml",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",6,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Direct contact with studyID 4",,,22,10,2,days,3,days,,,,,,,24,"After challenge","Virus Isolation (VI)","Cut-off 1 log10 EID50/ml",Virus,,"Other (specify)","oropharyngeal swab",10,10,5.7,"Other: specify","log10 EID50/ml",,,
50728,"Bublot, M., Le Gros, F.-X., Nieddu, D., Pritchard, N., Mickle, T.R., Swayne, D.E. (2007).  Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand Avian Diseases, 51(SUPPL. 1),  332",seungeun.han,,4,,"United States",2006,"HPAI - Highly Pathogenic Avian Influenza",serotype,,"A/Chicken/Supranburi/2/04, H5N1",6,"Chickens (Gallus)",,0.75,animal,,10,SPF,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen","OTHER: specify","Direct contact with studyID 4",,,22,10,2,days,3,days,,,,,,,24,"After challenge","Virus Isolation (VI)","Cut-off 1 log10 EID50/ml",Virus,,"Rectum-anal swab (as part-nature)",,10,10,5,"Other: specify","log10 EID50/ml",,,
50927,"Miller, M.M., Bennett, K.E., Drolet, B.S., Lindsay, R., Mecham, J.O., Reeves, W.K., Weingartl, H.M., Wilson, W.C. (2015).  Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated rift valley fever virus vaccine candidate, in sheep Clinical and Vaccine Immunology, 22(8),  930",seungeun.han,,4,,"United States",2015,"Rift Valley fever virus",strain,,ZH501,1,"Sheep (Ovis aries)",,3,animal,,16,commercial,,"RVFV: MP-12 (Zoetis Inc., USA / Canada)",,Attenuated,,SUBCUTANEOUS,,0,"3 x 103 PFU/2.5ml",,,,,"Challenged with the pathogen",SUBCUTANEOUS,,"Cell culture media","2 x 10^7 PFU/1ml",21,0,,,,,,,,,,,22,"After challenge","Reverse-transcription PCR (RT-PCR)","< 3.1 log10 copy/ml was considered negative","Nucleic acid",,"Blood serum (as part-nature)",,16,1,4.8,"Other: specify","log10 copy/ml",,,"All animals were purchased from reputable breeders, but prior vaccination/treatment information were not provided. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50927,"Miller, M.M., Bennett, K.E., Drolet, B.S., Lindsay, R., Mecham, J.O., Reeves, W.K., Weingartl, H.M., Wilson, W.C. (2015).  Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated rift valley fever virus vaccine candidate, in sheep Clinical and Vaccine Immunology, 22(8),  930",seungeun.han,,4,,"United States",2015,"Rift Valley fever virus",strain,,ZH501,1,"Sheep (Ovis aries)",,3,animal,,16,commercial,,"RVFV: MP-12 (Zoetis Inc., USA / Canada)",,Attenuated,,SUBCUTANEOUS,,0,"3 x 103 PFU/2.5ml",,,,,"Challenged with the pathogen",SUBCUTANEOUS,,"Cell culture media","2 x 10^7 PFU/1ml",21,0,,,,,,,,,,,14,"Vaccinated, not challenged","Seroneutralisation test","Against wild type ZH501 using PRNT70","Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,16,16,25,"Not reported",,,,"All animals were purchased from reputable breeders, but prior vaccination/treatment information were not provided. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50927,"Miller, M.M., Bennett, K.E., Drolet, B.S., Lindsay, R., Mecham, J.O., Reeves, W.K., Weingartl, H.M., Wilson, W.C. (2015).  Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated rift valley fever virus vaccine candidate, in sheep Clinical and Vaccine Immunology, 22(8),  930",seungeun.han,,4,,"United States",2015,"Rift Valley fever virus",strain,,ZH501,1,"Sheep (Ovis aries)",,3,animal,,16,commercial,,"RVFV: MP-12 (Zoetis Inc., USA / Canada)",,Attenuated,,SUBCUTANEOUS,,0,"3 x 103 PFU/2.5ml",,,,,"Challenged with the pathogen",SUBCUTANEOUS,,"Cell culture media","2 x 10^7 PFU/1ml",21,0,,,,,,,,,,,21,"Challenge day","Seroneutralisation test","Against wild type ZH501 using PRNT70","Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,16,16,25,"Not reported",,,,"All animals were purchased from reputable breeders, but prior vaccination/treatment information were not provided. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50927,"Miller, M.M., Bennett, K.E., Drolet, B.S., Lindsay, R., Mecham, J.O., Reeves, W.K., Weingartl, H.M., Wilson, W.C. (2015).  Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated rift valley fever virus vaccine candidate, in sheep Clinical and Vaccine Immunology, 22(8),  930",seungeun.han,,4,,"United States",2015,"Rift Valley fever virus",strain,,ZH501,1,"Sheep (Ovis aries)",,3,animal,,16,commercial,,"RVFV: MP-12 (Zoetis Inc., USA / Canada)",,Attenuated,,SUBCUTANEOUS,,0,"3 x 103 PFU/2.5ml",,,,,"Challenged with the pathogen",SUBCUTANEOUS,,"Cell culture media","2 x 10^7 PFU/1ml",21,0,,,,,,,,,,,27,"After challenge","Seroneutralisation test","Against wild type ZH501 using PRNT70","Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,16,16,60,"Not reported",,,,"All animals were purchased from reputable breeders, but prior vaccination/treatment information were not provided. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50927,"Miller, M.M., Bennett, K.E., Drolet, B.S., Lindsay, R., Mecham, J.O., Reeves, W.K., Weingartl, H.M., Wilson, W.C. (2015).  Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated rift valley fever virus vaccine candidate, in sheep Clinical and Vaccine Immunology, 22(8),  930",seungeun.han,,4,,"United States",2015,"Rift Valley fever virus",strain,,ZH501,2,"Sheep (Ovis aries)",,3,animal,,12,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",SUBCUTANEOUS,,"Cell culture media","2 x 10^7 PFU/1ml",21,0,,,,,,,,,,,22,"After challenge","Reverse-transcription PCR (RT-PCR)","< 3.1 log10 copy/ml was considered negative","Nucleic acid",,"Blood serum (as part-nature)",,12,12,6.5,"Other: specify","log10 copy/ml",,,"All animals were purchased from reputable breeders, but prior vaccination/treatment information were not provided. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value. Among 12 control animals, 4 animals were inoculated in the current experiment and 8 animals were inoculated with the same challenge virus in the previous study."
50927,"Miller, M.M., Bennett, K.E., Drolet, B.S., Lindsay, R., Mecham, J.O., Reeves, W.K., Weingartl, H.M., Wilson, W.C. (2015).  Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated rift valley fever virus vaccine candidate, in sheep Clinical and Vaccine Immunology, 22(8),  930",seungeun.han,,4,,"United States",2015,"Rift Valley fever virus",strain,,ZH501,2,"Sheep (Ovis aries)",,3,animal,,12,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",SUBCUTANEOUS,,"Cell culture media","2 x 10^7 PFU/1ml",21,0,,,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)","< 3.1 log10 copy/ml was considered negative","Nucleic acid",,"Blood serum (as part-nature)",,12,12,6.8,"Other: specify","log10 copy/ml",,,"All animals were purchased from reputable breeders, but prior vaccination/treatment information were not provided. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value. Among 12 control animals, 4 animals were inoculated in the current experiment and 8 animals were inoculated with the same challenge virus in the previous study."
50927,"Miller, M.M., Bennett, K.E., Drolet, B.S., Lindsay, R., Mecham, J.O., Reeves, W.K., Weingartl, H.M., Wilson, W.C. (2015).  Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated rift valley fever virus vaccine candidate, in sheep Clinical and Vaccine Immunology, 22(8),  930",seungeun.han,,4,,"United States",2015,"Rift Valley fever virus",strain,,ZH501,2,"Sheep (Ovis aries)",,3,animal,,12,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",SUBCUTANEOUS,,"Cell culture media","2 x 10^7 PFU/1ml",21,0,,,,,,,,,,,24,"After challenge","Reverse-transcription PCR (RT-PCR)","< 3.1 log10 copy/ml was considered negative","Nucleic acid",,"Blood serum (as part-nature)",,12,12,5.8,"Other: specify","log10 copy/ml",,,"All animals were purchased from reputable breeders, but prior vaccination/treatment information were not provided. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value. Among 12 control animals, 4 animals were inoculated in the current experiment and 8 animals were inoculated with the same challenge virus in the previous study."
50927,"Miller, M.M., Bennett, K.E., Drolet, B.S., Lindsay, R., Mecham, J.O., Reeves, W.K., Weingartl, H.M., Wilson, W.C. (2015).  Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated rift valley fever virus vaccine candidate, in sheep Clinical and Vaccine Immunology, 22(8),  930",seungeun.han,,4,,"United States",2015,"Rift Valley fever virus",strain,,ZH501,2,"Sheep (Ovis aries)",,3,animal,,12,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",SUBCUTANEOUS,,"Cell culture media","2 x 10^7 PFU/1ml",21,0,,,,,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)","< 3.1 log10 copy/ml was considered negative","Nucleic acid",,"Blood serum (as part-nature)",,12,12,5.5,"Other: specify","log10 copy/ml",,,"All animals were purchased from reputable breeders, but prior vaccination/treatment information were not provided. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value. Among 12 control animals, 4 animals were inoculated in the current experiment and 8 animals were inoculated with the same challenge virus in the previous study."
50927,"Miller, M.M., Bennett, K.E., Drolet, B.S., Lindsay, R., Mecham, J.O., Reeves, W.K., Weingartl, H.M., Wilson, W.C. (2015).  Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated rift valley fever virus vaccine candidate, in sheep Clinical and Vaccine Immunology, 22(8),  930",seungeun.han,,4,,"United States",2015,"Rift Valley fever virus",strain,,ZH501,2,"Sheep (Ovis aries)",,3,animal,,12,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",SUBCUTANEOUS,,"Cell culture media","2 x 10^7 PFU/1ml",21,0,,,,,,,,,,,26,"After challenge","Reverse-transcription PCR (RT-PCR)","< 3.1 log10 copy/ml was considered negative","Nucleic acid",,"Blood serum (as part-nature)",,12,12,3.2,"Other: specify","log10 copy/ml",,,"All animals were purchased from reputable breeders, but prior vaccination/treatment information were not provided. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value. Among 12 control animals, 4 animals were inoculated in the current experiment and 8 animals were inoculated with the same challenge virus in the previous study."
50927,"Miller, M.M., Bennett, K.E., Drolet, B.S., Lindsay, R., Mecham, J.O., Reeves, W.K., Weingartl, H.M., Wilson, W.C. (2015).  Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated rift valley fever virus vaccine candidate, in sheep Clinical and Vaccine Immunology, 22(8),  930",seungeun.han,,4,,"United States",2015,"Rift Valley fever virus",strain,,ZH501,2,"Sheep (Ovis aries)",,3,animal,,12,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",SUBCUTANEOUS,,"Cell culture media","2 x 10^7 PFU/1ml",21,0,,,,,,,,,,,22,"After challenge","Virus Isolation (VI)","plaque assay",Virus,,"Blood serum (as part-nature)",,12,12,1.8,"Other: specify","log10 PFU/ml",,,"All animals were purchased from reputable breeders, but prior vaccination/treatment information were not provided. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value. Among 12 control animals, 4 animals were inoculated in the current experiment and 8 animals were inoculated with the same challenge virus in the previous study."
50927,"Miller, M.M., Bennett, K.E., Drolet, B.S., Lindsay, R., Mecham, J.O., Reeves, W.K., Weingartl, H.M., Wilson, W.C. (2015).  Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated rift valley fever virus vaccine candidate, in sheep Clinical and Vaccine Immunology, 22(8),  930",seungeun.han,,4,,"United States",2015,"Rift Valley fever virus",strain,,ZH501,2,"Sheep (Ovis aries)",,3,animal,,12,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",SUBCUTANEOUS,,"Cell culture media","2 x 10^7 PFU/1ml",21,0,,,,,,,,,,,23,"After challenge","Virus Isolation (VI)","plaque assay",Virus,,"Blood serum (as part-nature)",,12,12,3.8,"Other: specify","log10 PFU/ml",,,"All animals were purchased from reputable breeders, but prior vaccination/treatment information were not provided. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value. Among 12 control animals, 4 animals were inoculated in the current experiment and 8 animals were inoculated with the same challenge virus in the previous study."
50927,"Miller, M.M., Bennett, K.E., Drolet, B.S., Lindsay, R., Mecham, J.O., Reeves, W.K., Weingartl, H.M., Wilson, W.C. (2015).  Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated rift valley fever virus vaccine candidate, in sheep Clinical and Vaccine Immunology, 22(8),  930",seungeun.han,,4,,"United States",2015,"Rift Valley fever virus",strain,,ZH501,2,"Sheep (Ovis aries)",,3,animal,,12,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",SUBCUTANEOUS,,"Cell culture media","2 x 10^7 PFU/1ml",21,0,,,,,,,,,,,24,"After challenge","Virus Isolation (VI)","plaque assay",Virus,,"Blood serum (as part-nature)",,12,12,2.4,"Other: specify","log10 PFU/ml",,,"All animals were purchased from reputable breeders, but prior vaccination/treatment information were not provided. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value. Among 12 control animals, 4 animals were inoculated in the current experiment and 8 animals were inoculated with the same challenge virus in the previous study."
50927,"Miller, M.M., Bennett, K.E., Drolet, B.S., Lindsay, R., Mecham, J.O., Reeves, W.K., Weingartl, H.M., Wilson, W.C. (2015).  Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated rift valley fever virus vaccine candidate, in sheep Clinical and Vaccine Immunology, 22(8),  930",seungeun.han,,4,,"United States",2015,"Rift Valley fever virus",strain,,ZH501,2,"Sheep (Ovis aries)",,3,animal,,12,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",SUBCUTANEOUS,,"Cell culture media","2 x 10^7 PFU/1ml",21,0,,,,,,,,,,,25,"After challenge","Virus Isolation (VI)","plaque assay",Virus,,"Blood serum (as part-nature)",,12,12,1.4,"Other: specify","log10 PFU/ml",,,"All animals were purchased from reputable breeders, but prior vaccination/treatment information were not provided. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value. Among 12 control animals, 4 animals were inoculated in the current experiment and 8 animals were inoculated with the same challenge virus in the previous study."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",1,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"RVFV: RVF Clone 13 (OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/1 ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,0,,,,,,,,,,,21,"Challenge day","ELISA, Competitive ELISA (C-ELISA)","Against N-protein of RVFV. Titers are expressed as % competition ration of OD of sample and OD of neg. control (%S/N) and all values lower than 40% considered positive.",Antibody,,"Blood serum (as part-nature)",,8,8,30,"Other: specify","% S/N",,,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",1,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"RVFV: RVF Clone 13 (OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/1 ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,0,,,,,,,,,,,28,"After challenge","ELISA, Competitive ELISA (C-ELISA)","Against N-protein of RVFV. Titers are expressed as % competition ration of OD of sample and OD of neg. control (%S/N) and all values lower than 40% considered positive.",Antibody,,"Blood serum (as part-nature)",,8,8,20,"Other: specify","% S/N",,,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",1,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"RVFV: RVF Clone 13 (OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/1 ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,0,,,,,,,,,,,35,"After challenge","ELISA, Competitive ELISA (C-ELISA)","Against N-protein of RVFV. Titers are expressed as % competition ration of OD of sample and OD of neg. control (%S/N) and all values lower than 40% considered positive.",Antibody,,"Blood serum (as part-nature)",,8,8,20,"Other: specify","% S/N",,,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",1,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"RVFV: RVF Clone 13 (OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/1 ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,0,,,,,,,,,,,42,"After challenge","ELISA, Competitive ELISA (C-ELISA)","Against N-protein of RVFV. Titers are expressed as % competition ration of OD of sample and OD of neg. control (%S/N) and all values lower than 40% considered positive.",Antibody,,"Blood serum (as part-nature)",,8,8,20,"Other: specify","% S/N",,,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",1,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"RVFV: RVF Clone 13 (OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/1 ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,0,,,,,,,,,,,21,"Challenge day","Virus neutralisation test (VNT)","< 2.15 log10 of 50% end point titer was considered negative","Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,8,8,3,"Other: specify","log10 (50% end point titer)",,,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",1,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"RVFV: RVF Clone 13 (OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/1 ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,0,,,,,,,,,,,28,"After challenge","Virus neutralisation test (VNT)","< 2.15 log10 of 50% end point titer was considered negative","Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,8,8,3.8,"Other: specify","log10 (50% end point titer)",,,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",1,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"RVFV: RVF Clone 13 (OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/1 ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,0,,,,,,,,,,,35,"After challenge","Virus neutralisation test (VNT)","< 2.15 log10 of 50% end point titer was considered negative","Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,8,8,3.8,"Other: specify","log10 (50% end point titer)",,,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",1,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"RVFV: RVF Clone 13 (OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/1 ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,0,,,,,,,,,,,42,"After challenge","Virus neutralisation test (VNT)","< 2.15 log10 of 50% end point titer was considered negative","Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,8,8,4,"Other: specify","log10 (50% end point titer)",,,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",2,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,3,24,days,27,days,,,,,,,22,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,8,8,,"Other: specify","log10 RNA copy/ml",3,4,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",2,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,3,24,days,27,days,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,8,8,,"Other: specify","log10 RNA copy/ml",8,9.7,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",2,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,3,24,days,27,days,,,,,,,24,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,7,7,,"Other: specify","log10 RNA copy/ml",9.5,10.5,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",2,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,3,24,days,27,days,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,6,6,,"Other: specify","log10 RNA copy/ml",7.5,10,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",2,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,3,24,days,27,days,,,,,,,26,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,6,6,,"Other: specify","log10 RNA copy/ml",4,9,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",2,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,3,24,days,27,days,,,,,,,27,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,5,3,,"Other: specify","log10 RNA copy/ml",3,7,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",2,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,3,24,days,27,days,,,,,,,28,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,5,3,,"Other: specify","log10 RNA copy/ml",2,7,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",2,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,3,24,days,27,days,,,,,,,29,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,5,4,,"Other: specify","log10 RNA copy/ml",3.8,5.5,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",2,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,3,24,days,27,days,,,,,,,30,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,5,2,4.5,"Other: specify","log10 RNA copy/ml",,,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",2,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,3,24,days,27,days,,,,,,,23,"After challenge","Virus Isolation (VI)",,Virus,,"Animal blood",,8,8,6,"Other: specify","log10 TCID50/ml",,,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",2,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,3,24,days,27,days,,,,,,,28,"After challenge","ELISA, Competitive ELISA (C-ELISA)","Against N-protein of RVFV. Titers are expressed as % competition ration of OD of sample and OD of neg. control (%S/N) and all values lower than 40% considered positive.",Antibody,,"Blood serum (as part-nature)",,5,5,20,"Other: specify","% S/N",,,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",2,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,3,24,days,27,days,,,,,,,35,"After challenge","ELISA, Competitive ELISA (C-ELISA)","Against N-protein of RVFV. Titers are expressed as % competition ration of OD of sample and OD of neg. control (%S/N) and all values lower than 40% considered positive.",Antibody,,"Blood serum (as part-nature)",,5,5,25,"Other: specify","% S/N",,,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",2,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,3,24,days,27,days,,,,,,,42,"After challenge","ELISA, Competitive ELISA (C-ELISA)","Against N-protein of RVFV. Titers are expressed as % competition ration of OD of sample and OD of neg. control (%S/N) and all values lower than 40% considered positive.",Antibody,,"Blood serum (as part-nature)",,5,5,20,"Other: specify","% S/N",,,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",2,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,3,24,days,27,days,,,,,,,28,"After challenge","Virus neutralisation test (VNT)","< 2.15 log10 of 50% end point titer was considered negative","Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,3,"Other: specify","log10 (50% end point titer)",,,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",2,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,3,24,days,27,days,,,,,,,35,"After challenge","Virus neutralisation test (VNT)","< 2.15 log10 of 50% end point titer was considered negative","Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,4.3,"Other: specify","log10 (50% end point titer)",,,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50939,"Kortekaas, J., Oreshkova, N., van Keulen, L., Kant, J., Bosch, B.J., Bouloy, M., Moulin, V., Goovaerts, D., Moormann, R.J.M. (2014).  Comparative efficacy of two next-generation Rift Valley fever vaccines Vaccine, 32(39),  4901",seungeun.han,,4,,Netherlands,2014,"Rift Valley fever virus",strain,,"Cloned recombinent 35/74 strain virus",2,"Sheep (Ovis aries)",,3,animal,,8,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"Culture media","10^5 TCID50/1ml",21,3,24,days,27,days,,,,,,,42,"After challenge","Virus neutralisation test (VNT)","< 2.15 log10 of 50% end point titer was considered negative","Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,5.2,"Other: specify","log10 (50% end point titer)",,,"All animals were purchased from a research institute, but prior vaccination/treatment information were not provided.  Animals were challenged with molecularly cloned recombinant 35/74 strain virus. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR and neutralizing antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",1,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"RVFV: Rift Valley Fever (inactivated; OBP, South Africa)",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"1ml of manufactural prescribed dose",,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,0,,,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,6,6,4,"Other: specify","log10 RNA copy/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",1,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"RVFV: Rift Valley Fever (inactivated; OBP, South Africa)",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"1ml of manufactural prescribed dose",,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,0,,,,,,,,,,,19,"Challenge day","Virus neutralisation test (VNT)",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,6,5,2.5,"Other: specify","log10 (50% end point titer)",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",1,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"RVFV: Rift Valley Fever (inactivated; OBP, South Africa)",,"Other (specify):",Inactivated,SUBCUTANEOUS,,0,"1ml of manufactural prescribed dose",,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,0,,,,,,,,,,,37,"After challenge","Virus neutralisation test (VNT)",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,6,3,2.3,"Other: specify","log10 (50% end point titer)",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,20,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,6,5,1.5,"Other: specify","log10 RNA copy/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,21,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,6,5,6.5,"Other: specify","log10 RNA copy/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,22,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,6,5,8.5,"Other: specify","log10 RNA copy/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,23,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,6,5,8,"Other: specify","log10 RNA copy/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,24,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,6,5,6,"Other: specify","log10 RNA copy/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,25,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,6,5,5,"Other: specify","log10 RNA copy/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,26,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,6,5,4.5,"Other: specify","log10 RNA copy/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,28,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,5,4,3,"Other: specify","log10 RNA copy/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,35,"After challenge","Reverse-transcription PCR (RT-PCR)",,"Nucleic acid",,"Animal blood",,5,4,1,"Other: specify","log10 RNA copy/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,20,"After challenge","Virus Isolation (VI)",,Virus,,"Animal blood",,6,5,1.7,"Other: specify","log10 TCID50/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,21,"After challenge","Virus Isolation (VI)",,Virus,,"Animal blood",,6,5,2.8,"Other: specify","log10 TCID50/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,22,"After challenge","Virus Isolation (VI)",,Virus,,"Animal blood",,6,5,4.5,"Other: specify","log10 TCID50/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,23,"After challenge","Virus Isolation (VI)",,Virus,,"Animal blood",,6,5,3.2,"Other: specify","log10 TCID50/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,24,"After challenge","Virus Isolation (VI)",,Virus,,"Animal blood",,6,5,1.3,"Other: specify","log10 TCID50/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,25,"After challenge","Virus Isolation (VI)",,Virus,,"Animal blood",,6,5,0.8,"Other: specify","log10 TCID50/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,26,"After challenge","Virus Isolation (VI)",,Virus,,"Animal blood",,6,5,0.5,"Other: specify","log10 TCID50/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,28,"After challenge","Virus Isolation (VI)",,Virus,,"Animal blood",,5,4,0.5,"Other: specify","log10 TCID50/ml",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,37,"After challenge","Virus neutralisation test (VNT)",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,4,4,"Other: specify","log10 (50% end point titer)",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50980,"Kortekaas, J., Antonis, A.F.G., Kant, J., Vloet, R.P.M., Vogel, A., Oreshkova, N., De Boer, S.M., Bosch, B.J., Moormann, R.J.M. (2012).  Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine, 30(23),  3423",seungeun.han,,4,,Netherlands,2011,"Rift Valley fever virus",strain,,"Recombinant 35/74 virus",2,"Sheep (Ovis aries)",,1.5,animal,,6,commercial,,"Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAPERITONEAL,,,"10^5 TCID50",19,1,27,days,,,,,,,,,26,"After challenge","ELISA, Competitive ELISA (C-ELISA)","Against N-protein of RVFV. Titers are expressed as % competition ration of OD of sample and OD of neg. control (%S/N) and all values lower than 40% considered positive.",Antibody,,"Blood serum (as part-nature)",,6,5,38,"Other: specify","% S/N",,,"All animals were purchased from a commercial sheep farm, but prior vaccination/treatment information were not provided. Animals were challenged with a recombinant 35/74 strain virus rescued from cDNA. This article was not rejected to maximize the number of references in RVF literature review. The results of PCR, virus isolation and antibody tests were presented by visual graphs, so the result values were visually estimated to report on Question 45 test Value."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",1,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","RVFV: Rift Valley Fever (live; OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,0,,,,,,,,,,,14,"Vaccinated, not challenged","Seroneutralisation test",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,,titer,,64,512,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",1,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","RVFV: Rift Valley Fever (live; OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,0,,,,,,,,,,,21,"Vaccinated, not challenged","Seroneutralisation test",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,,titer,,192,512,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",1,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","RVFV: Rift Valley Fever (live; OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,0,,,,,,,,,,,28,"Challenge day","Seroneutralisation test",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,,titer,,192,512,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",1,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","RVFV: Rift Valley Fever (live; OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,0,,,,,,,,,,,35,"After challenge","Seroneutralisation test",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,512,titer,,,,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",1,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","RVFV: Rift Valley Fever (live; OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,0,,,,,,,,,,,42,"After challenge","Seroneutralisation test",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,512,titer,,,,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",1,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","RVFV: Rift Valley Fever (live; OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,0,,,,,,,,,,,49,"After challenge","Seroneutralisation test",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,512,titer,,,,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",1,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","RVFV: Rift Valley Fever (live; OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,0,,,,,,,,,,,56,"After challenge","Seroneutralisation test",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,512,titer,,,,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",2,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","RVFV: RVF Clone 13 (OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,0,,,,,,,,,,,7,"Vaccinated, not challenged","Seroneutralisation test",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,4,,titer,,4,16,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",2,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","RVFV: RVF Clone 13 (OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,0,,,,,,,,,,,14,"Vaccinated, not challenged","Seroneutralisation test",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,,titer,,24,256,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",2,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","RVFV: RVF Clone 13 (OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,0,,,,,,,,,,,21,"Vaccinated, not challenged","Seroneutralisation test",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,,titer,,12,64,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",2,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","RVFV: RVF Clone 13 (OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,0,,,,,,,,,,,28,"Challenge day","Seroneutralisation test",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,,titer,,32,64,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",2,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","RVFV: RVF Clone 13 (OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,0,,,,,,,,,,,35,"After challenge","Seroneutralisation test",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,512,titer,,,,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",2,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","RVFV: RVF Clone 13 (OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,0,,,,,,,,,,,42,"After challenge","Seroneutralisation test",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,512,titer,,,,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",2,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","RVFV: RVF Clone 13 (OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,0,,,,,,,,,,,49,"After challenge","Seroneutralisation test",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,512,titer,,,,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",2,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","RVFV: RVF Clone 13 (OBP, South Africa)",,Attenuated,,SUBCUTANEOUS,,0,"10^5 pfu/ml",,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,0,,,,,,,,,,,56,"After challenge","Seroneutralisation test",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,5,5,512,titer,,,,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",3,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,2,34,days,,,,,,,,,29,"After challenge","Virus Isolation (VI)",,Virus,,"Animal blood",,5,4,3.5,"Other: specify","log10 TCID50/ml",,,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",3,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,2,34,days,,,,,,,,,30,"After challenge","Virus Isolation (VI)",,Virus,,"Animal blood",,5,4,3.5,"Other: specify","log10 TCID50/ml",,,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",3,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,2,34,days,,,,,,,,,31,"After challenge","Virus Isolation (VI)",,Virus,,"Animal blood",,5,4,3.5,"Other: specify","log10 TCID50/ml",,,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",3,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,2,34,days,,,,,,,,,32,"After challenge","Virus Isolation (VI)",,Virus,,"Animal blood",,5,4,3.5,"Other: specify","log10 TCID50/ml",,,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
50993,"Von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A., Bouloy, M. (2011).  Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves Vaccine, 29(34),  5771",seungeun.han,,4,,"South Africa",2011,"Rift Valley fever virus",strain,,"RVF M35/74 strain",3,"Cattle (Bos taurus)",,7,animal,,5,"Other (specify)","Not described","Unvaccinated control",,,,,,,,,,,,"Challenged with the pathogen",INTRAVENEOUS,,"1 ml","4.5 x 10^6 pfu/ml",28,2,34,days,,,,,,,,,35,"After challenge","Seroneutralisation test",,"Other: specify","Neutralizing antibody","Blood serum (as part-nature)",,3,3,,titer,,8,32,"Information on prior vaccination/treatment of animals before the experiment was not provided. This article was not rejected to maximize the number of references in RVF literature review. All vaccinated animals were euthanized at the end of the experiment (D 56). Two of the 5 control animals were euthanized before D 35, but it was not clear when the rest of the 3 control animals were euthanized. It could be after D 35 and before D 42. The result of neutralizing antibody was provided for each animal, so the minimum and maximum scores were recorded at 47 Scale MIN and 48 Scale MAX, respectively."
